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 During development cells undergo highly synchronized, dynamic morphogenetic movements to 
pattern the complex 3D architecture of tissues and organs involving processes like cell adhesion, 
migration, shape and polarity. This cellular remodeling is brought about by proteins that can 
spatially and temporally modulate the dynamics and organization of the cytoskeleton. Shroom is 
a class of actin-associated proteins that has been implicated in regulating cell and tissue 
architecture. Shroom3 along with another cytoskeleton regulator protein Rock, a kinase, locally 
activates non-muscle myosin II and facilitates assembly of a contractile actomyosin network at 
the apical surface of cells which subsequently alters cell shape and behavior. In order to elucidate 
the molecular mechanism and dynamics of Shroom-Rock interaction it becomes important to 
map the residues mediating this interaction. My project aims to dissect the molecular nature of 
Shroom-Rock interaction using a variety of biochemical and cell based assays, guided by 
structural studies and novel Shroom3 mutants. Shroom SD2 is known to form a three segmented 
antiparallel coiled-coil dimer. We have identified a highly conserved patch of surface exposed 
residues in Shroom SD2 that are important for Rock binding and interiorly buried residues 
required for Shroom dimerization. I have shown that the SD2 mutants that fail to bind Rock or 
dimerize also fail to cause apical constriction in MDCK cells. I have also shown specifically an 
Arginine residue in Shroom SD2 to be essential for Rock binding, apical constriction and neural 
tube morphogenesis in mice. Next, we mapped the SBD of Rock to a stretch of 79 amino acids in 
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its coiled–coil region which is highly conserved across species. Using mutational analysis as well 
as in vitro and in vivo assays I have identified surface patches of highly conserved residues in 
Rock SBD that are important for Shroom binding, co-localization with Shroom, and apical 
constriction of MDCK cells. These results supplemented by the crystal structure of Rock SBD 
have facilitated a better understanding of the dynamics of Shroom-Rock interaction and 
ultimately cell morphogenesis. Overall, elucidating the Shroom-Rock interaction has helped 
establish an evolutionarily conserved signaling module as a paradigm for cellular and tissue 
morphogenesis.  
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1.0  INTRODUCTION 
During embryonic development epithelial cells undergo well synchronized and dynamic 
morphogenetic movements to pattern the complex 3D architecture of different organs and tissues 
like the central nervous system, vasculature, eye and kidney. When these morphogenetic 
movements occur synchronously in a group of cells, they can promote alterations in stiffness or 
architecture that facilitate tissue invagination, bending, folding, elongation and convergent 
extension [1, 2]. Although all these tissues are derived from polarized epithelial cells, they each 
undergo a unique morphogenetic program that defines their association and interaction with 
other cells to form different structures with distinct organization and function. Therefore any 
impairment in the cell’s ability to execute the correct morphogenetic program results in myriad 
human birth defects and diseases involving formation of the neural tube, vasculature, eye and 
kidney.  
At the cellular level this remodeling is brought about by spatially and temporally 
regulating the dynamics and organization of the cytoskeleleton. A wide array of cytoskeleton 
associated proteins have also been implicated in regulating cell behavior like adhesion, 
migration, shape and polarity that prove critical for normal embryonic development. In non-
muscle cells, the key cytoskeletal proteins actin and myosin II play a major role in altering 
epithelial cell shape by exerting cortical tension and elliciting apical constriction. Together they 
form a contractile actomyosin network whose localization and activation is tightly regulated by 
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cytoskeleton-associated proteins and kinases. This contractility of the actomyosin cable is 
dependent on the localized activation of myosinII brought about by phosphorylation of its 
regulatory myosin light chain [3]. Rho-kinase/Rock serves as the major regulator of RMLC 
phosphorylation in non-muscle cells and activates the ATPase activity of myosinII [4]. Rock 
recruitment to specific subcellular locales to bring about this localized activation of myosinII is 
however dependent on binding to various effector molecules like RhoA, lipid or Shroom3 [5-7].  
Shroom is a class of actin-binding proteins that is required for various developmental 
processes [8-14]. Shroom has the ability to regulate cell and tissue architecture by binding to 
Rock and activating the Rock-myosinII pathway [11, 15]. This Shroom-Rock interaction triggers 
a phosphorylation cascade that leads to the formation of a circumferential contractile actomyosin 
network that ultimately brings about change in cell shape and behavior. Though much is known 
about the downstream events of this Shroom-Rock signaling module, there is no sequence or 
structural homologs for the domain of Shroom that interacts with Rock and therefore the 
molecular mechanism and dynamics of this interaction still remain elusive. My dissertation aims 
to dissect the molecular nature of the Shroom-Rock interaction to unravel the basis for cellular 
and tissue morphogenesis and the spatio-temporal regulation of cytoskeletal dynamics.  
1.1 EPITHELIAL MORPHOGENESIS 
Epithelial cells are typically characterized by a monolayer of polarized cells with a distinct apical 
surface facing a lumen, a lateral surface adjoining neighboring cells and a basal surface that 
connects with the underlying extracellular matrix. Cellular adhesion encompasses stable but 
dynamic interactions which are important for maintaining tissue integrity, transducing 
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extracellular signals as well as integrating cytoskeletal dynamics across a tissue, especially 
during embryonic development when the tissue undergoes dramatic changes in morphology. 
During embryogenesis cells undergo highly coordinated morphogenetic movements like 
invagination, convergent extension, elongation, and tube formation that lead to the formation of 
complex structures of different tissues and organs (Figure 1C).  
At the cellular level, these morphogenetic processes are driven by cytoskeletal proteins 
actin and motor protein myosinII. Localized activation of myosinII via phosphorylation of its 
regulatory light chain in conjunction with actin filaments forms a contractile actomyosin 
meshwork that exerts cortical tension and generates force required to transform a columnar 
shaped cell into wedge shaped form [2, 16] (Figure 1A). Regulation of the localized assembly 
and activation of this contractile actomyosin network proves crucial for different cell processes 
like adhesion, migration, division, polarity and cell morphology. As each cell connected to its 
neighbors, pulls the plasma membrane inward it cumulatively causes coordinated apical 
constriction across the epithelial sheet that leads to tissue bending (Figure 1B). Epithelial 
morphogenesis thus serves as the basis for tissue remodeling and its regulation is important for 
coordination of these complex and dynamic changes during embryonic development (Figure 1C). 
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 Figure 1 : Epithelial morphogenesis forms the basis for cellular and tissue remodeling 
A). Epithelial cell shape change at the individual cell level. 
B). Bending of flat epithelial cell sheet due to contraction of apical actomyosin network.  
C). Morphogenetic movements in a group of cells causes remodeling of the cytoskeletal 
architecture leading to patterning of complex 3D structures of different organs. Images of 
different organs adapted from online google image. 
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1.2 ROLE OF THE CYTOSKELETON IN CELLULAR AND TISSUE 
MORPHOGENESIS 
Spatiotemporal regulation of cytoskeletal dynamics is imperative for precise coordination of 
morphogenetic movements during embryonic development and organogenesis. Actomyosin 
networks, the key mediators of this process, can thus have ramificatons at both the cellular level 
and the organismic level. A combination of these two levels of cytoskeletal regulation can help 
understand the molecular mechanics of how cells change shape and regulate tissue architecture. 
The sections below will elaborate on the structure of this contractile apparatus of cells and how 
actomyosin dynamics can influence cell bahavior and development. 
1.2.1 Actomyosin Contractility 
The cytoskeleton forms the basic supporting framework of cells. This framework is composed of 
actin filaments, microtubules and intermediate filaments each with unique functions that can 
either impart mechanical strength, direct intracellular transport or determine cell shape and guide 
locomotion. The actin and microtubule filaments however cannot function without the motor 
proteins myosin, kinesin and dynein which regulate assembly of these cytoskeletal filaments 
spatially and temporally. Molecular motors like myosin utilize the energy of ATP hydrolysis to 
either pull actin filaments together or deliver cargo along these polymerized filaments. 
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Actin and myosinII are the major cytoskeletal proteins that bring about cell and tissue 
morphogenesis. Actin monomers are globular proteins (G-actin) which polymerizes in a head to 
tail fashion to form helical filamentous actin (F-actin) [17]. These filaments are structurally polar 
with a fast growing plus end and a depolymerizing minus end (Figure 2A). Actin filaments 
underlie the plasma membrane of cells and hence their dynamic nature can influence cell shape 
and behavior, migration, adhesion and contractility. MyosinII is a heteromer composed of two 
heavy chains (MHC), two essential light chains (MLC) and two regulatory light chains (RMLC). 
Each heavy chain consists a globular head domain followed by a short neck region and an 
extended coiled-coil region that mediates heavy chain dimerization (Figure 2B). The MLC and 
RMLC bind close to the MHC head and neck regions and the long coiled-coil region forms tail-
tail interactions with other myosin molecules to generate a large thick bipolar filament [18]. 
Non-muscle myosinII is an actin-based motor that can bind to ATP, undergo a conformational 
change and utilize the energy from ATP hydrolysis to walk towards the plus end of an actin 
filament. By virtue of its opposing orientation of the heads in the thick filament the movement of 
the myosin motor effectively slides oppositely oriented actin filaments towards each other [19] 
(Figure 2C). This leads to contraction of the F-actin fibers generating tensile forces on the 
adhesion structures to which they are attached that can cause cell shape changes. On expending 
this energy from ATP hydrolysis actin filament dissociates from myosin. This cyclical actin 
binding and force generation motor activity of myosinII is greatly enhanced by phosphorylation 
of the Ser19 residue of the RMLC [20, 21] which alters the conformation of the myosin heavy 
chain and increases flexibility at the head-neck junction of myosin facilitating actin binding and 
stimulation of ATPase activity [22]. 
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Several kinases have been implicated in the phosphorylation of RMLC including myosin 
light chain kinase (MLCK), Rho-associated kinase (Rock), p-21 activated kinase [23], citron 
kinase, integrin-linked kinase (ILK), myotonic dystrophy protein kinase-related cdc42-binding 
kinase (MRCK) and death-associated protein kinases (DAPK) and its dephosphorylation by 
myosin phosphatase targeting subunit (MYPT) [21, 24-28]. The major contributors being 
MLCK, Rock, and its dephosphorylation by MYPT [21, 24-31]. All these kinases phosphorylate 
either Thr18 or Ser19 or both and cause myosinII activation, however the mode of myosinII 
activation differs with each kinase [32]. Of the three different isoforms of myosinII namely A, B 
and C, myosinIIA shows increased stroke activity due to increased rate of ATP hydrolysis 
whereas myosinIIB binds to actin in a force generating state for a prolonged time to maintain 
tension [33, 34]. 
The localized activation of myosinII by kinases and subsequent actin binding leads to the 
formation of a contractile actomyosin network in cells. These tensile forces when communicated 
across a cell sheet, brings about tissue morphogenesis. Thus tissue sculpting requires a fine 
balance between contractility and stiffness of the extracellular matrix which is achieved by 
spatial and temporal regulation of the actomyosin activity. 
 7 
 Figure 2: Actomyosin motors in cell contractility 
A) Process of nucleation of monomeric globular actin and formation of polymerized 
polarized filamentous actin. Nucleation and branching web formation by the ARP 
complex (depicted in green). Adapted from Molecular Biology of the Cell, Fifth 
edition, Bruce Alberts et al. 
B) Myosin motors: composed of two heavy chains and four light chains.  
C) Oligomerized myosin bipolar filament and contractile stroke action due to ATPase 
activity causing sliding of actin filaments towards each other. 
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 1.2.2 Role of actomyosin in cellular morphogenesis 
1.2.2.1 Stress fiber formation 
Stress fibers are bundles of antiparallel actin filaments with intermittent insertion of myosinII 
and forms an actomyosin based contractile network in cells (Figure 3). Various actin-myosin 
based contractile proteins like tropomyosin, α-actinin, filamin and others play a major role in 
bundling and maintenance of stress fibers as well as formation of cell-matrix adhesion sites 
called focal adhesions [35-37]. Rho proteins are known to be major modulators of organization 
of actin filaments including formation of stress fibers and focal adhesions [38, 39]. Of the known 
downstream effectors of RhoA, Rock and mDia have been shown to cooperatively activate 
myosinII to induce actin reorganization and formation of stress fibers [40]. Overexpression of 
Rock induces the formation of stress fibers and focal adhesions in several cell types [38, 41, 42] 
however they are not identical to Rho-induced stress fibers [43]. GTP-bound Rho activates mDia 
by disrupting its intramolecular interactions. mDia alone induces thin loosely bundled actin 
stress fibers in the absence of Rock. Additionally active mDia transforms Rock-induced 
condensed actin fibers into structures more reminiscent of Rho-induced stress fibers. Thus mDia 
and Rock work concurrently downstream of Rho during stress fiber formation [40]. It is the 
combinatorial effect of both Rock and mDia that leads to the formation of organized contractile 
actomyosin bundling in stress fibers [40]. While Rock induces formation of actomyosin stress 
fibers, mDia localizes to focal adhesion where it is involved in nucleating actin filaments [44]. 
Inhibiting either mDia or Rock activity leads to disruption of stress fiber and focal adhesion 
formation [45-48]. 
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Stress fibers are important determinants of cell dynamics. They impart tissue rigidity that 
is important for cellular remodeling during morphogenetic movements. They are important for 
establishment of cell-matrix connections through termination in dense plaques called focal 
adhesions. Stress fibers also help endothelial cells sustain shear stress due to blood flow by 
maintaining a smooth luminal surface [49]. Rock mediated phosphorylation of myosin regulatory 
light chain enhances its actin-binding and actin-induced ATPase activity thereby triggering 
contractility. As myosin is highly efficient in crosslinking F-actin the enhanced binding of 
myosin to actin by virtue of its phosphorylated state promotes reorganization of actin filaments 
into higher order structures namely actin bundles or stress fibers and formation of focal 
adhesions. Therefore actomyosin contractility is the key step in the formation and assembly of 
stress fibers and focal adhesions [50]. 
1.2.2.2 Cell migration 
Cell motility and locomotion is a complex process involving coordinated activity of cytoskeletal, 
membrane and adhesion systems. Directional cell motility is characterized by forward 
protrusions, substrate attachment and tail retractions [51, 52]. F-actin is required for each step of 
the cycle and its spatio-temporal regulation by specific binding proteins and myosin motors is 
required to perform such diverse mechanical functions. Cells form actin based finger like 
projections called filopodia or wave like protrusions called lamellopodia at the leading edge and 
makes contact with the substratum (Figure 3). Adhesion to the substrate triggers tail retraction 
allowing the cell to migrate in a specific direction. As one can imagine this forward protrusion, 
traction and retrograde retraction is mediated by dynamic polymerization and depolymerization 
of the underlying actin cytoskeleton in the cell. 
 10 
Protrusive structures like filopodia or lamellopodia at the leading edge of the cell are 
highly dynamic being composed of dense arrays of actin filaments. They are organized with their 
barbed/plus/growing ends oriented towards the direction of protrusion. Protrusion of the 
membrane is tightly coupled to actin polymerization. Actin polymerization or nucleation is 
brought about by Arp2/3 and profilin in the lamellipodium and myosinII does not seem to be 
essential for its formation [53-55]. The lamellopodium, along with actin rich adjoining lamellum, 
undergo retrograde actin flow that counteracts actin polymerization at the leading edge of the 
lamellipodium. Inhibiting myosinII activity collapses the lamellum and delays frontal protrusion 
of the cell [54]. On the other hand, excessive myosinII activity also impedes cell migration [56]. 
Adhesion to the substratum via formation of focal adhesion contacts exerts traction that balances 
these two opposing forces, the frontal protrusion and retrograde actin flow resulting in net 
protrusive activity [57]. MyosinII plays a major role in the formation and maturation of these 
focal adhesions utilizing other cytoskeletal proteins like vinculin and talin [58-60]. These focal 
adhesion sites therefore serve as a ‘molecular clutch’ to generate forces required for forward 
directional protrusion and effective migration [61]. 
The two different isoforms of myosinII, A and B have exclusive roles in cell motility and 
migration. MyosinIIA is dynamic and localizes to frontal protrusions as well as at the cell rear to 
mediate retraction and adhesion disassembly. MyosinIIB on the other hand, is non-dynamic and 
mediates actin cross-linking to establish front-back polarity in the cell [62, 63]. This differential 
localization of the two isoforms of myosinII ensures different actin dynamics at the front and 
rear of the cell. MyosinII inhibition deforms cell shape and causes cell elongation as they fail to 
undergo tail retraction [64]. MyosinII mutant mice embryos exhibit embryonic lethality 
stemming from brain, cardiac, and endodermal maturation defects or simply cell adhesion 
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defects further confirming the importance of the cytoskeleton during normal development [65, 
66]. Germ line ablation of the two different isoforms of myosinII in mice has revealed different 
phenotypes, thereby suggesting their unique functional roles. Also, knocking-in alternate 
myosinII isoform into a myosinIIA or IIB deficient mice partially rescues the developmental 
defects however they are still embryonic lethal [67, 68]. These results thus suggest a partially 
overlapping but non-redundant function of the different isoforms of myosinII. Several studies 
have noted differences in RNA expression patterns in tissues, intracellular localization 
biochemical properties and modes of regulation between the different myosin II isoforms [69-
73]. However it is hypothesized that the actomyosin dependent contractile apparatus of cells 
requiring only the actin cross-linking ability of myosinII and is not isoform specific [74]. 
1.2.2.3 Cell division 
Cell division is a precisely regulated process ensuring equal distribution of genetic material 
between two daughter cells. The dynamic nature of the cytoskeleton tightly controls the fidelity 
of this process both spatially and temporally. Cytokinesis begins after the segregation of the 
sister chromatids in anaphase and is marked by the assembly and appearance of a contractile ring 
called the cleavage furrow at the equator of the cell cortex. Contraction of this contractile ring 
results in the pinching off and formation of two daughter cells at the end of telophase (Figure 3). 
MyosinII is the primary motor protein responsible for cytokinesis [75, 76]. Myosin activation by 
phosphorylation of its regulatory light chain (RMLC) at residues Thr18/Ser19, allows it to 
interact with actin filaments to assemble a contractile actomyosin complex required for cell 
division [77]. RMLC phosphorylation also favors filament formation apart from filament 
assembly [22, 78, 79]. Genetic experiments using different model systems have shown the 
critical role of RMLC phosphorylation in cell division [3, 80]. Additionally, activated 
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phosphorylated myosin accumulates at the equator of a dividing cell after chromosomal 
segregation [81]. RMLC activation is tightly regulated by several kinases and phosphatases. 
Localized activation of myosin involves a tight balance between positive phosphorylation and 
negative dephospohrylation. Of the previously mentioned kinases, MLCK, Rock, citron kinase 
and MYPT are the key candidate regulators found to be localized to the cleavage furrow [82]. 
Therefore cells employ different kinases and phosphatases to regulate RMLC phosphorylation 
spatially and temporally to reorganize the cytoskeleton at the cleavage furrow for efficient cell 
division. 
 
1.2.2.4 Cell adhesion 
Cell adhesion is critical for integrating signals for cytoskeletal rearragements required for 
different morphogenetic processes as well as transition between mesenchymal and epithelial 
behavior. The adhesive properties of a cell, whether it needs to make cell-cell contacts via tight 
junctions or adherens junctions or anchoring to the underlying extracellular matrix via focal 
adhesions, requires F-actin [83, 84] (Figure 3). A tight balance between actomyosin networks 
and Ras superfamily of GTPases (Rho, Rac and Cdc42) is required to promote and maintain cell 
adhesion.  
In epithelial cells localized activation of Rac induces formation of actin-based filopodial 
projections enriched with a transmembrane adhesion protein E-cadherin, which extend into 
neighboring cells and establish nascent cell-cell contacts along with other actin binding proteins 
like α-catenin, vinculin, Mena, VASP and formin-1 [85-88]. Rac indirectly activates Cdc42 and 
Arp2/3, known actin polymerizing agents, via phosphatidylinositol 3-kinase and creates cellular 
contacts through extensive E-cadherin interactions [88]. Rac and Cdc42 also activate Par6 and 
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aPKC, key components of cell polarity machinery to form epithelia specific cell-cell adherens 
junctions [89]. RhoA mediates E-cadherin based cell adhesion through Rock and Dia1 [90]. 
Actomyosin networks play a formative role in mediating cell adhesion and tissue 
organization. Knocking down myosinIIA leads to loss of E-cadherin and beta-catenin 
localization to cell adhesion sites in both cell culture and intact embryos [65]. Further, myosinII 
isoforms have been shown to mediate distinct functions required for cell adhesion and tissue 
integrity [91]. MyosinII is also required for adherens junction formation and maintenance and 
involves key actin binding proteins like vinculin and α-catenin that serve as mechanosensors for 
remodeling cell-cell junctions [92, 93]. 
1.2.2.5 Cell polarity 
Cell polarity refers to spatial differences in shape, structure and function of cells. Epithelial cells 
grow as monolayers on a flat surface comprising tightly adherent cells via structures like tight 
junctions, adherens juctions and desmosomes and anchored to an underlying extracellular matrix 
by focal adhesions. When grown in three-dimension, like in collagen gels these cells form cysts 
with a central lumen. Epithelial cells exhibit either an apical-basal polarity or planar cell polarity 
or mostly both. Establishment of apical-basal polarity requires asymmetric distribution of 
membrane associated protein complexes like Par3-aPKC-Par6-Cdc42, Scribble or Crumbs to 
tight junctions to maintain polarization by interacting with cytoskeletal elements and separating 
apical and basal domains of the cell [94-98]. Planar cell polarity is mediated by yet another 
signaling pathway comprising Wnt, Frizzled, Dishevelled and its various tissue specific 
downstream targets [99-107]. These multiple cell polarity complexes execute their function by 
regulating and reorganizing the cytoskeleton (Figure 3). Rho-GTPases like Rac and Cdc42 have 
also been shown to play a formative role in establishment and maintenance of polarity [108-111]. 
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1.2.2.6 Cell morphology 
Cell shape changes like apical constriction, apical-basal lengthening or shortening and cell 
elongation are required universally by different species during development [112-114].  
Actomyosin networks are required for these behaviors and when this shape change occurs 
synchronously in a group of neighboring cells it can alter the geometry of a tissue [16] (Figure 
3). The actomyosin cytoskeleton is composed of networks of actin filaments cross-linked by 
myosinII. MyosinII oligomerizes in a tail-to-tail fashion to form bipolar filaments that allow anti-
parallel actin filaments to be pulled towards each other thereby generating a contractile or tensile 
force. These tensile forces when transmitted across neighboring cells through cell-cell junctions 
or cell-matrix focal adhesions, brings about change in cell shape and tissue architecture [115]. 
Apico-basal cell elongation is sometimes concomitantly accompanied with apical 
constriction in different organisms [116-118]. Microscopy as well as pharmacologic inhibitor 
studies have shown microtubules to be the key cytoskeletal component in cell elongation [116, 
119-121]. γ-tubulin, the key promoter of microtubule nucleation possibly plays an important role 
in cell elongation by organizing robust parallel array of microtubules that drive apicobasal cell 
lengthening [120]. 
1.2.2.7 Wound closure 
Individual epithelial cells function in the context of the entire epithelium where tissue integrity 
poses to be a crucial requirement for cell function. Closure of wounds or tissue lesions involves 
coordinated cell migration into the wound as well as cell adhesion. This epithelial resilience is 
mediated by thick actomyosin cables at the leading edge of the wound that function as a purse-
string in drawing cells together and closing the wound [122, 123] (Figure 3). Differential 
recruitment of myosinII as a contractile ring in tight junctions near the apical surface of the cell 
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or basally in lamellopodia immediately after wounding has been shown to be responsible for 
wound healing in polarized epithelial cells. Also Rock seems to be the primary effector molecule 
mediating this actomyosin dynamics in wound healing [124]. The tight junction protein ZO-1 
performs multifaceted roles as it localizes to apical myosinII to initiate purse string contractions 
at the leading edge during the wound healing process and regulates localization and assembly of 
cell polarity proteins for directional cell migration [125]. 
 
1.2.2.8 Vesicular transport 
Intracellular transport by random vesicle diffusion would be slow in a crowded cytoplasmic 
environment of a cell. Therefore a cell needs molecular motors to assist in the delivery of 
specific vesicles to assigned destinations. Cytoskeletal motor proteins associate with their 
filament tracks and move unidrectionally along these tracks by utilizing energy from ATP 
hydrolysis.  There are three groups of cytoskeletal motor proteins: myosins which associate with 
actin filaments and kinesin and dyneins which are microtubule motor proteins. The structural 
similarity of myosin and kinesin motor domain core indicates a common evolutionary origin of 
these motor proteins. Although kinesin and dynein are the most well known mediators of 
intracellular transport of membrane enclosed vesicles, myosin motors have a significant role in 
organelle transport along actin filaments. MyosinV was the first to be shown to mediate 
intracellular transport of membrane bound pigment granules called melansomoes to the 
overlying keratinocytes of the skin [126]. Actin filaments provide the track for vesicle transport 
in the endocytic pathway [127, 128] whereas myosin motors utilizes this actin track as a scaffold 
for transporting the cargo inside a cell (Figure 3). The myosin superfamily of molecules is 
characterized by a globular motor domain and a α-helical rod domain in the heavy chain [129]. 
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The motor domain binds to actin filaments in an ATP-dependent manner whereas the rod domain 
oligomerizes to form a coiled-coil that can bind to different cargo thus forming an intracellular 
transport system where the myosin can walk along the actin filament [130, 131]. The coil-coil 
domain also tethers multiple motor domains to facilitate processive transport along the actin 
filament. This intracellular transport machinery is fueled by the host of GTPases of the endocytic 
machinery and it is probable that regulation of actin dynamics or myosin via the Rho-Rock 
pathway can play a role in vesicular trafficking [132]. 
 
Figure 3: Role of Actomyosin contractility in cellular morphogenesis 
Contractile actomyosin network forms the basis for various cell processes. Diagrammatic 
representation of some of them has been shown above. Actomyosin networks/filaments are 
labelled red and nucleus by turquoise circles. 
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 1.2.3 Role of actomyosin in development.  
The ability of the cytoskeleton to respond to external as well as internal cues to elicit changes 
within a single cell or a field of cells proves critical for the normal progression of development. 
This remodelling of the cytoskeletal architecture serves as the core of many morphogenetic 
programs. Fully activated and tightly regulated actomyosin networks thus emerge as a recurring 
theme in different developmental processes, some of which are discussed below. 
 Neural tube closure is a complex morphogenetic process involving well synchronized 
and coordinated cell movements that involve extensive reorganization of the cytoskeleton. The 
crucial role of the cytoskeleton in this process has been explicitly demonstrated by cytochalasin 
treatment (a potent disruptor of actin) experiments where mice embryos exhibit cranial 
exencephaly, a signature neural tube closure defect caused by loss of an intact actin cytoskeleton 
[133-135]. During vertebrate eye development formation of a contractile actomyosin network is 
essential for lens formation, eyelid closure, failure of which leads to eye open at birth phenotype 
(EOB), and various eye deformities [136, 137]. Gut morphogenesis is yet another example of 
orchestrated action of Rho/Rock/myosinII mediated cellular rearrangements for proper tube 
lengthening and luminization [138]. Axon guidance and neurite tail retraction are all mediated by 
tight regulation of actin polymerization and depolymerization where actomyosin networks prove 
indipensable for proper neuronal architecture and function [139-141] and also for immunologic 
function of the natural killer (NK) cell [142]. Tissue vascularization or sprouting of blood vessels 
from existing ones is an important event in development. Angiogenesis is brought about by the 
leading migrating tip cell forming filopodial extensions to provide guidance cues for directional 
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migration [143]. VEGF, a tip cell specifying morphogen, works via activation of Rho GTPases 
namely Rac, Cdc42 and RhoA to induce tip cell migration [144, 145]. Abrogating RhoA or Rock 
activity blocks VEGF mediated cytoskeletal rearrangements and prevents angiogenesis [146, 
147]. Also Rock negatively regulates sprouting in a myosinII dependent pathway [148]. 
Glomerular epithelial cells of the kidney known as podocytes are critical determinants of normal 
kidney function. Podocytes form actin-rich projections known as foot processes required for 
effective glomerular filtration and kidney function. Specialized myosin motors, in conjunction 
with actin, form these foot processes, thereby illustrating the role of the cytoskeleton in normal 
kidney development and function [149-152]. Germ line ablation of myosinII isoforms in mice 
leads to embryonic lethality with severe brain, cardiac, and endodermal maturation defects or 
simply cell adhesion defects, further confirming its importance during normal development [65, 
66]. Lastly, Drosophila, an excellent invertebrate model system, portrays the importance of 
actomyosin based contractile networks in myriad cellular functions and tissue morphogenetic 
events like ventral furrow invagination, dorsal closure, compartmentalization and germ band 
extension [16, 113, 153-155].  Thus precise spatio-temporal regulation of cytoskeletal dynamics 
proves crucial for proper embryonic development. 
1.2.4 Regulation of actin cytoskeleton by the Rho-family of GTPases 
There are different pools of actin in a cell. The variety of actin networks in a cell must undergo 
remodeling to bring about epithelial morphogenesis. This reorganization of the cytoskeleton is 
mediated by actin binding proteins and nucleation promoting factors. The Rho-family of small 
GTPases regulate a variety of these actin binding proteins, kinases and polarity proteins to 
regulate cell behavior like adhesion, migration, polarity and proliferation. Rho family GTPases 
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act as molecular switches cycling between an inactive GDP bound form and an active GTP 
bound form to interact with downstream effectors in transducing signaling pathways [156, 157]. 
GTP hydrolysis by GTPases is accelerated through interactions with GTPase activating proteins 
(GAPs) causing Rho inactivation whereas Rho activation is facilitated by guanine nucleotide 
exchange factors (GEFs) that exchanges GDP for GTP [158, 159]. The GTP or GDP bound to 
Rho GTPase dictates its affinity towards its downstream targets leading to very specific effector 
recognition in the ‘on’ state only [160]. Another means of GTPase regulation comes in the form 
of guanine-nucleotide dissociation inhibitors (GDIs), which block effector activation by binding 
to GDP-bound GTPases and prevent nucleotide exchange [161].  
The Rho family of GTPases namely RhoA, Rac1 and Cdc42 have been shown to be key 
cytoskeletal regulators based on overexpression studies in Swiss3T3 fibroblasts. RhoA induced 
stress fibers and focal adhesions formation, Rac1 caused flat lamellipodial projections and Cdc42 
induced filopodial extension [39, 162-164]. Therefore it is important that the cortical actin is 
tightly regulated. This regulation of actin polymerization is orchestrated by Rho GTPases. To 
date the Rho GTPases have been shown to play a role in numerous actin-dependent cellular 
processes such as platelet aggregation, lymphocyte and fibroblast adhesion, cell motility, 
contraction and cytokinesis [165]. Thus these observations indicate that Rho regulates 
cytoskeletal dynamics in a cell by linking extracellular stimuli to the reorganization of the actin 
cytoskeleton. The different external stimuli that can activate Rho GTPases are signaling through 
receptor tyrosine kinase (RTK), lysophosphatidic acid (LPA), integrins and cadherins [166-168]. 
As stated above Rho induces formation of focal adhesions in addition to stress fibers. However it 
is currently debatable whether the two are sperate or inter-dependent events. 
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Rac also transduces a similar type of signaling pathway and can mobilize the 
cytoskeleton to generate lamellipodia or membrane ruffles. Rac signals to a complex of proteins 
called the WAVE or SCAR complex (a member of the WASP family of proteins) consisting of 
Arp2/3 activating protein WAVE, two Rac binding proteins (Nap125 and PIR121), HSPC and 
Abi2 [169, 170]. Active Rac causes this complex to dissociate resulting in derepression of 
WAVE and enhancing Arp2/3 actin polymerization and induce branched actin networks as found 
in lamellipodia [171, 172]. Rac is also able to signal through other serine threonine kinases like 
PAK, which signals to downstream effectors to promote actin polymerization and stabilization of 
existing actin filaments [157].  
Both Rac and Cdc42 have been shown to induce assembly of multimolecular focal 
complexes at the plasma membrane of fibroblasts [163]. These complexes are morphologically 
distinct from Rho-regulated focal adhesions though the protein components of both complexes 
appear similar. Moreover other labs have shown the involvement of Rac in cell motility in 
MDCK cells [173], actin and microtubule polymerization towards antigen-presenting cells [174], 
control of cytokinesis in fibroblasts, HeLa cells and Xenopus embryos [175-179]. WASP binds 
to Cdc42 in a GTP-dependent manner and links it to the actin cytoskeleton via another adaptor 
protein [180, 181]. Furthermore, over expression of WASP induces ectopic actin polymerization 
that could be blocked by dominant-negative Cdc42, suggesting that WASP-induced cytoskeletal 
rearrangements are controlled by Cdc42 [181]. Several potential targets of Rac and Cdc42 have 
been identified to date and several of them bind to both Rac and Cdc42.  Though current 
evidence suggests that Rock is a downstream effector for RhoA only and not Rac and Cdc42, it 
is not surprising that the Rho-family signaling pathways often converge to either directly activate 
each other or utilize common downstream targets to elicit a response. 
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 1.3 APICAL CONSTRICTION AND NEURAL TUBE MORPHOGENESIS 
Apical constriction will be used to demonstrate how specific alterations in cytoskeletal 
organization and contractility can drive cell shape change during a developmental process. 
1.3.1 Apical Constriction 
A phenotypic readout of localized actomyosin contractility is apical constriction. Cells 
undergoing apical constriction exhibit dynamic apical enrichment of activated myosinII that 
colocalizes with actin filaments at the adherens junctions at the apical boundary of the cell. 
Together they form a contractile actomyosin cable, which undergoes pulsatile contractions to 
constrict the apical surface of cells, transforming a columnar shaped cell with roughly equal 
apical and basal surface into a wedge shaped form with narrow apical surface and wide 
basolateral surface. However these pulsatile contractions need to be stabilized for maintaining 
tension and retaining tissue integrity. Different models of epithelial morphogenesis have 
described these pulsatile contractions at the apical junctional complex to be a ratchet mechanism 
for maintaining tension across the cell sheet needed for tissue remodeling in fruit flies [182-184].  
Apical constriction is widely utilized by polarized epithelial cells. In an epithelial layer, 
when this shape change occurs synchronously in a group of cells, it can cause cell sheet bending 
with a concave apical surface and convex basal surface. This leads to sheet invagination, tube 
formation and internalization of cells. Apical constriction forms the basis of many 
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morphogenetic events like gastrulation in invertebrates such as nematodes [185], sea urchins 
[186], Xenopus [187, 188]  and Drosophila [189]. In Drosophila, apical constriction is also 
required for dorsal closure, eye development, formation of the salivary gland and tracheal tubes, 
ventral furrow formation and internalization of mesoderm [117, 190-193]. During vertebrate 
morphogenesis apical constriction is required for neural tube closure [194-196], lens placode 
formation and primitive streak formation [197]. Thus apical constriction is a conserved process 
used by different organisms for altering cell shape during embryonic development. In most of the 
above outlined cases Rho-GTPases and Rock activate myosinII and triggers formation of a 
contractile actomyosin network [198-205]. Thus, though these developmental processes differ 
greatly in their upstream regulators, actin and myosinII form the central effectors in bringing 
about apical constriction 
One of the most widely studied examples of cells undergoing extensive morphogenetic 
movements is the process of neural tube closure which will be discussed next. 
1.3.2 Neural Tube Morphogenesis 
Neurulation is a critical event in the development of the vertebrate central nervous system. The 
neural tube serves as the embryonic precursor to the brain and spinal cord and failure of its 
closure leads to congenital malformations classified as Neural Tube closure Defects (NTDs). 
While less common in the developed world, NTDs including spina bifida and excencephaly are 
among the most common birth defects worldwide affecting approximately 1 in 1,000 child births 
[206-208]. While over 200 genes have been implicated in neural tube morphogenesis in mice, a 
clear understanding of the etiology of human NTDs has remained elusive [208-210]. 
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The process of neurulation starts with a flat sheet of neural epithelial cells called the 
neural plate undergoing concerted morphogenetic movements to bend and form lateral folds. 
Further bending of the neural plate as a result of apical constriction of neural epithelial cells 
leads to formation of dorsolateral hinge points, elevations of the lateral folds and juxtaposition of 
the folds across the dorsal midline that fuse to form a closed neural tube [208-212] (Figure 4). 
Fusion of the neural folds is initiated at discrete locations along the neural axis and proceeds in a 
zipper-like fashion towards the anterior and posterior directions. The anterior part of this closed 
tube forms the brain and the posterior part becomes the spinal cord. Cranial NTDs cause 
anencephaly or exencephaly whereas caudal NTDs cause spina bifida [208-212]. 
The intrinsic forces driving neurulation are orchestrated by the contraction of the 
subapical actin microfilaments of the neural epithelial cells [213-217]. Inhibitor studies using 
cytochalasin, have shown the dependence of cranial neural tube closure on actin microfilaments 
[134, 135, 218]. Thus it has been suggested that this extensive morphogenetic event relies 
heavily on dynamic reorganization of the cytoskeletal components to provide necessary force 
and tension for proper closure of the neural tube. Indeed mutations in various cytoskeletal 
regulator proteins such as Nap1 [219], Abl1/2 [220], p190RhoGap [221], Mena/profilin [222], 
Vinculin [223], NF1 [224], paladin[225], Epb4.1l5 [226, 227] and Marcks [228], all cause neural 
tube defects.  
Shroom3, is a member of one such class of cytoskeleton-associated or actin-binding 
proteins that is required for neural tube closure [11]. Shroom3 induces apical constriction in 
neural epithelial cells and is required specifically for hingepoint formation during neural tube 
closure [195]. A detailed description of individual members of the Shroom family of proteins can 
be found in the following section. 
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Figure 4: Neural Tube Morphogenesis 
Process of neural tube closure a.k.a. neurulation whereby the neural plate undergoes 
complex morphogenetic movements to bend and form lateral folds which elevate and 
fuse along the dorsal midline to form a closed neural tube (Smith and Schoenwolf, 
1997) 
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 1.4 SHROOM-FAMILY PROTEINS 
Shroom comprises a family of actin-binding proteins that are key regulators of the cytoskeleton 
and are implicated in different developmental processes. There are four family members in 
vertebrate Shroom which were originally named as Apx [229], Apxl [230], Shroom [11] and 
KIAA1202 [231] and later renamed as Shroom1, Shroom2, Shroom3 and Shroom4 respectively 
[232]. All the above mentioned Shroom family members are important mediators of epithelial 
morphogenesis during development [233]. 
Shroom proteins are characterized by some signature sequence motifs that are required 
for its localization and conserved in vivo activity. They possess an N-terminal Psd-95/DlgA/ZO1 
(PDZ) domain, followed by a serine/proline rich region [10], a centrally located Shroom 
Domain1 (SD1) (except Shroom 4) and a highly conserved C-terminal Shroom Domain2 (SD2) 
[11] (Figure 5). The SD1 binds directly to F-actin and causes Shroom3 localization to the 
adherens junctions of cells whereas the SD2 is required for Shroom-mediated contractile activity 
[11, 231, 234].  All Shroom proteins identified to date bind both Rock (a serine-threonine kinase) 
and F-actin [9, 11, 15, 195, 234-236]. Shroom3, the best characterized member from this family 
has been shown to bind and bundle F-actin and recruit Ena/Vasp proteins to the zonula adherens 
of epithelial cells to induce apical constriction [11-13, 237].  Other Shroom family members 
differ in their actin-binding properties and subcellular localization [234]. Shroom2 and 
invertebrate Drosophila Shroom binds to cortical actin while Shroom4 localizes to a punctate 
cytoplasmic pool of F-actin [234, 235, 238]. Shroom3 can induce apical constriction in polarized 
epithelial cells whereas Shroom2 or Shroom4 lack this ability [234]. dShroom isoforms can 
induce varying degrees of apical constriction, depending on their subcellular distribution, and 
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their ability to  bind Rock and assemble organizationally distinct actomyosin networks at specific 
locales [235]. This unique function of the different Shroom family members can be attributed to 
its differential subcellular localization conferred by association with distinct compartments of the 
actin cytoskeleton. However, all Shroom proteins reorganize the actomyosin network via a 
conserved interaction with another cytoskeleton regulator protein, Rock [5, 235]. 
 
 
Figure 5: Shroom family of Proteins 
A) Schematic representation of different domains of Shroom3, secondary structure 
prediction and conservation profile of SD2. PDZ: Psd-95/DlgA/ZO1, SPR: 
Serine Proline rich region, MBR: Myosin Binding Region, ABR: Actin 
Binding Region, SD1: Shroom Domain 1, SD2: Shroom Domain 2.  Secodary 
structure predicts Shroom3 SD2 to be mostly α-helical represented by 
magenta bars A-G. Predominance of yellow bars in the sequence conservation 
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profile of SD2 across different Shroom SD2 constructs represents a highly 
conserved C-terminal region (helices D-G) and a slightly less conserved N-
terminal region (helices A-C). 
B) Comparison of domain structure of different Shroom family members. Numbers 
correspond to percentage identity of mouse proteins to mShroom3. dShroom 
= Drosophila Shroom. 
 
1.4.1 Shroom3 
Shroom3 was identified in a gene trap mutagenesis screen in mice where embryos homozygous 
for this mutant allele exhibited extensive NTDs including exencephaly, acrania, spina bifida, 
facial clefting and ventral closure defects resulting in organ herniation [11]. In these mutant 
embryos, the cranial neural folds, instead of converging and fusing along the dorsal midline, 
‘mushroom’ out and have a poorly formed lumen [11]. The importance of Shroom3 in neural 
tube closure has also been demonstrated in other model systems like Xenopus and chick embryos 
[5] where morpholino mediated knockdown of xShroom3 or over expression of dominant-
negative xShroom3 caused NTDs [195]. The neural epithelial cells that form the hingepoint 
undergo robust apical constriction and it is this cell shape change that ensures proper neural plate 
bending and elevation of neural folds critical for neurulation. Dominant-negative expression 
experiments in Xenopus have shown that inhibiting Shroom3 activity leads to failure of 
hingepoint formation, and subsequent errors in neural tube closure [195]. Shroom3 is sufficient 
to induce apical constriction in polarized epithelial cells in both cell culture and in the Xenopus 
blastula [195]. Apical constriction is thought to be brought about by contractile forces exerted by 
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a subapical actomyosin network in neural epithelial cells.  Shroom3 mutant mice embryos do not 
show an apical enrichment of myosinII which can therefore explain the loss of apical constriction 
as well as failure of neural tube closure [15]. The defects caused by Shroom3 mutation however 
do not affect other apects of cell bahavior like proliferation, cell survival or tissue patterning, 
thereby demonstrating the critical role of Shroom3 in neural tube morphogenesis in vertebrates 
[11, 15, 195]. 
Shroom3 binds to F-actin, localizes to the apical junctional complex (AJC) of MDCK 
cells and forms a circumferential apical ring at the tip of adherens junctions of neural epithelial 
cells. In these cells, Shroom can induce apical constriction and apico-basal lengthening without 
perturbing apical-basal polarity [15, 195, 233]. However, in MDCK cells, not every cell 
expressing Shroom3 apically constricts, rather some constrict and the neighboring ones expand 
their apical surface and form taut tight junctions to balance the tension and maintain integrity of 
the monolayer [15]. However, in a mixed polulation of cells or in spheroidal cysts Shroom3 
expressing cells show robust apical constriction and form clusters [15]. The apically constricting 
cells  show an enrichment of actin filaments at the apical surface of cells thereby demonstrating 
that Shroom can redirect actomyosin distribution and modulate cytoskeletal organization for 
bringing about cellular morphogenesis [15]. Microtubules are the primary causative agents of 
apico-basal cell elongation and γ-tubulin serves as the key player in regulating its assembly into 
robust parallel arrays [120, 239]. In Xenopus, Shroom3 regulates γ-tubulin distribution and 
regulates assembly of robust parallel microtubules that drive apico-basal cell elongation [227]. 
The SD1 and SD2 motifs of Shroom have unique roles. SD1 is required for Shroom 
localization mediated by direct binding to F-actin and SD2 is required for apical constriction. 
The two domains however need to be present in a cis configuration to elicit cell shape change 
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[195, 234]. The SD2, when expressed by itself is diffusely localized in the cytoplasm and fails to 
cause apical constriction. However, targeting the SD2 to the apical plasma membrane causes 
robust apical constriction [15]. These results therefore suggest that Shroom localization is 
important for its activity. 
However Shroom3 is not the only player in bringing about cell shape change. Shroom3 in 
addition to F-actin requires the molecular motor nonmuscle myosinII and another cytoskeletal 
regulator, a kinase, called Rock to bring about apical constriction [15]. The SD2 of Shroom3 
mediates Rock binding and recruits it to specific subcellular locales. Rock on being activated 
triggers a phosphorylation event that causes localized activation of myosinII, binding of actin, 
formation of a contractile actomyosin network at the apical surface of cells and subsequent apical 
constriction [5, 15]. Ectopic expression of Shroom3 or apically targeted SD2 ellicit apical 
constriction by redistributing phosphorylated myosin and actin to the apical junctional complex 
of MDCK cells or apical tip of adherens junctions of neural epitheial cells [5, 15, 234].  
Transcriptional regulators of Shroom3 identified to date are few. Pax-6, is a 
transcriptional factor expressed in the lens placode and has been shown to be essential for 
Shroom3 expression [12]. Pitx1 is another transcription factor shown to regulate Shroom3 
expression in Xenopus gut [240, 241]. In zebrafish, Shroom3 is as a transcriptional target 
downstream of FGF signaling during proneuromast assembly [236]. Some studies have also 
shown the importance of RhoA and RhoA-GEF Trio as upstream regulators in Shroom3 
mediated apical constriction [242]. 
 In addition to expression in the neural epithelium Shroom3 is also expressed in the eye, 
hindgut, foregut, lungs, kidney and somites [11] and presumably plays an important role in their 
morphogenesis as evidenced by Shroom3 mutant embryos which display defects in lens placode 
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invagination, foregut looping, neuronal architecture and function, pulmonary arterial 
hypertension [10, 12-14, 240, 243], chronic kidney disease (CKD) [23] and heterotaxy in 
humans [244]. Shroom3 can also act as a scaffold or adaptor protein by binding to Plenty of SH3 
(POSH) protein and negatively regulating axon outgrowth [14] or to Mena/Vasp via its EVH1 
domain and recruiting it to apical surface of cells [12]. Although Shroom3 has been shown to be 
required in numerous developmental processes the underlying theme of its function is universal 
where it redistributes and reorganizes the actomyosin cytoskeleton in conjunction with Rock and 
brings about cellular and tissue morphogenesis.  
1.4.2 Shroom2 
Shroom2 was first discovered in a large X-chromosomal deletion associated with the disorder 
Ocular Albinism TypeI (OA1) [230, 245]. OA1 is characterized by retinal hypopigmentation, 
visual impairment and defective melanosomes. Shroom2 is upstream of the OA1 gene but its 
direct involvement in the disease still remains to be established. The retinal pigmented 
epithelium (RPE) is a layer of epithelial cells that prevents light scattering within the retina 
[246]. RPE mediates this function by melanosome pigmentation during retinal development. 
Many genes have been identified to play a role in melanosome biogenesis as well as its 
localization. Mutations in these genes lead to human disorders affecting retinal development 
[247]. xShroom2 has been shown to play a role in RPE development in Xenopus [8]. Ectopic 
expression of Shroom2 in naive epithelial blastomeres causes pigment accumulation at the apical 
surface. Morpholino mediated knockdown of Shroom2 in the developing eye leads to 
hypopigmentation and loss of RPE in Xenopus, all of which can be attributed to defective 
melanosome biogenesis and localization [8]. The exact role of Shroom2 in eye development is 
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still unclear, however it presumably plays an important role in melanosome transport and 
recruitment to the apical surface of RPE by apical accumulation of γ-tubulin and assembling 
parallel array of microtubules. This activity of Shroom2 specifically requires Rab27aGTPase [8]. 
Another human pigmentation disorder Ocular Albinism with Sensorineural Deafness (OASD) for 
which no causative mutation has been identified to date, also maps to the same X-chromosomal 
deletion region as OA1. The Shroom2 locus lies within the critical region for these albinism-
associated disorders, its loss of function leads to RPE pathologies similar to that found in patients 
with OA, and Shroom2 is expressed in the retina of mice [234, 248]. So it is possible that 
Shroom2 is a contributing factor in normal human visual system function [249, 250]. A Shroom2 
mutant mouse to look at the developmental defects associated with Shroom2 loss in vivo will 
greatly advance these studies. 
Shroom2 has also been shown to bind to myosin VIIa, an unconventional myosin 
abundantly present at cell-cell junctions [248]. Mutation in myosin VIIa causes Usher syndrome 
characterized by congenital deafness and retinitis pigmentosa [251, 252]. Shroom2 binding to 
myosin VIIa proves dispensable for Shroom2 localization as myoinVIIa mutant shaker-1 mice 
exhibit correct Shroom2 localization to tight junctions of hair cells [248, 253]. Since both 
Shroom2 and myosin VIIa are expressed in the inner hair cells of the ear they serve as interesting 
candidates in the development of auditory disorders associated with mutations in these genes 
[254, 255]. 
Shroom2 is also expressed in the vasculature, gut, neural tube and kidney and other 
epithelial tissues [8, 9, 233, 234, 248]. In the vascular endothelium Shroom2 binds to cortical 
actin for proper subcellular localization at the tight junctions. Rock and myosinII have been 
shown to be critical determinants of vascular architecture as inhibition of myosinII or Rock 
 32 
promotes endothelial sprouting and angiogenesis [148, 256-258]. This negative regulatory effect 
of Rock and myosinII is thought to be due to cortical tension that prevents membrane protrusions 
and migration [148]. Shroom2 also plays a role in promoting contractility and regulating 
endothelial morphogenesis as depleting Shroom2 in vascular endothelia decreases Rock and 
myosinII activity and promotes endothelial sprouting and angiogenesis [9].  
Previous work has shown that the PDZ domain along with the Serine/Proline rich region 
is required for efficient Shroom2 localization to tight junction of MDCK cells [234]. Results 
from a yeast two hybrid screen using the PDZ/SPR region of Shroom as bait against an inner ear 
cDNA library identified ZO-1 as an interacting partner of Shroom2 in the tight junctions [248]. 
The mechanism of Shroom2 localization at tight junctions is a little confounding as it is not 
dependent on the PDZ domain but on the SPR domain, although the PDZ domain is a common 
domain for scaffolding and tight junction proteins and shares substantial identity between 
different Shroom proteins [11, 248]. A closer investigation into the specific roles of the different 
domains of Shroom proteins in Shroom function is necessary for delineating the exclusive and 
overlapping roles of different Shroom family members. 
1.4.3 Shroom4 
Gross defects in morphogenesis can cause lethality however subtle defects in morphogenesis 
during development can still be tolerated though they can cause non-lethal debilitating diseases. 
Mental retardation is one such example of subtle impairment in neural development affecting1-
3% of the world’s population [259]. Over 10% of these cases have been attributed to gene 
mutations or chromosomal abnormalities in the X-chromosome and are collectively termed as X-
linked Mental Retardation  (XLMR). Of the different gene mutations that have been linked to the 
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development of XLMR, one of the most prominent categories involves gene products that 
regulate actin dynamics including several Rho effectors and actin binding proteins [260]. 
Additionally XLMR patients have shown X-chromosomal aberrations and several mutations 
within the Shroom4 locus [231]. Since Shroom4 is an actin-binding protein involved in myosinII 
dependent reorganization of the actin cytoskeleton required during vertebrate adult and foetal 
brain development, it is quite probable that it plays a crucial role in cognitive function and 
development [238]. Since Shroom4 is prominently expressed in different embryonic and adult 
structures like lung, neural epithelium, kidney and developing vasculature, it will be interesting 
to characterize Shroom4 and its interaction with upstream and downstream effector molecules to 
elucidate its role in normal vertebrate development.  
 
1.4.4 Shroom1 
One of the least characterized member of the Shroom family of proteins is Shroom1. It was 
identified in Xenopus oocytes where it is constitutively expressed and is required for amiloride 
sensitive sodium channel (ENaC) expression [261]. hShroom1 was recently identified in a yeast 
two hybrid screen as an interacting protein to the cytoplasmic domain of a membrane bound 
protein Melanoma Cell Adhesiom Molecule (MCAM) and is involved in linking MCAM to the 
cytoskeleton [262]. hShroom1 possesses both  the signature SD1 and SD2 domains. However, 
hShroom1 SD2 shows relatively low similarity to the SD2 domain from hShroom 2, 3, 4 or the 
SD2 of xShroom1 which suggests that hShroom1 is not the human homlogue of xShroom1 
[262]. hShroom1 is widely expressed in different tissues including brain, heart, skeletal muscle, 
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colon, small intestine, kidney, placenta, lung,  melanoma cell lines and tumor tissues, however a 
clear role of Shroom1 in these tissues is yet to be established [262]. 
1.4.5 Invertebrate Shroom proteins and its evolutionary implications 
Shroom proteins have been identified in several invertebrate animal phyla like cnidaria, ascidia, 
arthropoda and echinodermata, thereby hinting at its early appearance in the animal lineage 
[234]. The putative Shroom proteins from sea squirt and sea urchin do possess a PDZ domain 
unlike Drosophila Shroom (dShroom). Yeast and Arabidopsis do not contain Shroom-like 
proteins, suggesting that Shroom may be animal specific, however nematodes like 
Caenorhabditis elegans and flatworms Schmidtea mediterranea do not possess any Shroom 
homologs. Phylogenetic analysis of SD2 sequences in vertebrates suggest that a duplication of 
the ancestral Shroom gene gave rise to two homologs, one that became Shroom4 and the other 
duplicated again to give rise to Shroom2 and Shroom3 [234]. Of all the invertebrate Shroom 
proteins characterized to date dShroom is the most thoroughly characterized. 
dShroom lacks the N-terminal PDZ domain but possesses a loosely conserved  central 
SD1 region and a conserved C-terminal SD2 domain [234, 235]. Two isoforms of dShroom, 
namely a longer dShroomA and a shorter dShroomB, are detected with dShroomA being the 
more abundant one. These isoforms exhibit different subcellular localization with dShroomA 
localizing to adherens junctions and dShroomB to the apical plasma membrane. This differential 
distribution can be attributed to differences in their N-termini where they employ different 
mechanisms for localization. dShroomA utilizes its SD1 to directly bind to F-actin and localize 
to the adherens junctions of cells. Since the shorter dShroomB isoform lacks this actin binding 
motif it localizes elsewhere [235]. Apart from differential localization, the isoforms exhibit 
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different functions, for example whereas dShroomA fails to elicit apical constriction in MDCK 
cells dShroomB induces apical constriction. Overexpression of dShroomA in the fly dorsal 
ectoderm induces apical constriction by aseembling a cicumferential actomyosin network 
whereas dShroomB assembles a disorganized actin network at the apical surface [235]. Over 
expression of either isoform in the Drosophila in the dorsal ectoderm leads to improper dorsal 
closure as a consequence of aberrant apical constriction of cells over expressing dShroom. 
Similar to vertebrate Shroom, dShroom induced apical constriction is mediated by apical 
enrichment of activated myosinII and F-actin at the adherens junctions. These Shroom mediated 
cytoskeletal reorganizations are Rock dependent and in vitro studies have indicated a direct 
interaction between dShroom SD2 and dRock [235]. These results suggest that the Shroom-Rock 
signaling module has been evolutionarily conserved and may serve as a paradigm for cellular and 
tissue morphogenesis. 
1.4.6 Conserved domains of Shroom implicated in Shroom localization and activity 
Shroom proteins are typified by the presence of signature sequence motifs, namely the N-
terminal PDZ domain, the centrally located SD1 and the C-terminal SD2. Not all Shroom family 
members possess the PDZ or the SD1 motifs. However, strikingly all Shroom family members 
possess the C-terminal highly conserved SD2 and can regulate myosinII activity via this domain. 
Though only Shroom3 can cause apical constriction in polarized MDCK cells, other Shroom 
family members acquire the same capacity when their SD2 domain is apically targeted [234]. 
Shroom2, or Shroom4 by itself fail to elicit actomyosin based apical constriction however 
chimeric versions of Shroom protein encoding the N-terminal portion from Shroom3 and SD2 
from any of the other Shroom proteins can induce apical constriction in MDCK cells. This 
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suggests that the SD2 from any Shroom members is capable of activating the constriction 
pathway provided they are localized at the apical surface of cells and the difference in function 
between the different Shroom members is due to their differential distribution in cells [234]. 
Shroom directly interacts with Rock via the SD2 and this interaction recruits Rock to specific 
subcellular locales [5], whereby Rock can phospohrylate RMLC and induce assembly of a 
contractile actomyosin network. Thus as evidenced above Shroom mediated changes in cell 
morphology are Rock and myosinII dependent. A detailed discussion of the cytoskeletal 
regulator Rock, follows next to better understand the interplay of Shroom-Rock and the 
cytoskeleton in bringing about cellular and tissue morphogenesis. 
1.5 RHO-ASSOCIATED KINASE/ROCK 
Rho-associated coiled-coil kinase or Rock, is a downstream target of the small GTPase Rho and 
is involved in reorganization of the actin cytoskeleton [41]. It was identified biochemically as a 
binding partner for RhoA-GTP [6, 263, 264]. Rock is a serine/thereonine kinase and is 
characterized by an N-terminal catalytic domain, a central coiled-coil region containing the 
Shroom Binding Domain (SBD) and the Rho binding Domain (RBD) and a C-terminal 
Pleckstrin Homology domain [265] split by a cysteine rich region. Structural insights into the 
above mentioned domains of Rock have shown it to be a parallel coiled-coil homodimer [266, 
267].  
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1.5.1 Rock1, Rock2 and dRok 
Vertebrate Rock is encoded by two different genes, Rock1/RockI/Rho-kinase β/p160-Rock and 
Rock2/RockII/Rho-kinase α. Rock1 and 2 share an overall 65% sequence identity with 92% 
identity in their kinase domains [41, 264, 268, 269]. Rock1 and 2 are both ubiquitously 
expressed in most mouse and rat tissues. However, Rock2 is more abundantly expressed in 
skeletal muscle and brain whereas Rock1 is found in the tissues of the lung, liver, heart, stomach, 
spleen, kidney, placenta and testis [268]. The C-terminus of Rock has been shown to negatively 
regulate Rock activity [270]. In that context Rock1 and Rock2 are differentially regulated by 
either caspase cleavage or granzyme B mediated cleavage of the C-terminus, respectively [271, 
272]. Rock1 and 2 have been shown to play different roles during development. Rock1-/- mice 
exhibit defects in closure of eyelids and ventral body wall leading to Eye Open at Birth (EOB) 
phenotype and omphalocoele [136] whereas Rock2-/- mice display intrauterine growth 
retardation and fetal death due to placental dysfunction [273]. However, it was further shown 
that backcrossing Rock2 knock out mice resulted in Rock1 knock out phenotypes namely EOB 
along with umbilical herniation [137]. These data suggest that Rock1 and 2 have some specific 
roles but function redundantly in regulating the assembly of actin bundles essential for closure of 
the eyelid and ventral body wall in mouse embryos. In support of this, embryos heterozygous for 
either Rock1 or Rock2 showed no abnormal phenotype whereas Rock1+/- Rock2+/- compound 
heterozygotes showed EOB and omphalocoele phenotypes [137]. Also Rock1-/- Rock2-/- double 
mutant mice are embryonic lethal dying between embryonic day 3.5-9.5, but Rock1-/- Rock2+/- 
or Rock1+/- Rock2-/- embryos show impaired yolk sac vasculature [274]. Based on the above 
results and lack of information on Rock isoform specific substrates, it is presumed that Rock1 
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and Rock2 have largely redundant functions and will therefore be henceforth referred as simply 
Rock.  
Drosophila possesses a single dRok gene which is homologous to vertebrate Rock [275, 
276]. It contains a similar conserved N-terminal kinase domain which is 74% identical to 
hRock1, a central coiled-coil domain containing the Shroom binding domain (SBD), Rho 
binding domain (RBD) and a C-terminal split Pleckstrin homology (PH) domain which is 31% 
identical to human Rock PH domain. dRok has been shown to be a downstream effector of 
Drosophila Rho1 [275, 276]. dRok is ubiquitously expressed throughout embryogenesis, 
indicating a significant maternal contribution [275]. Embryos that are zygotic null for dRok do 
not survive beyond the 2nd instar larval stage. Genetic analysis of loss-of-function mutation of 
dRok in the form of somatic clones of dRok2 generated by recombination have revealed a role of 
dRok in Frizzled-Dishevelled, planar cell polarity pathway, to regulate ommatidial rotation 
during eye development and restrict actin bundle formation in fly wing [276]. dRok has also 
been shown to be essential for tissue morphogenesis during multiple aspects of oogenesis [277] 
during dorsal closure, ventral furrow formation and germ band extension [265]. dRok mediates 
these functions by phosphorylating the RMLC of myosin in Drosophila [278], thereby 
demonstrating the conserved mechanism which dRok employs to direct asymmetric cytoskeletal 
organization and cell polarity in fruit flies. 
1.5.2 Rock domain structure and regulation 
The N-terminal kinase domain is the most conserved region with 92% sequence identity between 
Rock1 and Rock2 [41] (Figure 6). Crystallographic studies have elucidated the structure of the 
kinase domain to be arranged into a head-to-head homodimer. Each monomer comprises an N-
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terminal α-helical domain which aids in dimerization, a bilobed kinase domain, with a typical 
Ser/Thr kinase fold and a kinase tail. This dimerization domain links the two monomers together 
and spatially arranges the kinase active sites and regulatory sequences on a common face 
facilitating access to both kinases simultaneously for interaction with dimeric substrates or 
inhibitory domains [267]. Rock kinase domain shares close similarity to the PKA kinase domain 
and resembles the catalytically competent conformation of PKA in that its active sites are 
arranged similarly to PKA kinase domain active sites [267, 279]. However, unlike PKA, Rock 
does not exhibit phosphorylation of its serine or threonine residues in the activation loop 
suggesting a phosphorylation independent mode of activation [267]. 
Immediately following the kinase domain is an extended central coiled-coil region. 
Previous work by the Takeichi lab had identified amino acids 698-957 in the central coiled-coil 
region to physically interact with SD2 of Shroom3 and both Rock1 and 2 can bind equally well 
to the SD2 [5]. This region was named the Shroom binding domain (SBD) of Rock. Importantly, 
this region of the coiled-coil region is distinct from the Rho binding domain which spans amino 
acids 934-1015 [5]. This extended helical coiled-coil region exhibits high sequence conservation 
across different species thereby suggesting that it serves as a binding platform for Shroom, 
however it is important to map the boundaries of this domain and identify the critical residues 
mediating the Shroom-Rock interaction (Figure 6). 
In close proximity to the SBD is a 79 amino acid long domain called the Rho-binding 
Domain (RBD) (amino acids 934-1015) that marks the end of the coiled-coil region of Rock 
[280]. This region contains a Rho-binding motif and binds specifically to the GTP-bound form of 
RhoA (Figure 6). The RBD contains two patches, amino acids 934-945 and 1005-1015, that 
seem to play a role in Rho recognition and binding [280]. The structure of Rock RBD indicates 
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that it forms a coiled-coil homodimer with differences in the N-terminal and flexible central 
portions of the coiled-coil but strong similarity in the C-terminal portions between the two Rock 
isoforms [281, 282]. Mutational studies have identified critical residues in the C-terminal part of 
the RBD that are important for mediating Rho-Rock interaction [41, 280-282]. The structure of 
the RhoA-Rock complex shows that the C-terminal portion of the RBD dimer binds to the switch 
regions of RhoA in a complementary manner and this interaction is primarily mediated by 
hydrophobic interactions [281].  
Rock proteins remain in an auto-inhibited, folded inactive state. This autoinhibitory 
conformation is thought to be mediated by intramolecular interactions between the N-terminal 
kinase domain and the C-terminal domain containing the RBD and PH domains of Rock forming 
a head-to-tail closed, catalytically inactive state [267] (Figure 7). One of the most extensively 
studied examples of effector activation by small GTPases is the Cdc42-PAK interaction, where 
Cdc42 binding to PAK induces a conformational change in PAK resulting in its disassociation 
and phosphorylation to an activated state [283]. The hydrophobic interactions at the Cdc42-PAK 
interface resembles the hydrophobic interactions between RhoA-Rock [283, 284]. It can 
therefore be hypothesized that RhoA-GTP binding to Rock relieves the autoinihibitory 
conformation of Rock and renders it catalytically active. Indeed there is evidence that RhoA-
GTP physically interacts with Rock RBD and activates Rock [6, 263]. Though the SBD and 
RBD of Rock are in close proximity to each other, Shroom and RhoA bind independently and 
simultaneously to the respective domains without competing with each other [237]. 
The C-terminal region of Rock contains a Pleckstrin Homology Domain (PH) domain 
(Figure 6). The structure of PH domain of Rock2 shows a canonical PH fold composed 
predominantly of β-sheets and is split into two halves by insertion of an internal cysteine-rich C1 
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domain [7]. Contrary to other known C1 domain proteins Rock lacks the phorbol ester/DAG 
binding motif and probably does not bind to these proteins [7]. Interestingly Rock2 lacks the 
signature phosphoinositide-binding motif and instead possesses a flat positively charged surface 
made up of seven basic amino acids that mediate lipid membrane binding [7]. Thus lipid binding 
to the PH domain of Rock not only activates it but also localizes Rock subcellularly [269, 285]. 
The C-terminus of Rock acts as a negative regulator of Rock activity and Rock activation 
can be brought about by enzymatic cleavage of the C-terminus [271, 272]. The C-terminal PH 
domain of Rock has been implicated in mediating this autoinhibitory function by establishing 
intramolecular interactions with the N-terminal kinase domain, rendering Rock catalytically 
inactive [270]. Rock activation can also be brought about by lipid binding to the PH domain such 
as Arachidonic acid [256] and phosphatidyl-inositol triphosphate (PIP3) [269, 285].  
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 Figure 6: Rho-associated kinase 
A) Schematic representation of different domains of Rock, its disordered profile and 
sequence conservation across SBD. The numbers denote the amino acid 
residues spanning that domain. SBD: Shroom Binding Domain, RBD: Rho 
Binding Domain, PH: Pleckstrin Homology Domain. Disordered profile of 
hRock1 SBD spanning amino acids 685-943. Peaks are representative of 
disordered regions and troughs are representative of ordered regions. hRock1 
SBD fragment spanning amino acids 834-913 is the most ordered and shows 
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highest sequence conservation represented by yellow bars in the sequence 
conservation profile. 
B) Comparison of domain structure between human Rock and Drosophila Rock. 
Numbers indicate percentage identity between different Rock proteins. 
1.5.3 Rock activation 
Rock shares 44% sequence identity to myotonic dystrophy kinase and remains in a similar  
folded autoinhibitory conformation mediated by intramolecular interactions between the N-
terminal kinase domain and the C-terminal region rendering the kinase non-functional [270, 
286]. This autoinhibiotry C-terminal region comprises of the SBD, the RBD and the PH domain 
of Rock [266, 270]. Several lines of evidence support the negative regulation of Rock activity by 
this autoinhibitory C-terminal region. First, deletion or proteolytic cleavage of the C-terminus of 
Rock constitutively activates Rock [41, 271, 272]. Second, binding of lipids especially 
Arachidonic acid, to its PH domain [287] relieve this intramolecular inhibition and activate 
Rock. Third, DynaminI, a membrane regulator protein involved in protein trafficking has also 
been shown to bind to the PH domain of Rock and induce its catalytic activity [288]. Finally, the 
C-terminal region of Rock acts as a dominant-negative and inhibits constitutively active form of 
Rock [270]. Lastly, binding of small effector molecules or proteins to the autoinhibted region [4, 
6, 263, 264, 289] induces Rock activity [266].  
However, there is also a well known repository of proteins that negatively regulate Rock 
function. Gem and Rad, GTP binding proteins of the Ras superfamily, bind Rock independently 
in the central coiled-coil region and function as spatially regulated inhibitors of Rock activity. 
Though they do not abrogate Rock kinase activity directly, they block the downstream effects of 
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Rock activation [46]. RhoE, a member of the Rnd subfamily of GTP-binding proteins is another 
well known inhibitor of Rock. RhoE specifically binds to Rock1, and not Rock2, near the kinase 
domain and inhibits phosphorylation of its downstream targets thereby abrogating Rock function 
[47, 290]. 
Apart from the above mentioned mechanisms of Rock activation there is growing 
evidence of a Rho-independent mode of Rock activation [15, 195]. Rho binding presumably 
cooperates with Shroom in bringing about apical constriction but is not required for Shroom-
induced apical constriction [242]. Also, Shroom3 and RhoA have seperate binding sites on Rock 
and can bind to Rock simultaneously in vitro, indicating that they do not compete with each 
other [12]. Relief of intramolecular inhibition and opening up the folded autoinhibitory 
conformation seems to be the key theme for Rock activation. In addition to the known activators 
of Rock, it is possible that other protein-protein interactions in the SBD domain or other parts of 
the coiled-coil region can be potential contributors to Rock activation.  
 
Figure 7: Model of Rock activation 
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Rock remains in a folded autoinhibitory conformation mediated by intramolecular 
interactions between the N-terminal kinase domain and C-terminal region. Binding of RhoA-
GTP or lipids relieves this inhibition and renders Rock catalytically active 
1.5.4 Rock effectors and function 
Rock is a major cytoskeletal regulatory protein and it does so by bringing about localized 
activation of myosinII. The activated myosinII along with actin filaments can remodel the 
cytoskeletal architecture required for various important cell processes like smooth muscle 
contraction, formation of stress fibers and focal adhesion complexes, intermediate filament 
disassembly, neurite retraction, microvilli formation, cytokinesis, cell migration and centrosome 
positioning [38, 41, 42, 291-298]. Thus the actomyosin network needs to be tightly regulated 
both spatially and temporally. Phosphorylation at the Thr-18/Ser-19 of the RMLC allows 
myosinII to interact with actin, assembling an actomyosin network and initiating contraction. On 
the other hand removal of the phosphate moiety from this residue by myosin phosphatase 
targeting subunit (MYPT1) renders myosinII inactive [299-301]. One of the key regulatory 
mechanisms responsible for the induction of actomyosin networks is the fine balance between 
kinases that phosphorylate RMLC and MYPT1 that inactivates myosinII. Rock lies at the 
fulcrum of this balance as it can directly phosphorylate RMLC and activate its ATPase activity 
[4] and also phosphorylates and inactivates MYPT [289, 302-304], thereby increasing the 
population of activated myosinII in the cell. Rock can also phosphorylate ZIPK which can 
subsequently phosphorylate RMLC and MYPT, but its contribution in Rock-mediated 
actomyosin contractility still needs to be investigated [30]. 
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In addition to RMLC and MYPT, Rock phosphorylates other downstream targets that can 
regulate cytoskeletal dynamics. One such example is LIM kinase (LIMK), a serine/threonine 
kinase also implicated in cytoskeletal dynamics. Rock phosphorylates and activates both LIMK1 
and LIMK2 leading to phosphorylation of its downstream target ADF/cofilin [305]. 
Phosphorylation of cofilin by LIMK abolishes its actin depolymerizing activity [306]. Cofilin is 
essential for turnover of actin filaments [307, 308]. Hence there are more free ends of actin, 
which allows for more polymerization. Thus, Rock phosphorylation of LIMK, results in 
decreased cofilin activity and stabilizes F-actin. Rock also phosphorylates members of the 
Ezrin/Radixin/Moesin (ERM) family of proteins which link the actin cytoskeleton to 
transmembrane proteins in the plasma membrane [309]. The carboxyl termini of these proteins 
bind actin filaments while the amino termini bind the transemembrane proteins in the plasma 
membranes using other binding partners. ERM phosphorylation by Rock disrupts its head-to-tail 
inactive folded conformation and unmasks its protein and actin interaction domains. This 
facilitates actin filament and plasma membrane association and stabilizing the open 
conformation. This open active conformation of ERM can then act as an actin filament/plasma 
membrane linker [309-311]. The Sodium-Hydrogen-Exchanger (NHE-1), another target of Rock, 
gets activated and regulates Rho-induced stress fibers and focal adhesion formation [312-314]. 
Adducin, a filamentous protein, is phosphorylated by Rock and binds growing ends of F-actin, 
arrests polymerization and recruits spectrin. Adducin phosphorylation by Rock enhances its F-
actin binding activity and is required for membrane ruffling and cell motility [293, 315]. Rock 
also phosphorylates several sites in intermediate filament proteins such as Vimentin, glial 
fibrillary acidic protein (GFAP) and neurofilament L protein (NF-L) to induce depolymerization 
and filament disassembly during cytokinesis [294, 296, 316]. Rock phosphorylation of  other 
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actin-binding proteins like eukaryotic elongation factor 1α, myristylated alanine-rich C kinase 
substrate (MARCKS) and calponin inhibits their actin-binding function [317-320]. Rock 
mediated phosphorylation of neuronal proteins such as CRMP2 and other receptors facilitate 
axon outgrowth, growth cone collapse and cell migration [321-326]. 
Thus Rock has a plethora of downstream effector molecules mediating different functions 
but playing the central role of regulating the cytoskeletal dynamics in the cell to affect changes in 
cell shape, behavior and tissue architecture. Shroom has been shown to directly interact with 
Rock and this interaction regulate epithelial morphogenesis. A more detailed description of the 
Shroom-Rock signaling module is discussed next. 
 
Figure 8: Rock effectors and their function 
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Schematic representation of different Rock effectors and their role in the regulation of 
cytoskeletal dynamics 
1.6 SHROOM-ROCK SIGNALING PATHWAY IN CELLULAR AND TISSUE 
MORPHOGENESIS 
Vertebrate Shroom family of proteins consists of Shroom1-4, whereas most invertebrates contain 
a single Shrm gene [232].  Each Shroom family member has been implicated in regulating 
various morphogenetic events during embryonic development, including neural tube closure 
[11], remodeling of the vasculature [9], eye development [8, 12], gut morphogenesis [10, 13], 
neuronal architecture and function [14, 231], ENaC channel regulation [261], renal function [23], 
arterial hypertension [243] and heterotaxy in humans [244]. Though not all Shroom proteins 
possess all the signature sequence motifs, the highly conserved C-terminal SD2 is shared among 
all members and it is this domain that physically interacts with Rock. It is presumed that all the 
above mentioned developmental processes are orchestrated by this Shroom-Rock pathway and it 
is highly conserved between vertebrates and invertebrates [234]. Thus we think that a Shroom-
Rock signaling module operates in cells undergoing cytoskeletal remodeling and this forms the 
basis for epithelial morphogenesis during embryonic development.  
The Shroom-Rock signaling pathway entails Shroom directly binding to F-actin. This 
interaction recruits Shroom to the correct subcellular locale. Shroom then binds to the central 
coiled-coil SBD of Rock via its SD2. This Shroom-Rock interaction causes subcellular 
localization of Rock. Rock, once localized and activated, phosphorylates RMLC and MYPT, 
thereby positively increasing the population of activated myosinII in cells locally. This localized 
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phosphorylated myosinII then binds to F-actin and forms a contractile actomyosin network. All 
Shroom proteins can regulate cell morphology and tissue architecture by regulating the 
subcellular distribution of actomyosin networks and use this to elicit apical constriction or 
cortical contractility [9, 15].  
Shroom function is dependent on its correct subcellular localization as well as its ability 
to bind Rock. Shroom3 mediated apical constriction is dependent on its ability to bind both F-
actin and Rock [5, 15]. Shroom3 binding to F-actin targets it to the zonula adherens of polarized 
epithelial cells. Shroom3 can then bind to Rock via its SD2 and recruit it to the apical surface of 
cells. This results in Rock- mediated localized activation of non-muscle myosinII as described 
above. As a result, the subcellular distribution of the actomyosin network within these cells is 
reorganized to form an apically positioned contractile ring. This contractile actomyosin ring then 
exerts tensile forces at the apical surface of the cell, causing the apical surface to shrink or 
constrict transforming a columnar shaped cell into a wedge shaped one. When this cell shape 
change occurs synchronously in a group of cells, it facilitates bending or invagination that 
ultimately leads to tissue remodeling. 
Though much is known about the Shroom-Rock pathway, their role in developmental 
processes and its regulation of the cytoskeletal dynamics to bring about epithelial 
morphogenesis, a clear understanding of the molecular mechanism of Shroom-Rock interaction 
still evades us. Mapping the binding domains in both Shroom and Rock that mediates this 
interaction and determining the stoichiometry would thus prove extremely helpful in delineating 
the mechanistic details of Shroom-Rock interaction and Rock-myosinII regulation. Also, 
identification of the critical binding interface of Shroom and Rock will provide structural 
insights of the role of these residues in protein-protein interactions and Rock dimerization. An 
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interesting facet to this signaling pathway is whether the Shroom-Rock interaction is sufficient 
for Rock activation or whether Rho binding is required for the same. Rock has been shown to 
undergo both a Rho-dependent [242] and Rho-independent mode of activation [15, 195, 327] and 
since it is involved in a multitude of cell processes, a clear understanding of the different steps of 
Rock activation and localization will prove beneficial for designing Rock inhibitors for 
therapeutic purposes.  
 In order to elucidate the mechanistic details of the Shroom-Rock interaction, my project 
uses a variety of biochemical and cell based assays to dissect the molecular nature of this 
interaction. By adopting a multipronged approach to investigate the molecular dynamics of 
Shroom-Rock interaction, we hope to establish this evolutionarily conserved signaling module as 
a paradigm for cellular and tissue morphogenesis.  
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Figure 9: Shroom-Rock pathway in cellular morphogenesis 
Schematic representation of the Shroom-Rock signaling pathway operating in cells to 
bring about cellular morphogenesis 
 
 
1.7 DISSERTATION AIMS 
The Shroom-Rock pathway is essential for numerous developmental process in both vertebrates 
and invertebrates. Though much is known about this pathway, a clear understanding of the 
molecular mechanism of this interaction still remains elusive. It has been clearly established that 
different Shroom members all mediate binding to Rock via its SD2. The SD2 physically interacts 
with the central coiled-coil SBD of Rock, however the mechanistic details of this interaction 
have not yet been characterized. My project aims to understand the molecular mechanism, 
stoichiometry and global consequences of this interaction.  
Also, growing evidence suggests that Rock can undergo a Rho-independent mode of 
activation during Shroom induced apical constriction. We hypothesize two models of Rock 
activation. First, we suggest Shroom-Rock interaction proves sufficient for relieving the 
intramolecular inhibition and rendering Rock catalytically active. Second, Shroom-Rock 
interaction is required for Rock localization and Rock binding to other effector molecules, 
mainly RhoA, causes Rock activation. In order to dissect the intricacies of Shroom-Rock and 
Rho-Rock interaction it becomes imperative to map the binding domains mediating this 
interaction, namely Shroom SD2 and Rock SBD.  
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To this end, I identified amino acid residues in both Shroom SD2 and Rock SBD that are 
critical for mediating this interaction and analyzed the consequences of disrupting this interaction 
in embryonic development, especially neural tube morphogenesis. I then characterized the 
significance of the Shroom-Rock interaction in Shroom induced apical constriction and their 
contributions in Rock localization and activation. I used molecular biology techniques and 
adopted biochemical and cell based assays to analyze the molecular mechanism of Shroom-Rock 
interaction. These experiments were guided by structural studies performed by our collaborators, 
the VanDemark lab, and by the use of a novel Shroom SD2 mutant obtained from a genome wide 
ENU mutagenesis screen.  
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2.0  CHARACTERIZING THE SHROOM SD2 DOMAIN TO IDENTIFY RESIDUES 
CRITICAL FOR MEDIATING SHROOM-ROCK INTERACTION, SHROOM 
DIMERIZATION AND APICAL CONSTRICTION 
2.1 INTRODUCTION 
Shroom proteins are key regulators of cell morphology and tissue architecture. Shroom has been 
implicated in a variety of developmental processes including neural tube closure [11, 195], lens 
placode invagination, melanosome biogenesis [8, 12], gut morphogenesis [10, 13, 240], neuronal 
architecture and function in mice [14], lateral line morphogenesis in zebrafish [236] and has been 
linked to chronic kidney disease [23], pulmonary arterial hypertension [243] and heterotaxy in 
humans [244]. Shrooms proteins possess different domains that are required for its localization 
and activity. The central SD1 binds directly to F-actin and this interaction is necessary for 
Shroom3 localization to the apical surface of cells [234]. Though Shroom family members differ 
in the presence or absence of some sequence motifs, the C-terminal SD2 is highly conserved and 
is required for activity of all tested Shroom family members.  
Shroom3 bind to Rock via its SD2. This Shroom-Rock interaction recruits Rock to the 
zonula adherens of cells [5] where it phosphorylates the RMLC and locally activates myosinII. 
The activated myosin then binds to actin to form a subapical contractile actomyosin meshwork in 
the cell. Tensile forces exerted by this contractile network at the cell circumference leads to 
shrinking of the apical region of the cell, transforming columnar shaped cells to wedge shaped 
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form. This Shroom3 induced apical constriction is both Rock and myosinII dependent [15]. In 
order to elucidate the molecular mechanism and dynamics of the Shroom-Rock interaction it is 
important to define the structure of these proteins and map the residues critical for mediating this 
interaction. In collaboration with the VanDemark lab we identified the critical amino acid 
residues in SD2 that are required for Shroom-Rock interaction and the role of this interaction in 
regulating cell morphology.  
Analyzing the conservation profile of SD2 from Shroom proteins from different species 
revealed a core region of SD2 that is conserved.  I selected for amino acid residues that were 
highly conserved in this region for site-directed mutagenesis to create Shroom SD2 mutants. To 
this end I was guided by structural data from the Drosophila Shroom SD2. The dShroom SD2 
structure showed a novel fold and was a three segmented, antiparallel coiled-coil dimer. I 
generated multiple mouse Shroom3 SD2 mutants and tested their ability to bind Rock, cause 
apical constriction and activate the myosinII pathway. Using mutational analysis and other 
biochemical and cell based assays I successfully identified conserved surface exposed patches on 
the SD2 that are critical for Rock binding and apical constriction. Also we have shown Shroom 
dimerization to be important for Rock binding and Shroom function. Thus we have been 
successful in mapping the binding domain of Shroom and identifying the critical amino acid 
residues of the SD2 that mediate Shroom-Rock interaction [328]. 
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2.2 RESULTS 
2.2.1 Structure of Drosophila Shroom SD2 
The VanDemark lab solved the structure of the core dShroom SD2 spanning amino acid residues 
1393-1576 in dShroomA. Crystallization trials set up with this purified homogeneous protein 
produced cube like crystals that diffracted at 4Å. These crystals were subjected to multiple 
optimization trials to ultimately produce high quality crystals that diffracted at 2.7Å. Using these 
crystals an electron density map was generated using Coot software and the structure of dShroom 
SD2 was determined.  
The dShroom SD2 structure revealed a three-segmented anti-parallel coiled-coil 
homodimeric conformation [328]. In each monomer there is a coiled-coil helical segment that is 
twice the length of the other two short helical segments (Figure 10). The long coiled-coil 
segments wrap around each other in a dimer to form the ‘body’ segment whereas the short 
helices wrap around each other to form the ‘arm’ segments. A predominance of hydrophobic 
residues observed at the junctions between the body segment and the arm segment are thought to 
play a role in stabilizing the arm segments in this conformation. Since no structural homologs 
were found for the dShroom SD2, this arrangement of three anti-parallel coiled-coil segments 
appears to be unique [328]. 
The dShroom SD2 crystal exhibits an extended surface with several conserved patches 
that might mediate protein-protein interactions by providing a binding interface to its partner. 
Extensive coiled-coil interactions in the protein form a dimerization interface with interiorly 
buried residues composed of conserved leucines and isoleucines characteristic of leucine zippers. 
These residues are predicted to function in either Shroom dimerization or intramolecular 
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interactions required for Shroom activity.  A unique feature of this structure is the co-existence 
of symmetry as well as asymmetry in the protein.  The protein displays internal symmetry with 
one half dimer possessing all the amino acid residues that comprise one whole monomer and 
thus, each half dimer is structurally identical to the other half. The protein is shaped 
asymmetrically such that the arm segments are rotated away from each other due to a twist in the 
body segment of the dimer. We term the region separating the left and right halves of the dimer 
as the symmetry point and it exhibits a predominance of glycine and proline residues making it 
highly disordered. This geometrical uniqueness of the protein poses important biological 
implications for Shroom function and activity as it now presents two potential binding sites for 
Rock on opposite faces of the dimer.  Therefore, guided by the dShroom SD2 crystal structure, I 
designed mouse Shroom3 SD2 substitution mutants and tested their function and activity. 
 
Figure 10: Ribbon diagram of dShroom SD2 protein 
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dShroom SD2 exhibits a unique three segmented anti-parallel coiled-coil structure. It 
consists of a long coiled-coil body segment flanked by two shorter arm segments that wrap 
around each other in the dimer. Each monomer is represented by a different color.The symmetry 
point location in the dimer is indicated by a box. 
2.2.2 Making mShroom3 SD2 mutants 
Since the dShroom SD2 exhibited an extended conformation with invariant residues and 
conserved patches broadly distributed on the protein, a major concern was the ability to develop 
assays that were sensitive enough to record any perturbations caused by single amino-acid 
substitutions in the SD2. These small changes in the SD2 might not destabilize the Rock binding 
interface or the dimerization interface enough to produce measurable or observable effects. In 
order to overcome this problem we used sequence conservation as well as structural data to 
identify regions which might have the greatest impact on Shroom structure and function (Figure 
11A). We designed multi-residue variants that were either surface exposed, named Surface 
Cluster mutants (SC), or interiorly buried residues at the dimerization interface named 
Homodimerization mutants (HD) (Table 1) [328]. We hypothesized that the SC mutants target 
the Rock-binding interface and mutating them would disrupt Rock binding but not affect Shroom 
dimerization. Three patches of highly conserved residues were selected as potential candidates 
for SC mutations to be tested (Figure 11B). The HD mutants on the other hand targeted residues 
which were interiorly buried with the assumption that they are involved in Shroom dimerization 
and the structural integrity of the dimer but do not directly affect the Rock binding site. Based on 
sequence conservation and structural data, two highly conserved regions were selected as 
potential candidates mediating dimerization (Figure 11B). I created three SC mutants (one in the 
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arm segment and two in the body segment of the dimer) and two HD mutants (one in the body 
segment and the other in the arm segment) in mouse Shroom3 SD2 by site-directed mutagenesis 
(Table1). I selected for correct mutant clones based on the sequencing results and we tested them 
for their ability to bind Rock or dimerization [328].   
Mouse Shroom3 SD2 spanning amino acids 1372-1986 in pCS2-endolyn-Shroom3 
eukaryotic expression plasmid was used as a template to create the different SD2 mutants by 
site-directed mutagenesis. Since Shroom localization is dependent on F-actin binding via its SD1 
domain, using only the Shroom SD2 domain might give us erroneous results stemming from its 
mislocalization in the cell. Therefore, a chimeric version of the protein consisting of Endolyn and 
Shroom3 SD2 was used to ensure constitutive targeting of Shroom to the apical surface of cells 
irrespective of its actin-binding capacity [15]. Endolyn is a transmembrane protein that trafficks 
to the apical plasma membrane in MDCK cells and can be over expressed without altering cell 
morphology [15]. These five different SD2 mutants were transiently transfected in polarized 
MDCK cells grown as a monolayer in transwell filters and then immunostained to detect 
Shroom3 and ZO-1 using specific antibodies. For in vitro biochemical studies the mutated 
sequence encoding amino acids 1562-1986 was cloned from the Endolyn-Shroom3 vector into 
the pGex-2TK expression vector, transformed into E.coli CodonPlus (RIPL) cells and expressed 
to produce recombinant proteins, which were subsequently purified using glutathione beads. 
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 Figure 11: Alignment of Shroom SD2 protein sequence and SD2 mutants created 
A) Sequence conservation of Shroom SD2 across different species using CLUSTAL W. 
Invariant residues are highlighted in blue, while highly conserved residues are 
highlighted in pink. Sequence of each SC and HD mutants are indicated by boxes. 
B) Ribbon diagram of dShroom SD2 dimer showing the SC and HD mutants created. 
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 Table 1: Sequence and position of mouse Shroom3 SD2 mutants created 
Name mShroom3 SD2 mutant sequence Position in the dShroom SD2 structure 
SC1 1766KKAEL1770 1766AKARA1770 Surface exposed 
SC2 1840SLSGRLA1846  1840ALEADLE1846 Surface exposed 
SC3 1878LKENLDRR1885  1878AAENLDDA1885 Surface exposed 
HD1 1832LLSL1835  1832AASA1835 Interiorly buried 
HD2 1915LLIEQRKL1922  1915ALIEQAKA1922 Interiorly buried 
 
 
2.2.3 Residues in central coiled-coil body segment of Shroom SD2 are important for 
Shroom-Rock interaction 
In order to test the ability of the Shroom SC and HD mutants to bind Rock, we performed an in 
vitro pull down assay using glutathione beads. The Shroom SD2 mutant proteins were expressed 
as GST-fusion proteins and added to glutathione beads. Purified human Rock SBD protein was 
added in solution and incubated at room temperature for 1 hour and the complex resolved on a 
12% SDS- PAGE gel and then stained with Coomassie Blue. The wild type Shroom3 SD2 
protein can bind Rock and both protein species are detected in the bead fraction. The SC1 mutant 
behaves similarly to WT SD2 in being able to bind Rock, however all other SC and HD mutants 
fail to bind Rock and Rock can be seen only in the supernatant fraction with Shroom3 in the bead 
fraction (Figure 12). Thus the data clearly suggests that the surface exposed residues in the 
Shroom3 SD2 body segment SC2 and SC3 play a role in Rock binding whereas the surface 
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exposed residues in the SD2 arm segment, SC1, seem to be dispensable for Rock binding [328]. 
The HD mutants also fail to bind Rock, indicating that disrupting the Shroom-Shroom 
dimerization interface affects Shroom’s ability to bind Rock and implies that the Rock-binding 
interface on Shroom SD2 is composed of residues from both chains of the dimer. Alternatively 
the HD mutant protein might be non-functional due to its structural deformity and proteolytic 
sensitivity and hence fail to bind Rock. 
Our data suggest that the Rock-binding interface is molecularly conserved with surface 
exposed residues within the SD2 body segment playing a critical role in Rock binding whereas 
the conserved residues in the arm segment are dispensable for Rock binding. 
 
Figure 12: The Rock binding interface in Shroom SD2 is composed of surface exposed residues in the 
body segment of the SD2 protein 
GST-tagged versions of WT or mShroom SD2 mutants were tested for their ability to 
bind Rock via an in vitro pull-down assay. WT or mutant SD2 proteins were bound to 
Glutathione beads and Rock added in solution.  The ability of the WT or mutant Shroom SD2 
proteins to bind Rock was assayed by resolving the pellet and supernatant fraction to detect 
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bound complexes by SDS-PAGE. Quantification of the amount of Rock bound to Shroom was 
assessesed using ImageJ software and represented as percentage. This experiment was performed 
by Ryan Rizaldy. 
2.2.4 Interiorly buried residues in Shroom SD2 are required for Shroom dimerization 
These mShroom3 SD2 mutants were next tested for their dimerization ability with the prevailing 
hypothesis that the surface exposed residues are probably required for mediating Shroom-Rock 
interactions whereas the interiorly buried residues are required for dimerization and do not affect 
the Rock binding interface.  All five different GST-tagged mShroom3 SC and HD mutants were 
bound to glutathione beads and untagged mShroom3 SD2 added in solution and incubated for 1 
hour at room temperature. The bound complexes were then resolved on a 12% denaturing SDS–
PAGE gel and stained with Coomassie blue. As expected, the WT mShroom3 SD2 protein bound 
to Shroom3 SD2 to form dimers whereas the HD mutants failed to dimerize. The SC mutations 
on the other hand did not impair Shroom3 dimerization (Figure13). Similar results were obtained 
with dShroom SD2 mutants using in vitro pull down assays, crosslinking assays and native gel 
mobility shift assays [328]. Since HD mutants failed to bind Rock as well as dimerize, our data 
suggests that Shroom dimerization is critical for Rock binding but not the other way around. 
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 Figure 13: Shroom homodimerization mutants fail to dimerize and abrogate Rock binding 
GST-tagged versions of Surface Cluster or Homodimerization mutants were tested for 
their ability to bind untagged mShroom SD2 using a GST-pull down assay. As evident, the HD 
mutants fail to dimerize whereas the dimerization ability of SC mutants remain unaffected. 
Quantification of the amount of untagged Shroom bound to GST-Shroom was assessesed using 
ImageJ software and represented as percentage. This experiment was performed by Ryan 
Rizaldy. 
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2.2.5 Shroom-Rock binding is essential for apical constriction and myosinII activation 
In order to assess the importance of these amino acid residues in the Rock-binding interface or 
dimerization interface in mediating Shroom induced changes in cell morphology, we transiently 
transfected WT or mouse Shroom3 SD2 mutants in a pCS2-endolyn-Shroom3 eukaryotic 
plasmid into polarized MDCK cells. MDCK cells were grown as a monolayer on transwell filters 
and 24 hours post transfection, cells were stained with tight junction marker ZO-1 and anti-
Shroom3 antibody to assess Shroom3 expression and apical constriction (Figure 14A). The WT 
as well as Shroom3 mutant proteins were apically localized in the cell as evidenced by Shroom3 
staining and distribution of ZO-1 indicative of apical boundaries of the cell. In accordance with 
the in vitro results, the SC1 mutant that retained the ability to bind Rock showed apical 
constriction, whereas the remaining SC and HD mutants that failed to bind Rock, also failed to 
elicit apical constriction in MDCK cells (Figure 14A). Western blot analysis using anti-Shroom 
antibodies confirmed comparable expression of WT and mutant mShroom3 SD2 proteins, 
thereby suggesting that the phenotypic effect of loss of apical constriction is due to disruption in 
the Rock-binding interface of Shroom and not due to insufficient protein expression or protein 
degradation (Figure 14B). 
Apical constriction is brought about by localized activation of myosinII by Rock. 
Phosphorylation of the regulatory myosin light chain at Thr-18/Ser-19 is the key step of myosinII 
activation and is considered as a readout of activated myosinII. This phosphorylated RMLC 
along with F-actin forms a contractile actomyosin network at the apical surface of the cells that 
exerts tension to apically constrict the cell surface. In order to assess whether these mShroom3 
surface cluster or homodimerization mutants are capable of activating the Rock-myosinII 
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pathway mShroom3 WT or SD2 mutants were transiently transfected into MDCK cells and 
stained with anti-Shroom antibody and pMLC to assess for an enrichment of activated myosinII 
in cells expressing Shroom proteins. Confirming our in vitro binding results and apical 
constriction assay, the SC1 mutant behaved similarly to WT in exhibiting apical recruitment of 
activated myosinII at the apically constricted cell surface whereas all other surface cluster or 
homodimerization mutants that failed to induce apical constriction failed to show apical 
enrichment of pMLC (Figure 14C) [328]. Collectively, the data suggest that Rock binding is 
critical for Shroom induced apical constriction and this apical constriction activity is dependent 
on both Rock and myosinII. Thus alterations that disrupt the Rock-binding interface or the 
dimerization interface in Shroom negatively affect its apical constriction activity. 
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Figure 14: Rock binding is essential for Shroom mediated apical constriction 
A). Endolyn tagged WT or mutant Shroom3 SD2 were transiently transfected in MDCK 
cells and stained for ZO-1(red) and Shroom3(green). The cells expressing either WT or mutant 
Shroom3 proteins are indicated by arrow heads. Scale bar 20 μm. 
B). Western blot from cell lysates transfected with either WT or mutant mShroom3 SD2 
was performed using anti-Shroom3 antibody. Blot was reprobed using anti-tubulin antibody to 
verify equal protein loading. 
C). Endolyn tagged WT or mutant Shroom3 SD2 were transiently transfected in MDCK 
cells and stained for pMLC (red) and Shroom3 (green). Apart from SC1 mutant, no other mutant 
can elicit apical constriction and recruitment of active myosinII when targeted to the apical 
membrane in MDCK cells. Scale bar 20 μm. This experiment was performed by Dr.Jeff 
Hildebrand. 
 
2.2.6 The Shroom-Rock binding interface is evolutionarily conserved 
The C-terminal SD2 domain of Shroom is highly conserved across species [11, 234]. Drawing 
inference from the sequence conservation of Shroom SD2 across different species, equivalent 
mutations were made in Drosophila Shroom SD2 by the VanDemark Lab. Similar biochemical 
assays performed with the dShroom SD2 SC and HD mutants recapitulated the above results 
obtained with mShroom3 SD2 [328]. The dShroom SC1 mutant retained the ability to bind 
dRock whereas all other dShroom SC and HD mutants failed to bind dRock. The dShroom HD 
mutants failed to dimerize whereas dimerization capacity was not affected in the SC mutants 
when assessed by crosslinking assays using glutaraldehyde or native gel mobility shift assays 
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[328]. Chimeric version of Endolyn-dShroom SD2 when transfected in MDCK cells also 
triggered apical constriction. Thus the Rock-binding interface is evolutionarily and molecularly 
conserved and the Shroom-Rock pathway seems to be the universal signaling module employed 
by cells undergoing apical constriction. 
2.3 DISCUSSION 
2.3.1 The Shroom SD2 possess a unique fold with implications in Shroom structure and 
function 
Solving the structure of the SD2 provided a wealth of testable hypotheses regarding the function 
of the SD2 motif. The Drosophila Shroom SD2 protein exhibited a unique fold consisting of an 
antiparallel dimer composed of three helical segments; a long coiled-coil body segment flanked 
by two short arm segments. Guided by the sequence conservation profile and the structural data, 
several conserved patches of residues were selected for mutation. In order to achieve the greatest 
impact of these mutations on Shroom structure and function multiple residues were targeted 
simultaneously. Given the large extended dimerization interface and the broad distribution of 
conserved patches, two classes of mutants were created; residues which were either surface 
exposed, and presumably implicated in Rock binding, and residues which were interiorly buried, 
and proposed to mediate Shroom dimerization. 
Results from the mouse Shroom3 SD2 mutants suggest that among the conserved surface 
exposed patches, amino acid residues in the body segment of the protein mediate Rock binding, 
whereas conserved residues in the arm segment are not involved. The anitparallel nature of the 
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Shroom SD2 structure suggests that these surface patches lie on opposite sides of the molecule. 
Importantly, abrogation of Rock binding also affects Shroom’s ability to induce apical 
constriction and results in a loss of activated myosinII enrichment at the apical surface of cells. 
As for the HD mutants, the dimerization interface is extended such that different mutations 
targeting the coiled-coil in either the body segment or the arm segment disrupt Shroom 
dimerization. However, it is difficult to predict whether these interiorly buried patches affect 
dimerization of the whole Shroom protein or just the structure of the SD2 domain. Structural data 
on other domains of Shroom or the protein as a whole still awaits discovery. Importantly these 
HD mutants are also defective for Rock binding and eliciting apical constriction, thereby 
suggesting that perturbing the Shroom-Shroom dimerization interface has dramatic consequences 
on its ability to bind Rock. Thus, the Rock-binding site on SD2 is probably made up of amino 
acid residues from both chains of the dimer, and the SD2 motif should retain the ability to both 
dimerize and bind Rock in order to trigger apical constriction. Interestingly the internal 
symmetry in the dShroom SD2 dimer suggests that there are two independent but identical Rock-
binding sites. One half of the SD2 dimer is structurally identical to the other half and contains 
both the Rock-binding sites and should be competent for Rock binding. Alternatively, it can be 
proposed that each Shroom monomer can fold back on itself at the symmetry point to form a half 
dimer. In that case, the internal patches are still necessary for the monomer to fold properly and 
position conserved residues on the SD2 surface into an orientation competent for Rock binding. 
Similar biochemical results obtained with Drosophila Shroom SD2 mutants suggest that the 
Rock-binding interface has been both evolutionarily and molecularly conserved with important 
functional and biological implications [328]. 
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2.3.2 Molecular models of Shroom-Rock complex formation 
Other biochemical assays have elucidated the stoichiometry of Shroom-Rock binding to be in a 
1:1 molar ratio and the binding affinity of Shroom-Rock interaction to be 0.58μM [328]. This 
quantification has prompted us to suggests two different models of the Shroom-Rock interaction. 
Previous studies have elucidated the structure of other regions of Rock including the kinase 
domain, PH domain, portions of the central coiled-coil domain, RBD domain and a RhoA-RBD 
complex to be a parallel coiled-coil homodimer [7, 267, 281, 282, 329-332]. It is therefore 
reasonable to predict that the SBD of Rock also forms a parallel coiled-coil homodimer. In view 
of its parallel coiled-coil structure it would suggest that there exists two independent Shroom 
binding sites in Rock SBD. With the identification of distinct surfaces required by Shroom for 
Rock binding or dimerization and its presence as a dimer, a probable mode of Shroom-Rock 
binding might be opening up of individual dimers and annealing to form a Shroom-Rock 
heterodimer (Figure 15A), however it is energetically unfavorable and conformationally 
impossible to position the two Rock-binding sites, each on a half-dimer of Shroom, to align with 
the two independent Shroom binding sites on the parallel coiled-coil of Rock SBD.  
It is difficult to envision how the two independent Rock-binding sites on Shroom would 
contact the two independent Shroom binding sites of Rock without evoking large conformational 
remodelling.  Thus it is reasonable to predict that these two independent and identical Rock 
binding sites probably form contacts with the two independent Shroom binding sites on Rock by 
positioning two half dimers on opposite side of Rock coiled-coil (Figure 15B, C). These half 
dimers can either be from a single Shroom SD2 dimer or from a Shroom SD2 monomer that has 
folded back on itself at the symmetry point to generate a half dimer. A probable model of 
Shroom-Rock complex formation would be Rock SBD dimer binding to Shroom SD2 and 
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inducing a huge conformational change that can position the two independent Rock binding sites 
to interact with the Shroom binding sites on the coiled-coil of Rock SBD simultaneously (Figure 
15B, C). The latter tetrameric model is favored, however evidence of Shroom SD2 in other 
conformations or in a complex with Rock need to be analyzed to establish this model. 
 
Figure 15: Model of Shroom-Rock complex formation 
A) Opening of individual Shroom and Rock homodimers and annealing to form a 
heterodimer. 
B) Each Shroom dimer hinging at the symmetry point to form half dimers and binding to 
opposite surface of Rock homodimer. 
C) Each Shroom monomer hinging at the symmetry point to form half dimers and 
binding to opposite surface of Rock homodimer. 
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3.0  INVESTIGATING THE ROLE OF SHROOM-ROCK INTERACTION IN 
NEURAL TUBE MORPHOGENESIS 
3.1 INTRODUCTION 
Cellular remodeling, driven by the dynamic nature of the cytoskeleton, is critical for  regulating 
cell processes like adhesion, division, polarity, migration, secretion and morphology [1, 2, 16, 
139-142, 155, 333-340]. Through the use of genetic models systems and the mapping of 
mutations that cause human diseases, it is well-established that errors in these processes lead to a 
wide range of maladies, including birth defects, cancer, kidney disease, and neuronal 
degeneration. One example of a congenital birth defect associated with improper cell 
morphogenesis arising due to errors in cytoskeletal dynamics are those that affect closure of the 
neural tube, the precursor to the brain and spinal chord [206-208].  While less common in the 
developed world, neural tube closure defects (NTDs), including spina bifida and excencephaly, 
are among the most common birth defects worldwide affecting approximately 1 in 1,000 births 
[206, 207]. While over 200 genes have been implicated in neural tube morphogenesis in mice, a 
clear understanding of the etiology of human NTDs has remained elusive [208-210].  
Shroom3, a class of F-actin associated proteins is one of over 200 genes that have been 
shown to be a key regulator of cell morphology in neural tube closure [11, 232, 234, 235, 238]. 
In vertebrates, the Shroom family is comprised of four members, Shroom 1-4 [232] each of 
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which has been implicated in the regulation of various developmental processes including neural 
tube closure [11], remodeling of the vasculature [9], eye development [8, 12], gut morphogenesis 
[10, 13], neuronal architecture and function [14, 231], ENaC channel regulation [341], renal 
function [23], arterial hypertension [243], and heterotaxy in humans [235, 238, 244, 262]. 
Importantly, Shroom-mediated cellular morphogenesis is dependent on its proper localization 
and protein-protein interactions. Most Shroom proteins (Shroom 2,3,4 and dShroom) bind to 
both F-actin and Rho-associated kinase (Rock) via signature sequence motifs known as Shroom 
domain 1 (SD1) and 2 (SD2), respectively. Shroom3 binding directly to F-actin localizes actin to 
the zonula adherens of polarized epithelial cells [15, 234]. Shroom3 binding to Rock ensures 
Rock localization to the zonula adherens of cells [5]. Rock, a Ser/Thr kinase, then 
phosphorylates the myosin regulatory light chain (RMLC), resulting in localized activation of 
non-muscle myosinII [5, 12, 15]. As a result, a contractile circumferential actomyosin ring gets 
sub-apically positioned in the cell. This ring exerts tension and elicits apical constriction, 
facilitating the transition of columnar shaped cells into a wedge-shaped form [15]. When this cell 
shape change occurs synchronously in a group of cells it alters tissue stiffness and causes 
invagination or bending, leading to tissue morphogenesis. 
A new Shroom3 allele, Shroom3m1nisw has been identified in mice using a genome-wide 
ENU mutagenesis screen to identify mutants that exhibit neural tube closure defects [342, 343]. 
Shroom3m1nisw homozygous mutant mice embryos exhibit exencephaly and spina bifida similar to 
the gene trap allele of Shroom3, Shroom3gt(ROSA)53sor. In order to investigate the molecular basis 
of this loss-of-function phenotype, I characterized the ENU-induced mutation, a substitution in a 
highly conserved arginine residue (R1838) in Shroom SD2 in the ENU-mutant embryos. In this 
study, I look at the role of R1838 directly, demonstrating the pronounced effect of alterations at 
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this position on the development of neural tube defects, Rock binding and Shroom-mediated 
apical constriction via activation of the Rock-myosinII pathway. This mutation in Shroom3 SD2 
abrogates Rock binding and renders it incapable of triggering apical constriction. Thus my data 
suggest the essentiality of Shroom-Rock interaction in neural tube morphogenesis and apical 
constriction in polarized epithelial cells. I also demonstrate that the equivalent mutation in 
Drosophila Shroom results in a loss of Rock-binding activity, thereby showing that the Shroom-
Rock signaling module is molecularly and functionally conserved across animal evolutionary 
history. 
3.2 RESULTS 
3.2.1 The Shroom3m1/Nisw allele harbors a substitution mutation in Shroom3 SD2 
Previous studies have identified a novel, ENU-induced allele of Shroom3 called Shroom3m1Nisw 
[342, 343]. Embryos homozygous for this allele phenocopy embryos homozygous for a gene trap 
null allele at the Shroom3 locus, Shroom3gt(ROSA)53sor, suggesting that this allele is a functional 
null (Figure 16A). However, analysis of the Shroom3m1Nisw allele indicates a C-to-T missense 
mutation at nucleotide position 5744 in the Shroom3 cDNA (accession number NM_015756), 
resulting in an Arginine to Cysteine amino acid substitution at position 1838 of Shroom3 
(accession number NP_056571) (Figure 16C). This would suggest that the mutant allele should 
still express full-length protein that is localized to the apical adhesion sites of cells. Alternatively 
the substitution mutation could destabilize the protein, causing it to be degraded. Consistent with 
the first hypothesis, the staining of neural epithelium from wildtype or homozygous 
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Shroom3m1Nisw embryos indicates that Shroom3 protein is expressed at approximately equal 
levels and exhibits similar subcellular distribution (Figure 16B). Additionally, this substitution 
mutation does not appear to affect the stability or folding of the protein (see below).  Sequence 
analysis indicates that R1838 is within the SD2 of Shroom3 and maps to a highly conserved 
patch of amino acids that is surface exposed (Figure 16C, D). Our previous work on the SD2 has 
identified the cluster of residues 1834SLSGRLA1840, as being essential for Shroom-Rock 
interaction [344]. In fact, in all SD2 motifs identified to date, an arginine is conserved in this 
position (Figure 16C). Taken together, these data indicate that the Shroom3 R1838C protein is 
defective for a specific activity that is required for neural tube closure in mice. 
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Figure 16: Arginine 1838 of Shroom3 SD2 is required for neural tube closure in mice but does not 
regulate protein expression or localization 
A). Embryos homozygous for Shroom3 null allele Shroom3Gt(ROSA)53Sor exhibit the same 
phenotype as the ENU Shroom3 allele Shroom3m1Nisw  
B) Expression of the Shroom3 R1838C protein. Sections of either wild type or 
Shroom3m1Nisw neural epithelium was analyzed by indirect immunofluorescence to detect 
Shroom3 and visualized by confocal microscopy. Scale bar, 10μm. 
C) The Shroom3m1Nisw mutation results in the substitution of a cysteine for a highly 
conserved arginine. Top panel shows the point mutation while the bottom panel shows the 
sequence conservation of the SD2 in the vicinity of arginine 1838. 
D) Surface view of the Drosophila Shroom SD2 with the conserved arginine (R1474) 
residue highlighted in green. Blue patches are representative of highly conserved residues. 
3.2.2 Shroom3 SD2 R1838 is specifically required for Rock SBD binding 
Based on the above results and previous studies, we predicted that the Shroom3 R1838C protein 
is unable to interact with Rock.  To test this hypothesis, I generated two substitution variants 
R1838A and R1838C of mouse Shroom3 SD2 and tested their ability to bind to the Shroom-
Binding domain (SBD) of human Rock1 using in vitro binding assays. I created an alanine 
subsitution in addition to the cysteine substitution to replace the hydrophobic nature of arginine 
with alanine and also see the effect of replacing the long side chain of arginine with only a small 
hydrophobic methyl moiety in alanine. First, I performed pull-down assays by mixing GST-
Shrm3 SD2 variants bound to beads with soluble, His-tagged Rock-SBD spanning amino acids 
707-946. In this assay, the R1838A and R1838C variants exhibit an approximate 45% and 95% 
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reduction, respectively, in the ability to bind Rock protein relative to the wildtype SD2 (Figure 
17A). To verify the results from the pull-down assay and assess the stability of the interaction, I 
tested this interaction by mixing GST-Shrm3 SD2 with His-tagged SBD in solution and resolved 
the proteins by native gel electrophoresis. In this assay, wildtype GST-Shrm3 SD2 and the SBD 
form a stable complex that has reduced mobility in the native gel  (Figure 17B).  In agreement 
with the pulldown assay, I found that the R1838C variant is incapable of forming a stable 
complex and essentially all of the SD2 and SBD proteins remain in the unbound state. In 
contrast, the R1838A exhibits an intermediate level of binding, with 51% of the GST-SD2 
protein remaining unbound. These data suggest that the R1838 position is important for binding. 
However, since the alanine substitution results in an intermediate level of binding, it suggests 
that the cysteine mutation is more severe and that there may be some tolerance for different 
amino acids at this position. To further investigate this interaction and to verify that the GST 
moiety, because it is a dimer, didn’t influence the binding, we assessed the ability of untagged 
SD2 and SBD proteins to form stable complexes using native gel mobility shift assays 
(Figure17C).  In these experiments, we can readily detect a complex with wild type SD2 and 
Rock SBD whereas neither the R1838A nor the R1838C variant were able to form a stable 
complex, suggesting a significant decrease in the binding affinity for Rock SBD.  
Although the Drosophila Shroom SD2 structure suggests that the R1838C mutation 
should be surface exposed, it is possible that the substitution mutation perturbs the 
intramolecular interactions and thus influences protein folding and stability. However, the 
R1838C and R1838A variants exhibit the same mobility on a native gel (Figure 17B and 17C), 
suggesting this is not the case.  To further test this we analyzed the stability of these proteins in 
the presence of protease and their behavior in size-exclusion chromatography, which would 
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indicate if the proteins had a dramatically different conformation or were forming aggregates.  
Shroom3 WT, R1838A and R1838C proteins all exhibit the same stability when subjected to 
digestion by Subtilisin A for 15, 30, and 60 minutes, suggesting that they are all in a stably 
folded conformation (Figure 17D). Similarly, all of the proteins exhibit the same elution profile 
using size exclusion chromatography, suggesting there are no dramatic changes in overall protein 
tertiary structure or protein aggregation (Figure 17E). Taken together, these data indicate that the 
R1838A and R1838C proteins are virtually indistinguishable from the wildtype SD2, suggesting 
these substitutions do not effect the overall folding or stability of the protein.  Thus, these results 
suggest that R1838 is playing a prominent role in mediating the Shroom-Rock interaction and 
not other aspects of the SD2 structure. 
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 Figure 17: Arginine R1838 is required for the interaction between Shrrom3 and Rock 
A). In vitro pull down assay using wild type and R1838 substitution variants of GST-
Shroom3 SD2 (GST-SD2) bound to glutathione beads and His-tagged hRock SBD (His-SBD) in 
solution. The amount of Rock SBD in the pellet relative to wild type, is indicated under the gel. 
B). Gel mobility shift assay to detect the binding of GST-Shroom3 SD2 variants to the 
SBD of hRock1. Purified GST-Shroom3 SD2 and SBD proteins were mixed in solution, resolved 
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on native PAGE gels, and detected by Coomassie Blue staining.  The amount of complex formed 
relative to wild type is indicated beneath the gel.   
C).  Gel mobility shift assay to detect the interaction of untagged Shroom3 SD2 variants 
(Shrm3-SD2, amino acids 1642-1951) and untagged hRock1 SBD (Rock-SBD, amino acids 707-
946).  Increasing concentrations of SD2 proteins (indicated at top) were mixed with 5 µM SBD, 
resolved by native PAGE, and detected by Coomassie Blue staining.  Values beneath the wild-
type panel indicate the relative amount of free SBD. 
D).  Purified, untagged SD2 proteins were exposed to Subtilisin A for 0, 15, 30, or 60 
minutes, resolved on SDS-PAGE gels, and stained with Coomassie Blue. 
E). Elution profiles of size exclusion chromatography of purified Shroom3 SD2 
substitution variants.  Experiments shown in panel D and E were done by Jenna Zalewski from 
the VanDemark Lab. 
3.2.3 Shroom3 SD2 R1838 variants fail to colocalize with Rock 
Shroom proteins bind directly to the coiled-coil Shroom Binding Domain (SBD) of Rock via its 
C-terminal SD2 domain and recruits it to specific subcellular locales to regulate cell morphology 
and behavior [5, 9, 234, 327]. Based on the above data showing that Shroom3 variants R1838A 
and R1838C fail to bind Rock, we predict that these mutants would also fail to recruit Rock to 
proper subcellular locales in vivo and therefore fail to colocalize with Rock. To test this 
hypothesis, we co-expressed the Rock SBD with either wild type or substitution variants of 
Shroom3 in MDCK and Cos7 cells and assayed their co-localization (Figure 18). Shroom3 
usually localizes to the cell-cell junctions in MDCK cells and to cortical actin and stress fibers in 
Cos7 cells, while the Rock SBD is typically cytoplasmic in these cells [5]. If Shroom3 is capable 
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of binding Rock and recruiting it, Rock will then colocalize with Shroom3. As expected, the wild 
type Shroom3 and Rock colocalize to cell-cell junctions in MDCK cells and to actin stress fibers 
in Cos7 cells (Figure 18A). A Shroom3 version lacking the SD2 domain fails to recruit Rock 
SBD and serves as the negative control (Figure 18B). Similar to the SD2 deletion variant, 
Shroom R1838A and R1838C mutants fail to colocalize with Rock when coexpressed in either 
MDCK or Cos7 cells (Figure18C). Colocalization analysis performed to quantify the degree of 
co-distribution between Shroom3 and Rock SBD in Cos7 cells demonstrate a linear relationship 
in cells expressing WT Shroom and Rock whereas it is greatly reduced in cells expressing 
R1838A and R1838C indicating a lack of co-distribution. Thus, our data suggest that Shroom-
Rock binding is required for directing Rock to specific subcellular locales. 
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 Figure 18: Shroom3 SD2 R1838 mutants fail to colocalize with Rock SBD in vivo. 
MDCK and Cos7 cells co-expressing the hRock1 SBD and either wild type Shroom3 (A), 
Shroom3 ΔSD2 (B), Shroom3 R1838A (C) or Shroom3 R1838C (D) were grown on either 
transwell filters (MDCK cells) or fibronectin-coated coverslips (Cos7) and stained to detect 
Shroom3 (green) and the myc-tagged Rock SBD (red). The furthest right-hand panels are color 
scatter plots and indicate the degree of overlap between Shroom3 and the Rock-SBD with 
Pearson’s r value indicated in each scatter plot. Scale bar, 10µm. 
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3.2.4 Shroom3 SD2 R1838 is required for apical constriction of polarized epithelial cells 
Shroom3 directly interacts with F-actin through its SD1 domain and this interaction is required 
for Shroom3 localization to the apically positioned sites of cell-cell adhesion, the zonula 
adherens [15, 234]. Previous work has shown that the Shroom3 SD2 is both necessary and 
sufficient to cause apical constriction in polarized Madin-Darby canine kidney (MDCK) cells 
and this activity is dependent on the catalytic activity of both Rock and myosinII [15, 234]. To 
address whether alterations at R1838 prevent apical constriction, we expressed either wild type 
or R1838 variants of Shroom3 in MDCK cells and tested their ability to elicit apical constriction. 
MDCK cells expressing wild type Shroom3 show dramatic apical constriction, demonstrating a 
89% decrease in apical area relative to non-transfected cells (Figure 19A, B).  In contrast, cells 
expressing the Shroom3 R1838A or R1838C variants largely fail to induce apical constriction to 
the same extent as wildtype.  Consistent with the in vitro binding data, the R1838A variant 
induces a small degree of apical constriction, a 22% decrease in apical area relative to non-
transfected cells.  The R1838C variant exhibits no apical constriction and is more severe, 
inducing a minimal decrease of 8% in average apical area (Figure 19A, B). We predict that these 
results are due to the inability of these proteins to bind Rock and not the degree of protein 
expression or stability as all of the Shroom3 proteins are expressed at comparable levels (Figure 
19C). The above results are consistent with the hypothesis that the ability of Shroom3 to bind 
Rock directly correlates with the ability of Shroom3 to induce apical constriction and thus 
Shroom3-induced changes in cell morphology are the result of its interaction with Rock and not 
the actin cytoskeleton or other possible effectors.   
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 Figure 19: Shroom3 R1838 variants fail to induce apical constriction in MDCK cells 
A). MDCK cells were transiently transfected with expression vectors for Shroom3, 
Shroom3 R1838A, or Shroom3 R1838C, grown overnight on transwell filters, and then stained 
to detect Shroom3 (green) and the tight junction marker ZO-1 (red). Scale bar, 10 µm. 
B). Quantification of apical constriction induced by wild type, R1838A and R1838C 
Shroom3 proteins when expressed in MDCK cells. Apical area was determined by measuring the 
area encircled by ZO1 staining of cells expressing the indicated Shroom3 proteins using ImageJ 
software. Error bars represent standard error variation in the positive and negative range for 30 
cells.  The statistics are shown for 30 cells picked at random from a single experiment and the p 
value is <<0.01 for R1838A and R1838C relative to control cells, cell expressing wild type 
Shroom3 cells and in between R1838A and R1838C. 
C).  Equal amounts of total lysate from MDCK cells expressing the indicated Shroom3 
proteins were assayed by western blot analysis using anti-Shroom3 sera. Membranes were 
reprobed to detect α-tubulin to demonstrate equal protein loading in each lane. 
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3.2.5 Shroom3 SD2 R1838 variants causes decreased activation of the Rock-MyosinII 
pathway 
Shroom SD2 domain is both necessary and sufficient to induce changes in cytoskeletal 
organization and subsequent alterations in cell morphology [11, 15]. SD2 elicits changes in cell 
morphology by altering the cellular distribution of contractile actomyosin networks [15].  This 
function of SD2 is accomplished by the direct association of Shroom SD2 to Rock [5]. We 
hypothesize that this binding recruits Rock to specific subcellular compartments and activates it, 
resulting in the phosphorylation of its downstream targets, specifically Regulatory Myosin Light 
Chain (RMLC) and Myosin phosphatase targeting subunit (MYPT). This results in the localized 
activation of myosinII which then binds to F-actin to form a contractile actomyosin network at 
the zonula adherens of cells, which induces apical constriction. Since the Shroom3 R1838A and 
R1838C mutants fail to bind Rock or cause apical constriction I wanted to test if they are also 
incapable of activating the Myosin II pathway by assaying the phosphorylation status of RMLC 
in polarized MDCK cells expressing either wild type or Shroom3 SD2 variants. Consistent with 
our previous findings cells expressing either the R1838A or the R1838C mutant do not show 
enrichment of phosphorylated RLC at cell junctions contrary to the the cells expressing wild type 
Shroom protein (Figure 20A, B, C). Taken together, these results substantiate the role of this 
conserved arginine residue in the SD2 in mediating Shroom-Rock interaction and demonstrate 
that Rock binding and subsequent localized activation of actomyosin is required for proper 
neural tube morphogenesis. 
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 Figure 20: Shroom3 R1838 substitution mutations causes decreased activation of the Rock-MyosinII 
pathway 
MDCK cells were transiently transfected with expression vectors for hRock1 and either 
Shroom3, Shroom3 R1838A, or Shroom3 R1838C and stained to detect Shroom3 (green) and 
phosphorylated RLC (pRLC, red).  Right-hand panels show the fluorescent intensity of Shroom3 
(green) and pRLC (red) at the position of the dotted line in the corresponding merge panels. 
Scale bar, 10 µm. 
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 3.2.6 dShroom SD2 R1838 variants behave similarly to mShroom3 SD2 mutants 
Our previous work had identified a Rock-binding interface on mouse Shroom SD2 that was 
conserved in invertebrate Drosophila Shroom [327, 328]. The mShroom SC2 mutant 
(1834SLSGRLA1840) behaved similarly to dShroom SC2 mutant in that it failed to bind Rock or 
cause apical constriction in MDCK cells. Since the R1838 is highly conserved across species I 
wanted to test whether this residue had an evolutionarily conserved role in Shroom-Rock 
interaction. To test this I created equivalent mutations in dShroom SD2, R1474A and R1474C 
and tested their ability to bind dRock. Purified untagged dShroom SD2 proteins wild type 
(2mg/ml), R1474A (2mg/ml) or R1474C (10mg/ml) were subjected to solution binding with 
dRock and complex formation assessed via native gel mobility shift assay. As expected, the wild 
type dShroom SD2 protein formed a stable complex with dRock, as represented by the higher 
molecular weight species on the native gel. In contrast, no complex formation was detected when 
the R1474A or R1474C variants were used (Figure 21A). These substitution mutations did not 
affect the overall structure or stability of the protein as evidenced by crosslinking and protease 
sensitivity assays (Figure 21B, C). Thus, this arginine residue plays an evolutionarily and 
molecularly conserved role in mediating the Shroom-Rock interaction.  
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 Figure 21: dShroom SD2 variants R1474A and R1474C behave similarly to mShroom3 SD2 mutants 
A). Gel mobility shift assays to detect interaction and complex formation between 
untagged wild type or dShroom SD2 variants (dShroom-SD2, amino acids 1393-1576) and 
untagged dRock (amino acids 724-938). Increasing concentration of dShroom SD2 proteins were 
mixed with a constant concentration of dRock, resolved by native PAGE, and detected by 
Coomassie Blue staining. 
B) Chemical crosslinking of dShroomSD2 wild type or R1474 variants to detect dimer 
formation in solution. Wild type or mutant dShroom SD2 proteins were incubated with 0.004% 
glutaraldehyde (GA) and samples taken at various time points were resolved by SDS-PAGE and 
detected by Coomassie Blue staining. 
C) Limited proteolysis to detect protein stability of dShroom wild type or R1474 SD2 
mutants. dShroom wild type or mutant proteins were treated with 40μg of the protease Subtilisin 
A for the indicated times and samples taken at each time point were resolved by SDS-PAGE and 
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detected by Coomassie Blue staining. Experiments shown in panel B and C were done by 
Swarna Mohan from the VanDemark Lab. 
3.3 DISCUSSION 
Neurulation is a complex morphogenetic event and an intensely studied field because of the high 
prevalence of congenital birth defects associated with failure of neural tube closure [207]. 
Shroom3 plays an important role in neurulation in Xenopus, chick and mouse embryos [5, 11, 
195]. Shroom3 is a key regulator of tissue morphogenesis and cell morphology and it does so by 
modulating the cytoskeletal dynamics in the cell. Shroom3 directly binds to F-actin and Rock via 
signature sequence motifs and these interactions are required for its in vivo activity. We predict 
that other Shroom family members function analogously to Shroom3 [8, 9, 11, 15, 195, 229, 232, 
234, 238], thereby suggesting that a conserved Shroom-Rock signaling module operates in a 
variety of cell types to regulate cell morphology and behavior. However the molecular basis of 
the Shroom-Rock interaction is still unknown.  
Mutant mice embryos, obtained from a genome-wide ENU mutagenesis screen exhibiting 
neural tube closure defects similar to the null allele of Shroom3, lead to the discovery of a novel 
allele of Shroom3; Shroom3m1Nisw. Molecular analysis of these Shroom3m1Nisw mutants lead to the 
identification of a substitution mutation in a specific region of Shroom SD2 that fortuitously 
coincides with the highly conserved surface cluster patch of residues on Shroom SD2 that we 
previously identified to be important for Rock binding and apical constriction [328]. In this study 
I investigated the role of this Shroom SD2 substitution variant in Rock binding and apical 
constriction and showed that this specific region of SD2 is required for Rock binding and its 
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recruitment to the apical surface of cells to bring about Shroom induced apical constriction and 
neural tube morphogenesis. 
3.3.1 R1838 is essential for Rock binding and Shroom3-induced changes in cell 
morphology 
Shroom3m1Nisw mutant mice exhibit severe exencephaly that is attributed to a point mutation in 
Shroom3 SD2 that changes a highly conserved arginine 1838 to a cysteine. One of our 
previously generated surface cluster mutants, SC2 of Shroom SD2 (1834SLSGRLA1840) removes 
this arginine residue and abrogates Rock binding as well as apical constriction [328]. In this 
study I showed that changing the positively charged arginine to either an uncharged polar amino 
acid cysteine, or to a nonpolar amino acid alanine, disrupts Rock binding. Out of the two Shroom 
SD2 variants, R1838C seems to be more severe in disrupting Rock binding thereby suggesting 
some tolerance at this position. It is probable that the R1838C mutant has a reduced binding 
affinity for Rock relative to the alanine substitution mutant. A more stringent quantitation of the 
binding affinity of these two SD2 variants using fluorescence anisotropy would address this 
issue.  Our previously characterized SC2 mutant substitutes the R1838 with an aspartic acid and 
this dramatic change from a positively charged amino acid to a negatively charged one might 
account for its failure to bind Rock. Alternatively, it might be a cumulative effect of mutating 
multiple resiudes in the surface cluster patch. In our single R1838 variants it is a little surprising 
that the alanine substitution, which is hydrophobic, shows a milder effect compared to the 
cysteine substitution mutant which is hydrophilic, similar to arginine. The presence of a 
sulfhydryl group in cysteine might account for the severity of this mutation, as being a weak acid 
it cannot mediate hydrophilic interactions comparable to arginine. Also, cysteine can form 
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disulphide bonds to form a strongly hydrophobic and nonpolar cystine that mediate protein 
protein interactions. However the SBD of human Rock does not contain a cysteine residue and 
therefore forming disulphide bridges to strengthen Shroom-Rock interaction seems improbable. 
Rather the absence of a cysteine residue in Rock SBD might contribute to its inability to bind 
Rock. The R1838A mutant, because of its hydrophobic character, might cluster inside the SD2 
however since it retains the helical propensity, it probably does not disrupt the secondary 
structure of the extended SD2 body segment and therefore has milder effects on Rock binding. 
Our native gel shift assays however predict a smilar behavior of both R1838 variants in their 
inability to bind Rock and form a stable Shroom-Rock complex. Solving the structure of these 
proteins will help us better understand the side chain interactions mediated by this residue in the 
Shroom-Rock complex. Nonetheless, both the mutants are severely affected in their ability to 
cause apical constriction in MDCK cells, suggesting that this arginine residue is essential for 
altering cell shape in vivo.  
Neural tube closure is a complex embryological process requiring precisely orchestrated 
cell movements that are brought about by spatio-temporal regulation of cytoskeletal architecture 
and dynamics. Using mice as a genetic model system, other labs have demonstrated the 
importance of actin architecture and regulation in neural tube morphogenesis as mutations in 
cytoskeletal regulators like Nap1 [219], Abl1/2 [220], p190RhoGap [221], Mena/profiling [222], 
Vinculin [223], NF1 [224], paladin [225], Epb4.1l5 [226, 227], and Marcks [228],  all cause 
neural tube closure defects. Shroom3 has been shown to directly bind and bundle F-actin and 
apart from Rock, it can also bind Ena/Vasp proteins and recruit them to the apical surface of cells 
to induce apical constriction [11, 12, 345]. Shroom can thus employ different mechanisms to 
regulate actin dynamics required during neural tube closure and mutating it could have global 
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consequences on embryonic development. That being said, the Shroom3m1Nisw mutant embryos 
have neural tube closure defects that match the Shroom3 null embryos. If they had a more severe 
phenotype it would be indicative of something else that is going on. Based on our previous 
results, I predict that the above-mentioned activities, though required for in vivo function of 
Shroom3, are not perturbed in the R1838 substitution variant and are thus dispensable for neural 
tube morphogenesis. 
3.3.2 The Shroom SD2-Rock interaction is evolutionarily conserved 
In Drosophila, apically localized contractile networks of actomyosin exert forces that are critical 
for germ band extension, ventral and dorsal closure, and various invaginations [153, 190, 202, 
205, 265, 276, 346-352].  These processes exhibit extensive and robust apical constriction. 
Vertebrate Shroom protein has limited overall sequence homology to Drosophila Shroom, 
however the SD2 motif is highly conserved. Previous work from our lab has shown that 
Drosophila Shroom functions similarly to Shroom3 in binding to dRock, F-actin, inducing robust 
apical constriction, and localizing to specific subcellular compartments [235]. The VanDemark 
lab has solved the structure of the SD2 from dShroom and based on the structure we predict that 
R1838 of Shroom3 is surface exposed [344]. To verify that the Shroom-Rock interface is 
conserved, mutation of the analogous arginine in the dShroom SD2 (R1474 in dShroomA) 
renders the protein incapable of binding Rock. Additionally these dShroom SD2 proteins are 
proteolytically stable, confirming that these substitutions do not affect the overall structure or 
stability of Shroom protein. It would be interesting to knock-in the mutant allele in fly and assess 
the effect of this mutation in vivo. Thus, we conclude that the Shroom-Rock pathway is 
evolutionarily conserved.  
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3.3.3 Implications of understanding the Shroom-Rock interaction 
An interesting facet of the Shroom-Rock pathway is whether Shroom binding can directly 
activate Rock or if it is merely required for Rock localization where Rock is activated by some 
other effector molecule. It is predicted that Rock adopts a folded, autoinhibited conformation via 
intramolecular interactions between the C-terminal tail and the N-terminal kinase domain that 
renders it inactive. It is thought that binding of proteins such as RhoA (in the GTP bound state), 
lipids, or caspase cleavage of the C-terminus, relieves this intramolecular inhibition and activates 
Rock [6, 41, 42, 263, 266, 269-272, 285, 287, 353, 354].  However, there is evidence for both 
Rho-dependent [237] and Rho-independent modes of Rock activation during Shroom3-induced 
apical constriction [15, 195, 344]. We predict that if Shroom binding is both necessary and 
sufficient for activation of Rock, then the Shroom3 R1838C substitution variant would be unable 
to localize as well as activate Rock. 
It has already been shown that the Rock-MyosinII pathway controls vital morphogenetic 
processes in animals and is central to diverse signaling networks [136, 137, 273, 355, 356]. 
Therefore global disruption of Rock function affects multiple cellular processes with detrimental 
side effects. Targeted Rock inhibition hence serves as a potential therapeutic approach for many 
debilitating diseases including cancer [357-360], obesity [361-363], diabetes [364], hypertension 
[365], atherosclerosis [366] and cardiovascular diseases [367]. It would thus prove helpful to 
understand the different mechanism of Rock activation and its interaction with different 
downstream substrates for targeted modulation of Rock activity. Finally establishing our 
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proposed model of Shroom-Rock interaction to be necessary and sufficient for Rock activation, 
independent of RhoA, will provide a new paradigm of Rock activation and facilitate an improved 
understanding of disease pathogenesis associated with dysregulation of Rock activity. This will 
aid in designing strategies to alter Rock regulation for therapeutic purposes. 
 96 
4.0   CHARACTERIZING THE SHROOM BINDING DOMAIN OF ROCK TO 
IDENTIFY RESIDUES CRITICAL FOR SHROOM-ROCK INTERACTION AND ROCK 
LOCALIZATION 
4.1 INTRODUCTION 
Rock proteins are required for various cellular processes such as cell motility, migration, 
adhesion, shape change, cytokinesis, centrosome positioning and cell polarity [292, 368-370]. It 
is a Serine/Threonine kinase that can regulate the cytoskeletal dynamics by phosphorylating 
various downstream targets, including RMLC, MYPT, LIMK, Adducin, ERM proteins and many 
others. Rock phosphorylates the MLC causing localized activation of myosinII [4] which 
contributes to the assembly of a contractile actomyosin network. Of the different Rock binding 
proteins that have been identified to date, Shroom is one such candidate that binds to Rock via its 
SD2 [5]. Previous work has shown the essentiality of Rock activity in Shroom mediated 
processes, especially Shroom3 induced apical constriction [5, 15, 235]. Rock is a multidomain 
protein characterized by several signature sequence motifs. Rock binds to the C-terminal SD2 of 
Shroom via its centrally located Shroom Binding Domain (SBD). The SBD is part of a larger 
central coiled-coil fragment that comprises the SBD, the Rho-binding domain (RBD) and spans 
amino acids 421-1105 in hRock1. The Shroom-Rock interaction recruits Rock to specific 
subcellular locales where it can locally activate myosinII and form a contractile actomyosin 
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network [5, 235]. Shroom3 SD2 mutations that abolish Rock binding also results in a loss of 
phosphorylated RMLC at the apical junctions of cells [328]. Thus it demonstrates that Rock is 
required for Shroom3 mediated apical constriction.  
Rock remains in an inactive autoinhibitory folded conformation in the native state. This 
folded conformation is mediated by intramolecular interactions between the N-terminal kinase 
domain and C-terminus of Rock. Previous studies have shown the negative regulatory effect of 
the C-terminus of Rock [270]. Binding of RhoA, lipids, arachidonic acid or caspase cleavage is 
thought to relieve this autoinhibition [6, 41, 42, 263, 266, 269-272, 285, 287, 353, 354]. 
However there is evidence of Rho-dependent [242] as well as Rho-independent modes of Rock 
activation [15, 195] during Shroom3 mediated apical constriction. Though much is known about 
the expression pattern of Rock, its subcellular localization, downstream targets and function, 
regulation of its catalytic activity still remains confounding.  It is unclear as to how Rock gets 
activated once it is recruited to the zonula adherens following Shroom binding. This questions 
the contribution of Shroom-Rock interaction in Rock activation, forming an alternate pathway 
contrary to the canonical Rock activation pathways known to date. 
In order to dissect the role of Shroom binding in Rock localization and Rock activation, it 
becomes imperative to characterize the domains in both Shroom and Rock that are mediating this 
interaction. I have first characterized the SD2 domain of Shroom and identified surface patches 
important for Rock binding. Here, I characterize the highly conserved Shroom Binding Domain 
(SBD) of Rock to map the residues critical for Shroom binding. I, along with our collaborator, 
the VanDemark lab designed various human Rock1 SBD mutants, based on secondary structure 
prediction and sequence conservation, and identified residues that are critical for Shroom 
binding. 
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4.2 RESULTS 
4.2.1 Identifying the minimal SBD of Rock and making SBD mutants 
Rock is a 160kDa multidomain protein with signature sequence motifs required for its 
localization and catalytic activity (Figure 22A). A large central region in the coiled-coil domain 
of Rock was shown to mediate binding to Shroom SD2, however residues that specify this 
interaction have not yet been identified [5]. Since both Rock1 and Rock2 bind to Shroom SD2 
we predicted that there is a conserved sequence motif in Rock that mediates this interaction. 
Previous work from our lab had identified the minimal core hRock SBD (amino acid 834-913) 
that is capable of Shroom binding and is proteolytically stable (Figure 22B, C). I analyzed the 
sequence conservation of this core region across different species using CLUSTALW sequence 
alignment (Figure 22D). I selected those amino acid residues that were highly conserved across 
species and targeted them by site-directed mutagenesis. Due to the extended helical coiled-coil 
region of the Rock SBD, I created multi-residue alanine substitution mutants and tested them for 
their ability to bind Shroom SD2. I used pET151D/TOPO expression plasmid containing the 
hRock1 template amino acids 707-946 or 834-913. The correct mutants were selected based on 
sequencing results and then transformed into E.coli CodonPlus RIPL cells. Protein expression 
was induced using 0.5 mM IPTG. Proteins were purified with Ni-NTA beads and then mixed 
with untagged mouse Shroom3 SD2 protein in solution. I then resolved the bead and supernatant 
fraction of the bound or unbound complex on a 12% SDS-PAGE and stained with Coomassie 
blue. A table summarizing the hRock SBD mutants created and their position on the hRock SBD 
protein structure is presented below (Table 2). 
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 Figure 22: Identification of a minimal binding region in the central coiled-coil domain of Rock 
A) Schematic of domain structure of human Rock1 
B) hRock SBD spanning amino acids 834-913 is the minimal Shroom SD2 binding 
region in the central coiled-coil of Rock. In vitro pull down assay using His-tagged hRock SBD 
spanning amino acids 834-913 and untagged human Shroom2 SD2. Ni-NTA beads were bound 
to His-tagged hRock fragment and untagged Shroom SD2 was added in solution. Complexes 
were precipitated by spinning down beads and resulting samples were resolved by SDS-PAGE. 
This experiment was performed by Jenna Zalewski from the VanDemark lab. 
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C) Purified hRock SBD protein spanning amino acids 834-913 is proteolytically stable 
and is resistant to Trypsin at room temperature. This experiment was performed by Ryan Rizaldy 
from our lab. 
D) Sequence conservation of Rock SBD (amino acids 834-913) across different species. 
Colored residues indicate highly conserved residues that were targeted for Site-directed 
mutagenesis. Green residues indicate different multiresidue SBD mutants created. Pink and 
orange residues are indicative of Leucines present in the N-terminal and C-terminal part of SBD 
and were mutated to alanine. Blue residues are indicative of buried residues that were targeted 
for mutational analysis. 
                  
 
 
                 Table 2: Position and sequence of hRock1 SBD mutants created 
Residue number Sequence Position in SBD structure hRock1 template 
834-845 QDQ Surface exposed 707-946 
865-866 EE Surface exposed 707-946 
900-902 ESE Surface exposed 707-946 
850-852 QYF Surface exposed 707-946 
857-859 KTQ Surface exposed 707-946 
872,873,876,879 RE..K..Q Surface exposed 707-946 
842,846 Leu  Buried interiorly 707-946 
860,863 V..L Buried interiorly 707-946 
849-852 EQYF Both (E buried) 707-946 
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900-906 ESEQLAR Both  707-946 
842,846,855 3 LEU Both (842,846Leu buried) 707-946 
856-859 YKTQ Both (Y buried) 834-913 
855-859 LYKTQ Both  (L & Y buried) 834-913 
881,888 2 LEU Buried interiorly 834-913 
 
4.2.2 Identifying conserved surface patch residues on hRock SBD critical for Shroom SD2 
binding 
Mapping the selected amino acid mutations onto the hRock SBD structure solved by the 
VanDemark lab showed some of them to be surface exposed, some to be interiorly buried and 
some a mixture of both. I tested each of the fifteen different hRock1 SBD mutants individually 
for their ability to bind Shroom via an in vitro pull down assay. hRock proteins were purified 
using Ni-resin and beads were mixed with untagged mShroom3 SD2 in solution and incubated 
for 2 hrs at room temperature. Both the bead and supernatant fraction were resolved on a 12% 
SDS-PAGE and subsequently stained with Coomassie blue. The wild type hRock1 SBD protein 
spanning amino acids 707-946 (Kd = 1.7 ± 0.2 μM) or 834-913 (Kd = 5.3 ± 1.5 μM) can bind to 
SD2 albeit with differing affinity and both the Rock and Shroom protein are detected in the bead 
fraction.  The binding affinities for the two Rock1 proteins are comparable to that observed 
between Drosophila Rock and Shroom [327, 328]. A truncated hRock protein spanning amino 
acids 707-841, serves as a negative control and fails to bind Shroom and is detected in the 
supernatant fraction (Figure 23A). This indicates that this fragment does not contain the Shroom 
binding site. Blank beads, serving as a negative control fail to bind Shroom as evidenced by 
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Shroom in the supernatant fraction (Figure 23A). Of the different mutants tested, six alanine 
substitution mutants fail to bind Shroom as evidenced by absence of Shroom from the pellet 
fraction. Mapping these residues onto the hRock SBD structure reveals a surface patch of 
conserved residues at the N-terminus of the minimal SBD (Figure 23F). Some mutants with 
interiorly buried residues also affected Shroom binding whereas mutants containing residues in 
the central portion or C-terminal portion of SBD did not affect Shroom binding. The surface 
exposed residues 850QYF852 and 857KTQ859 were found to be critical for Shroom binding as 
mutating them abolished Shroom binding (Figure 23B) [327]. Two other mutants, 856YKTQ859 
and 855LYKTQ859, variants of the above KTQ mutant, as well as the 849EQYF852 mutant a variant 
of the surface exposed QYF, were also defective for Shroom binding (Figure 23D). Also the 
leucine residues 842, 846, 855 seem to be critical, as alanine substitutions at these positions 
abrogated Shroom binding (Figure 23D). Since this triple leucine mutation targets residues 
which are both surface exposed and buried, I might have disrupted both the coiled-coil 
dimerization interface (mediated by residues 842,846Leu) as well as the Shroom-Rock binding 
interface (mediated by the surface exposed residue 855Leu) rendering Rock incapable of binding 
Shroom.  Interestingly mutating interiorly buried residues like V860 and L863 or L842 and L846 
did not affect Shroom binding (Figure 23C). Similarly, alanine substitutions made in the N-
terminal part of the SBD (843QDQ845, 865EE866), or the central part (872RENLKKIQ879), or C-
terminal part (884EKE886, 900ESEQLAR906, 881,888Leu) did not affect Shroom binding (Figure 23B, 
D) [327]. This helped in the identification of a Shroom binding site on Rock SBD located 
between 839-860, with surface exposed residues between 850-859 serving as the critical binding 
determinants (Figure 23F) [327]. A summarization of the in vitro pull down results is presented 
below (Figure 23E). 
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Figure 23: In vitro pull down assays with hRock SBD mutants and untagged mouse Shroom3 SD2 
A) In vitro pull down assay using 20 μl of 10μM His-tagged hRock1 SBD (707-946) 
bound to Ni-NTA beads and 10 μl of 10 μM purified untagged mouse 
Shroom3 SD2 (B:beads, S:supernatant). ΔSBD hRock1 (707-841), a truncated 
version fails to bind Shroom and serves as the negative control. Blank Ni-
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NTA beads fail to bind Shroom3 SD2 and Shroom is recovered in the 
supernatant fraction. 
B) In vitro pull down assay using 20 μl of 10μM His-tagged hRock1 SBD wild type 
or surface exposed mutants and 10 μl of 10 μM purified untagged mouse 
Shroom3 SD2 (B:beads, S:supernatant). The fraction of Shroom bound to 
Rock is indicated below each gel (Fraction bound = Shroom Bound/Total 
Shroom input) 
C) In vitro pull down assay using 20 μl of 10μM His-tagged hRock1 SBD (707-946) 
wild type or interiorly buried mutants and 10 μl of 10 μM purified untagged 
mouse Shroom3 SD2 (B:beads, S:supernatant). The fraction of Shroom bound 
to Rock is indicated below the gel (Fraction bound = Shroom Bound/Total 
Shroom input) 
D) In vitro pull down assay using 20 μl of 10μM His-tagged hRock1 SBD (707-
946)/(834-913) wild type or mixed mutants and 10 μl of 10 μM purified 
untagged mouse Shroom3 SD2 (B:beads, S:supernatant). The second gel in 
this panel is a 15% SDS-PAGE to better resolve the small wild type hRock 
fragment. The fraction of Shroom bound to Rock is indicated below each gel 
(Fraction bound = Shroom Bound/Total Shroom input) 
E) Summarization of in vitro pull down results of hRock1 SBD mutants with 
untagged mouse Shroom3 SD2 highlighting the mutants that abrogate Shroom 
binding. 
F)  Cartoon ribbon diagram of hRock1 SBD (amino acids 834-913) highlighting the 
N-terminal residues critical for Shroom SD2 binding. 
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4.2.3 Conserved surface patch residues are important for Shroom-Rock colocalization 
Previous work has shown that Shroom-Rock interaction is essential for directing Rock to specific 
subcellular locales. They identified that this recruitment of Rock to the apical junctions of 
polarized MDCK cells or neural epithelial cells was dependent on Shroom3 SD2 binding [5]. In 
order to test the above identified Rock SBD mutants for their capacity to colocalize with 
Shroom3, I recreated these mutants in a myc-tagged version of Rock spanning amino acids 681-
942 in a pCS3 expression plasmid (Table 3). I cotransfected either wild type or hRock SBD 
mutants with Shroom3S into cos7 cells. Shroom3S is a naturally occurring short isoform of 
Shroom3 that contains both the SD1 and SD2 domain but lacks the N-terminal PDZ domain. 
Shroom3S can directly bind to F-actin and Rock and can induce apical constriction in polarized 
epithelial cells [11, 195, 234]. Shroom3 localizes to actin stress fibers and cortical actin in cos7 
cells and Rock is usually cytoplasmic. Co-expression of Shroom3 with Rock results in Rock 
recruitment to actin stress fibers and cortical actin that colocalizes with Shroom3 (Figure 24A). 
However a Shroom3 variant lacking the SD2 domain fails to recruit Rock to actin stress fibers, 
showing that this interaction is SD2 dependent and it serves as the negative control. Similarly 
Rock SBD mutants that fail to bind Shroom also fail to get recruited to cortical actin or actin 
stress fibers and therefore were mostly cytoplasmic (Figure 24A) [327]. A color scatter plot 
indicating the codistribution of Shroom and Rock showed a significant decrease in the linear 
relationship for the mutants when compared to wild type Rock and Shroom (Figure 24B). All of 
the hRock SBD mutants tested 842LQDQL846, 842L846L855L, 856YKTQ859, 855LYKTQ859 were 
defective for colocalization with Shroom3, however with differing severity (Figure 24B). A 
colocalization plot using the fluorescent intensity of Shroom and Rock from a region of interest 
of wild type or each of the mutants, further confirmed our data (Figure 24C). These mutants were 
 107 
generated in highly conserved amino acid residues that were predicted to be critical for either the 
Shroom-Rock binding or the Rock coiled-coil interactions. Of the four different Rock SBD 
mutants stated above, the 856YKTQ859 and 855LYKTQ859 were the most severe as they virtually 
eliminated recruitment to stress fibers, indicating that this region plays a critical role in Shroom-
Rock interaction (Figure 24B, C). In contrast, the 842LQDQL846 mutant is less severe in that it 
exhibits reduced recruitment of Rock to stress fibers, indicating that these residues are important 
but not essential for Shroom-Rock interaction in this assay. The triple Leucine mutant 
842L846L855L is also severely defective in colocalizing with Shroom, however, since this mutation 
is predicted to remove both surface exposed (855Leu) and buried residues (842L846L) it might 
perturb both the Shroom binding interface and the coiled-coil interactions rendering Rock 
incapable of binding Shroom (Figure 24B, C) [327]. The colocalization data correlate well with 
the in vitro pull down results where I identified residues in Rock SBD important for Shroom SD2 
binding. My data thus suggest that the Shroom-Rock interaction is essential for efficient 
Shroom3 and Rock colocalization in vivo and that Rock dimerization is probably required for 
Shroom binding and subsequent colocalization. 
 
Table 3: hRock SBD mutants created to test for Shroom colocalization 
Residue Number Sequence  hRock template 
842-846 LQDQL 681-942 
842,846,855 3 Leu 681-942 
856-859 YKTQ 681-942 
855-859 LYKTQ 681-942 
 
 108 
 Figure 24: Shroom-Rock colocalization to actin stress fibers in cos 7 cells 
A) Myc-tagged wild type or hRock1 SBD mutants (681-942) were co-expressed with 
wild type Shroom3S or a Shroom3 variant lacking SD2 in cos7 cells grown on 
fibronectin-coated coverslips and stained to detect Shroom3 (green) or the 
myc tagged Rock SBD (red). Scale bar 10μm. 
B) The panels are colocalization plots and indicate the degree of overlap between 
Shroom3 and Rock-SBD with Pearson’s r value indicated in each scatter plot.  
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C) Furthest right hand panels show the fluorescent intensity of Shroom3 (green) and 
Rock (red) at the position of the dotted line in the corresponding merge 
panels. 
4.2.4 The Rock SBD is required for Shroom3 induced apical constriction 
Results from the above experiments indicate which amino acid residues in the hRock SBD are 
important for binding to Shroom3. This highly conserved patch encompasses amino acids 855-
859 situated in the N-terminal portion of the hRock 834-913 coiled-coil fragment. Previous work 
from our lab has shown that Shroom3 induced apical constriction in polarized MDCK cells is 
both Rock and myosinII dependent [4]. We hypothesize that Shroom binding triggers the kinase 
activity of Rock and therefore these hRock SBD mutants that fail to bind Shroom will be 
incapable of activating the constriction pathway in MDCK cells. In order to test this hypothesis 
we developed a knock-down/add back assay using specially engineered MDCK cells. These cells 
can express Shroom3 under the control of a Tet response element and the Tet transactivator [15]. 
We used T23 MDCK cells inducibly expressing a chimeric version of Shroom3 consisting of 
Endolyn and the C-terminus of Shroom3 containing the SD2 [4]. Endolyn is a trasmembrane 
protein that trafficks to the apical plasma membrane in MDCK cells and can be over expressed 
without altering cell morphology [371, 372]. It also increases the robustness of the apical 
constriction phenotype allowing easy identification of cells that are apically constricted. Upon 
induction of Endolyn-Shroom3 expression via removal of doxycyclin, cells exhibit robust apical 
constriction and disruption of tight junction organization as evidenced by ZO-1 staining (Figure 
25A). To test whether this apical constriction phenotype is Rock dependent, we treated Endolyn-
Shroom cells with siRNA specific to canine Rock1 and Rock2 and performed Western blot to 
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confirm their depletion (Figure 25B). Individual knockdown of Rock1 or Rock2 is unable to 
revert the apical constriction phenotype, whereas simultaneous knock down of both Rock1 and 
Rock2 effectively prevents the apical constriction phenotype, thereby suggesting that Rock1 and 
2 function redundantly in Shroom3 induced apical constriction (Figure 25A). Importantly re-
expression of full length wild type Rock in these siRNA treated cells effectively rescued apical 
constriction (Figure 25C) [327]. However, re-expression of a kinase dead version of Rock or 
Rock SBD mutant 855LYKTQ859 failed to rescue apical constriction, thereby suggesting that the 
catalytic activity of Rock as well as its ability to bind Shroom is required to mediate Shroom-
induced apical constriction (Figure 25C) [327]. Coexpression of Endolyn-Shroom and Rock in 
MDCK cells showed that the Rock SBD mutant 855LYKTQ859 fails to get recruited to the apical 
surface of cells unlike wild type Rock (data not shown). Wild type Rock1 however, cannot elicit 
apical constriction or get apically localized in uninduced MDCK cells (data not shown). Taken 
together, the data suggest that the ability of Rock to mediate Shroom3 induced apical 
constriction is dependent on its ability to bind the Shroom SD2 [327]. 
Interestingly apical constriction is rescued with re-expression of a Rock RBD mutant 
(I1009A) that is defective in RhoA-GTP binding [280] but localizes apically in T23-Endolyn-
Shroom cells similar to wild type Rock1 (Figure 25C) [327]. This suggests a unique Rock-
dependent but Rho-independent mode of Shroom3-induced apical constriction, which is contrary 
to the prevailing models of Rock activation. However, we cannot overlook the fact that these are 
over-expression studies that can mask the need for active RhoA. Therefore, additional 
experiments designed to address the contribution of Rho-Rock and Shroom-Rock interactions 
during Shroom3 induced apical constriction will be necessary. 
 111 
 Figure 25: Key residues in hRock SBD are important for Shroom3-induced apical constriction 
A) Parental or Endolyn-Shroom3 expressing T23 MDCK cells were treated with either 
control or Rock1 (1.2) and 2 (2.1) specific canine siRNAs and stained to detect ZO-1. siRNA 
mediated knock-down of Rock reverts apical constriction phenotype of cells. 
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B) Western blot analysis of Rock1 and Rock2 knockdown in MDCK cells. Three siRNAs 
specific for Rock1 (1.1, 1.2, 1.3) and Rock 2 (2.1, 2.2, 2.3) were tested for efficient knockdown 
via western blotting using rabbit anti-Rock antibodies. 
C) T23 MDCK cells expressing Endolyn-Shroom3 treated with Rock1/2 (1.2 + 2.1) 
siRNA for 48 hours, transfected with the indicated hRock1 expression vectors, grown on 
transwell membranes for another 24 hours and stained to detect ZO-1 (red) and hRock1 (green). 
Scale bar 10μm. 
4.3 DISCUSSION 
Cellular morphogenesis is critical for normal embryonic development. Non-muscle cells undergo 
shape change such as apical constriction by spatially regulating the assembly and activation of 
myosinII. The activated myosinII, together with F-actin, forms a contractile actomyosin network 
that generates force to shrink the apical surface of cells. This motor activity of myosinII is 
triggered largely by the phosphorylation of its regulatory light chain. Several kinases that can 
directly phosphorylate and activate myosinII have been identified, including Calcium-calmodulin 
dependent Myosin Light Chain Kinase (MLCK) and Calcium-independent Rock. Rock is a 
prominent candidate that has been studied extensively for its role in regulating cytoskeletal 
dynamics in various cell processes. Rock is a Ser/Thr kinase with an N-terminal kinase domain 
that dimerizes in a head-to-head arrangement followed by a large extended central coiled-coil 
region and finally ending in a C-terminal PH domain. Structural studies of the Rock kinase, PH, 
RBD domain and parts of the central-coiled-coil region (including the SBD), has revealed a 
parallel coiled-coil homodimer structure [7, 267, 281, 282, 329-332]. However, information 
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regarding the region of Rock that can bind to Shroom and whether it forms a discrete binding site 
distinct from the other domains remains unknown. Since the Shroom-Rock signaling pathway is 
important in bringing about change in cell shape and behavior required during development of 
multiple tissues, it becomes important to understand the molecular mechanism of the Shroom-
Rock interaction and its role in regulating cytoskeletal dynamics. In previous studies I have 
identified the Rock binding site in the Shroom SD2 and next wanted to map the SBD of Rock 
and identify residues that are critical for mediating this interaction. Guided by sequence 
conservation and structural studies I have successfully identified the minimal SBD and 
conserved surface residues critical for the Shroom-Rock interaction, Rock localization and 
Shroom3-induced apical constriction. 
4.3.1 Key conserved patches at N-terminus of hRock SBD are important for Shroom 
binding 
After examining the sequence conservation profile of Rock SBD across different species I 
predicted that the highly conserved or invariant amino acid residues in the SBD (834-913) 
probably are important for mediating the Shroom-Rock interaction. In order to test the 
hypothesis, I created numerous multi-residue hRock SBD alanine substitution mutants and tested 
the resulting substitution variants for their ability to bind Shroom. Alanine substitutions were 
selected to preserve the helical propensity of the coiled coil interface. I was able to identify six 
different SBD mutants that eliminated or reduced Shroom binding, thus helping me identify a 
region of the Rock SBD that is critical for SD2 binding. This highly conserved patch is in the N-
terminus of the SBD, encompassing amino acids 839-860. Importantly two surface clusters, 
850QYF852 and 857KTQ859, seem particularly important in binding to Shroom [327]. The presence 
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of Leucines at characteristic coiled-coil heptad positions suggests a canonical leucine zipper 
motif in the coiled-coil SBD that is required for Rock-Rock or Rock-SD2 binding. The Rock 
SBD crystal structure revealed a parallel coiled-coil homodimer with canonical knobs into holes 
packing interactions at the coiled-coil interface. Results from our in vitro binding, colocalization, 
and apical constriction assays, along with the conservation profile and surface position of these 
residues, collectively suggests that the residues which are surface exposed on the Rock SBD 
structure form the Shroom binding site whereas the interiorly buried residues are probably 
required for Rock dimerization [327]. Mutants that were a combination of both surface exposed 
and buried residues might locally disrupt the dimerization interface that affected the binding site 
and combinatorially were defective in Shroom binding. This represents a previously unidentified 
binding surface on the coiled-coil region of Rock and it spans two highly conserved surface 
patches, the KTQ and QYF, which might constitute a portion of the binding interface between 
Shroom SD2 and Rock.  The parallel coiled-coil homodimeric form of Rock SBD indicates the 
presence of an identical binding site on the opposite face of the coiled-coil dimer. Structural 
analysis of residues in this region reveals a protruded hydrophobic patch formed by the side 
chains of Y851, F852, L855 that might be important for mediating Shroom-Rock interaction 
[327].   
However, our present analysis does not negate the prospect that the SBD is formed by 
residues from both chains of the dimer on account of an extended coiled-coil interface. Results 
from the mutational analysis cannot distinguish between these possibilities but we are confident 
of the presence of two identical binding sites on opposite faces of the Rock coiled-coil. Each 
binding site is thus individually occupied by an SD2 probably via its body segment. On account 
of the extended coiled-coil surface, presumably mutations in conserved residues that are 
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interiorly buried in the SBD homodimer can abrogate Shroom binding either by disrupting the 
overall structure of the dimer, thereby distorting the binding site, or by preventing coiled-coil 
strand interactions within Rock that prevent residues in both monomers from coming together to 
form a composite binding site. Our present data cannot distinguish between these possibilities. 
However, based on the previous work and structural and biochemical data obtained thus far 
regarding the Rock SBD and Shroom SD2 a couple of possible outcomes of Shroom-Rock 
interaction on Rock activation can be proposed.  
Firstly, Shroom binding to Rock can localize it to cortical actin where it can be activated 
by other effector molecules like RhoA or lipids. This model therefore suggests that Shroom 
binds to an inactive conformation of Rock (Figure 26A). Secondly, Shroom can bind to pre-
activated Rock and recruit it to actin stress fibers. In this model Shroom plays an exclusive 
localizing effect on Rock where RhoA or lipids have already activated it (Figure 26B). A third 
possibility is Shroom binding is sufficient to localize as well as activate Rock (Figure 26C). 
Growing evidence strongly supports the third model and we envision that binding of Shroom 
SD2 on each face of the Rock homodimer can open up the head to tail folded autoinhibitory 
conformation of Rock. In light of the Shroom SD2 structure each half dimer of Shroom SD2 
contains the two surface patches required for Rock binding. Thus there can be two possibilities. 
Either each half of a Shroom SD2 dimer can form a half dimer and bind to opposite faces of the 
Rock SBD homodimer (Figure 26D) or each Shroom SD2 monomer can fold back on itself to 
form a half dimer that can bind to the Shroom binding site on the SBD homodimer (Figure 26E). 
This tetramer model would be in accordance with the Shroom-Rock binding stoichiometry of 1:1 
and align with the conformational remodeling that is required for bringing the two surface 
clusters on SD2 to interact with the two Shroom binding site on opposite faces of the Rock 
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helices simultaneously (Figure 26D, E). Further experiments designed to directly assess the 
kinase activity of Rock before and after Shroom binding, in presence or absence of RhoA will be 
required to distinguish between these possibilities and conclusively prove our proposed model.  
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Figure 26: Different models of Shroom-Rock complex formation and Rock regulation 
A) Shroom binding to Rock is required exclusively for Rock localization where it is 
activated by other effector molecules. 
B) Shroom binding to Rock is required for Rock localization after it has been pre-
activated by other effector molecules. 
C) Shroom binding to Rock is necessary and sufficient for Rock localization and 
activation. 
D) Half dimers from Shroom SD2 dimer binds to each binding site on opposite faces 
of Rock SBD homodimer. 
E) Half dimers from Shroom SD2 monomer binds to each binding site on opposite 
faces of Rock SBD homodimer. 
 
4.3.2 Shroom-Rock binding is important for Rock localization and apical constriction 
Shroom3 binding to Rock via its SD2 domain recruits Rock to apical junctions of polarized 
epithelial cells [5]. Our data show that Rock SBD mutants that fail to bind Shroom also fail to 
colocalize with Shroom in vivo. Alanine substitution mutations at these critical residues abrogate 
Rock recruitment to the actin cytoskeleton. While all of the mutants tested are compromised in 
their ability to colocalize with Shroom, there is differing severity, suggesting absolute and 
accessory roles of these residues in Shroom-mediated Rock localization. Thus, our data 
reinforces the fact that Shroom-Rock binding is important for Shroom mediated recruitment of 
Rock to specific subcellular locales. In order to validate the role of these residues in Shroom3 
mediated apical constriction, a rescue assay whereby over expression of wild type, kinase dead 
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or SBD mutant Rock was performed in siRNA treated cells expressing Shroom3. A failure to 
rescue apical constriction by the Rock SBD mutant clearly shows the importance of these 
residues in Shroom3 induced changes in cell morphology. These residues are moreover highly 
conserved across most vertebrate and invertebrate Rock proteins across different species thereby 
representing an evolutionarily conserved signaling module that regulates cell behavior during 
cell and tissue morphogenesis. Thus our in vitro binding results correlate with our in vivo data, 
thereby helping us to identify the important residues in Rock SBD that are essential for Shroom 
binding and colocalization. 
4.3.3 Implications of a distinct SBD in close proximity of RBD 
The presence of a distinct Shroom binding domain located in close proximity (50 amino acids 
away) to the Rho binding domain raises interesting possibilities of RhoA and Shroom binding to 
their respective domains and their involvement in Rock regulation. Previous work has shown that 
Shroom SD2 and active RhoA can simultaneously bind to Rock SBD in vitro and they do not 
outcompete each other [12]. Our in vivo results suggest a Rho-independent mode of Rock 
activation in mediating Shroom3 induced apical constriction. Thus we can conclude that Rock 
binds independently to both Shroom and RhoA and these interactions may have exclusive or 
combined roles in Rock regulation. However, in support of our model that Shroom-Rock 
interaction is necessary and sufficient for Rock activation, we predict that inputs from RhoA may 
modestly enhance Shroom induced cellular phenotype but is not absolutely required for the 
same. Our model directly contradicts previous models of Rho-dependent Shroom-induced apical 
constriction [242]. In the prevailing models, RhoA has been implicated in Shroom-Rock 
signaling but whether it is upstream or downstream of Shroom still needs to be determined. 
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RhoA can probably function upstream of Shroom3 in directing the assembly and organization of 
the actin cytoskeleton at the apical cell-cell adhesion sites that is required for proper Shroom3 
localization. Upon apical localization, Shroom can bind to Rock and locally activate myosinII to 
bring about apical constriction. This is supported by evidence that basally targeted activated 
RhoA can redistribute ZO-1 and Shroom3 to the basal surface [242]. Recent work from the 
Zallen lab has shown exciting evidence that Shroom acts downstream of Rho in Drosophila 
where its localization requires RhoGTPase activity but not vice versa [373]. Though Rho does 
not bind directly to Shroom it can influence Shroom localization indirectly by modulating the 
actin cytoskeleton [373]. Thus RhoA can function upstream of Shroom3 localization and 
subsequent apical constriction just like N-cadherin which genetically interacts with Shroom3 to 
regulate cell shape during gut morphogenesis in mice [241]. More direct kinase assays to assess 
the catalytic activity of wild type and SBD mutants in presence or absence of Shroom and RhoA 
will help address this question better. 
The identification of a distinct SBD in Rock separate from the other defined binding sites 
in the coiled-coil of Rock opens up a whole new area of research exploring the role of Shroom-
Rock interaction in Rock function and regulation during various developmental processes. I have 
successfully been able to identify a conserved binding site for Shroom in the central coiled-coil 
region of Rock and have shown it to be important for Shroom-mediated Rock recruitment to 
specific subcellular locales and apical constriction in polarized epithelial cells. This novel Rho-
independent mode of Rock activation may provide ways to regulate Rock activity in a spatially 
restricted manner to spatially regulate specific changes in cytoskeletal organization. Also this 
will provide ways for targeted modulation of Rock activity that would prove therapeutically 
beneficial in the development of treatment options for various human diseases. 
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5.0  DISCUSSION AND FUTURE DIRECTIONS 
My project involved mapping the binding domains of the two interacting proteins Shroom and 
Rock, which are key regulators of the cytoskeleton. I have successfully identified the key amino 
acid residues in the interacting domains of each of the proteins, the SD2 of Shroom and SBD of 
Rock, and illustrated their role in vivo.  I have also investigated the role of a single Arginine 
residue in SD2 in Shroom function in vivo. Though my work involved a streamlined 
investigation of only the interacting domains of Shroom and Rock, we cannot overlook the 
myriad other regulators of the cytoskeleton that also contribute to cellular and tissue 
morphogenesis by regulating the cytoskeletal dynamics. Localized activation and assembly of a 
contractile actomyosin network is the recurrent theme in altering cell behavior including cell 
shape, migration, adhesion, polarity and cell division. Hence understanding the signaling 
pathway that leads to the localized activation of this network is crucial for understanding how 
cells remodel their cytoskeletal architecture. This dissertation focuses only on Shroom and Rock 
and sections below will discuss the intricate implications of the Shroom-Rock interaction in 
regulating the cytoskeleton to alter cell shape and behavior. 
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5.1 DIFFERENTIAL ACTIN BINDING ABILITY AND LOCALIZATION OF 
SHROOM 
An important question that awaits revelation is how actin-binding proteins can target specific 
populations of actin. Shroom is a class of actin-binding protein and it physically binds to F-actin 
for its subcellular localization. However, different Shroom family members bind to different 
populations of F-actin in cells and this probably contributes to their differential localization.  
Shroom2 and Shroom3 both contain a centrally located SD1 domain that physically interacts 
with F-actin, however they do so differently. In fibroblasts, Shroom3 can directly bind and 
bundle actin stress fibers, whereas Shroom2 localizes to cortical actin and fails to induce actin 
bundling. On the other hand Shroom4 localizes to cytoplasmic pools of F-actin and forms 
discrete cytoplasmic puncta in the cell [234].  The PDZ and SPR domains of Shroom2 are 
required for its localization however they are dispensable for Shroom3 localization. The SPR of 
Shroom2 has also been shown to directly bind to the tight junction protein ZO-1 however the 
requirement of this interaction for Shroom2 localization still remains unanswered [248]. POSH, a 
scaffolding protein, has also been shown to directly bind to the SPR domain of Shroom3 via its 
third SH3 domain to negatively regulate axon outgrowth by modulating the actin-myosin 
networks [14]. 
  Shroom is a multidomain protein and there is evidence of other unique protein 
interactions outside of the SD1 and SD2 for both Shroom2 and Shroom3. Mena-Vasp family 
proteins are also known to regulate cytoskeletal dynamics and are involved in assembly of actin 
filament networks [345, 374]. It has been shown that mouse Mena/Vasp proteins facilitate 
localized apical assembly of actin filaments in neural epithelial cells undergoing active apical 
constriction during neurulation, formation of craniofacial features and during axon guidance 
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pathways during CNS and peripheral nervous system formation [375, 376]. Interestingly 
Mena/Vasp can bind to proteins that contain proline-rich consensus sequences via their EVH1 
domain. These proline-rich sequences are often found in actin-associated cytoskeletal proteins, 
Shroom3 being one example. Though a direct physical interaction between Mena/Vasp proteins 
and Shroom3 has not yet been tested, cell based assays have shown the requirement of this 
proline-rich sequence in Shroom3 induced apical constriction in polarized MDCK cells and 
apical accumulation of Vasp. Further, dominant-negative Mena can block apical constriction 
both in vivo and in vitro [12]. Lulu or EPB4.1l5, another cytoskeleton associated protein 
promotes apical accumulation of Shroom3 and cooperates with Shroom3 to induce apical 
constriction during neural tube closure in Xenopus [226]. There are other examples of 
cytoskeleton associated proteins that are critical regulators of actomyosin contractility and are 
required during embryonic development especially during neural tube closure, with defects 
resembling Shroom3 null mutant mice. However interactions between these proteins and Shroom 
have not yet been established and it remains to be revealed whether Shroom can act as a 
scaffolding protein in bringing together all these components that can modulate the cell 
architecture by reorganizing the actomyosin networks. Recent work by the Zallen lab has shown 
RhoGTPase to be the upstream regulator of Drosophila Shroom, directing its localization to 
adherens junctions of cells [373]. Their work also suggests a role of Shroom in directing planar 
polarized actomyosin contractility during axis elongation. It will be interesting to elucidate the 
role of Shroom-Rock signaling in establishment and maintenance of this polarized actomyosin 
contractility during neural tube morphogenesis and convergent extension in mice. 
It is still unknown whether Shroom exhibits an isoform specific binding to Rock or 
myosinII activation. It will be interesting to investigate whether selective binding of Shroom to 
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Rock1 and Rock2 as well as activation of myosinIIA, IIB or IIC, contributes to differential 
cellular outcomes. Thus it is probable that unique protein interactions outside of the known 
domains of Shroom can direct its differential subcellular localization. A structural insight into the 
SD1 domain from different Shroom family members will facilitate understanding of its ability to 
bind to different pools of actin to localize differentially in a cell and subsequently recruit Rock to 
these specific subcellular locales. 
5.2 SHROOM REGULATION 
Shroom is an actin-binding protein and it regulates cell shape and behavior by regulating F-actin 
and non-muscle myosinII both spatially and temporally. Thus, Shroom regulation proves critical 
for various developmental processes especially during neural tube morphogenesis, eye 
development, gut morphogenesis, neuronal architecture and function and many others.  A few 
upstream transcriptional activators of Shroom have been identified, however post-transcriptional 
or post-translational modifications of Shroom, if any, remains unknown. Shroom protein is 
typically apically localized in polarized epithelial cells and previous work from our lab has 
shown actin binding of Shroom to be the critical spatial determinant in its function [234]. 
Though there is no precedence for an inactive and active form of Shroom, a question that 
remains unanswered is what regulates Shroom activity. The temporal regulation of Shroom, as to 
how it gets expressed at the right place and at the right time, whether it is constitutively 
expressed, and if there is a threshold level of protein expression that can mediate Shroom 
function still needs to be addressed. Since phosphorylation is a widely used mode of regulation 
employed by different multidomian proteins and most cytoskeleton binding proteins, it becomes 
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an interesting avenue to investigate for Shroom regulation. ExPASy phosphorylation prediction 
tool identifies numerous serine, threonine and tyrosine residues as putative sites for 
phosphorylation. Also, prediction of kinase specific phosphorylation sites in Shroom3 reveals 
quite a few kinases like PKC, PKA, PKB and cdk5 among others to have putative 
phosphorylation sites in Shroom3 with the highest score of 0.92 for PKC targeting Threonine at 
position 1088. It will be interesting to test for Shroom phosphorylation on incubation with PKC.  
Rock can bind to lipids via its PH domain and since Rock is a binding partner for Shroom 
it might be interesting to investigate if Shroom is also a substrate for lipid membrane kinases. 
Lipid phosphorylation by PI3K can orchestrate complex cell behaviors like cell motility, 
migration, growth and survival all of which contributes to cancer. Various signaling proteins like 
serine threonine kinases, Rho effector molecules have specific domains to interact with these 
phosphorylated lipids. These interactions promote apical accumulation of these signal 
transducers and assembly of signaling complexes to initiate local responses like actin 
polymerization and assembly, or triggering phosphorylation cascades. Investigating the role of 
Shroom and Rock in acting as a scaffolding protein to assemble signaling complexes that can in 
turn phosphorylate Shroom in a feedback loop will shed some light on Shroom regulation. Other 
post translational modifications like acetylation and glycosylation which also play a role in 
regulating protein function are not detected by ExPASy for Shroom protein, however a direct 
investigation of the phosphorylation status of Shroom and its implications in Shroom activity 
need to be undertaken. 
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5.3 ROLE OF SHROOM-ROCK INTERACTION IN ROCK ACTIVATION AND 
CELL MORPHOLOGY 
An important aspect of the Shroom-Rock-MyosinII signaling pathway is the mechanism of Rock 
activation. Rock remains in a folded autoinhibitory conformation via intramolecular interactions 
between the N-terminal kinase domain and the C-terminal region. It is thought that relief of this 
intramolecular inhibition is brought about by RhoA-GTP binding, lipid binding or caspase 
cleavage of the C-terminus. RhoA-GTP binding modestly enhances the catalytic activity of Rock 
in vitro [6, 263] and there is no direct evidence that RhoA is the exclusive upstream activator of 
Rock. There is growing evidence of a Rho-independent mode of Rock activation and work from 
our lab and others have shown that inhibiting RhoA does not abrogate Shroom3-induced apical 
constriction in MDCK cells or Xenopus embryos. Also Shroom, Rock and Rho can form a 
trimeric complex in vitro despite the physical proximity of the Shroom binding and Rho binding 
domains in Rock, establishing a non-competitive simultaneous binding of Shroom and Rho to 
Rock [242]. A RhoA-Rock complex is however not detected in vivo. Also siRNA mediated 
knockdown and rescue assays have shown the requirement of Shroom-Rock binding and not 
Rho-Rock binding in eliciting apical constriction in polarized epithelial cells. 
  We propose that Shroom-Rock interaction is sufficient for Rock activation. There can be 
two possibilities, one being that Shroom binding to Rock is required for its subcellular 
localization whereas Rock activation is brought about by other effector molecules like RhoA-
GTP. The other possibility being Shroom binding is necessary and sufficient for Rock 
localization and activation. My data on Shroom SD2 has shown the requirement of Shroom-Rock 
binding in activation of Rock-MyosinII pathway. Using indirect immunofluoresence we have 
already shown the Shroom SD2 mutants that fail to bind Rock, fail to cause apical constriction 
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and apical enrichment of activated myosinII. An alternative way to test this will be to perform 
Western blotting using antibodies specific to the phosphorylated form of Rock substrates, mainly 
RMLC and MYPT, in cells that express Shroom3 or Shroom3 SD2 mutants to determine if 
Shroom3 can increase the phosphorylation levels of Rock targets. A direct estimation of the 
catalytic activity of Rock via kinase assays using WT Rock or SBD or RBD mutants, 
immunoprecipitated from cells in the presence or absence of Shroom SD2, towards a known 
substrate, will help us accurately determine the role of Shroom in Rock activation. Perhaps, 
switching to a baculovirus expression system for purification of a functional form of the kinase 
and utilizing it in direct kinase assays may prove helpful.  
Cell adhesion maintains tissue integrity as well as transduces signals from extracellular 
matrix and adjoining cell neighbors. Shroom localizes to the adherens junctions of epithelial cells 
by directly binding to actin. Therefore cell adhesion seems to be important for proper 
localization and function of Shroom. Previous work from our lab has shown that Shroom-
mediated apical constriction in polarized MDCK cells is Rock and MyosinII dependent. We can 
assess Shroom3-induced apical constriction in cells treated with siRNAs against RhoA, MyosinII 
and E-cadherin (an adherens junction protein). A Rho-independent mode of Rock activation 
would still cause apical constriction in RhoA siRNA treated cells whereas myosinII siRNA 
treated cells would fail to undergo apical constriction. I am in the process of creating stable 
MDCK cell lines expressing Shroom3 or Shroom3 SD2 mutants under an inducible promoter to 
assess the phosphorylation status of RMLC which will serve as a direct readout of activated 
myosinII and substantiate the role of Shroom-Rock signaling in activation of Rock-myosinII 
pathway to bring about apical constriction in polarized epithelial cells. However, these are all 
over expression systems and variable results regarding Rho-dependent or independent mode of 
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Rock activation can be attributed to the differences in models where it has been tested like chick, 
Xenopus, mice and MDCK cells. Thus in vitro biochemical approaches combined with in vivo 
results could provide a more convincing and accurate picture of the Shroom-Rock-MyosinII 
pathway operating in cells undergoing morphogenesis during development. To that end 
generating a Shroom-Rock compound heterozygous mouse will be helpful. Alternatively, 
conditionally knocking-out Rock1/2 in Shroom3 heterozygous mice will probably help elucidate 
the role of Shroom-Rock binding in cell and tissue morphogenesis. This in vivo model would 
also facilitate understanding of the role of Shroom in Rock activation and the consequences of 
simultaneous depletion of both Shroom and Rock on the downstream targets of this signaling 
pathway. 
Though data from our lab directly contradicts the canonical mode of Rock activation via 
RhoAGTP, the present body of data cannot determine if RhoA functions upstream or 
downstream of Shroom or Rock. Work from other labs have shown that apically targeted, 
activated RhoA can direct Shroom subcellular localization at the apical surface of cells. Basally 
targeted activated RhoA can also induce basal constriction and promote basal localization of 
Shroom3 with redistribution of ZO-1 at the basal surface [242]. Thus, it is probable that RhoA 
activity is required for reorganizing the actin cytoskeleton associated with apical cell-cell 
junctions, which is essential for proper Shroom3 localization. In fact recent work has shown 
evidence of RhoGTPase signaling upstream of Shroom in Drosophila to direct its subcellular 
localization to the adherens junctions of cells [373]. There is evidence of other adhesion proteins 
like N-cadherin that can genetically interact with Shroom3 to modulate the cytoskeleton 
machinery to drive apical constriction and cell elongation during embryonic gut development 
[13], thus further confirming an accessory and not an obligate role of RhoA in Shroom mediated 
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apical constriction. Conversely, both RhoA and Shroom binding may be required individually or 
combinatorially for regulating Rock activity in distinct biological processes that conforms a Rho-
dependent mode of Rock activation. In order to clearly dissect the contributions of RhoA and 
Shroom in regulating Rock localization and activity, experiments designed to directly measure 
the catalytic activity of Rock in presence of various combinations of RhoA and Shroom will be 
required.  
All the Shroom proteins tested to date can either bind to F-actin directly or can colocalize 
with actin [11, 15, 234, 235, 238, 248, 377, 378]. This Shroom-Actin interaction is mediated by 
the centrally located SD1 in Shroom2, Shroom3 and dShroom and a less conserved centrally 
located region in Shroom4. Aditionally Shroom proteins have the ability to regulate higher order 
architecture of actin filaments. Both Shroom3 and dShroom can cause actin bundling both in 
vivo and in vitro whereas Shroom2 and Shroom4 can induce ectopic actin structures when 
expressed in fibroblasts, endothelial or epithelial cells [11, 234, 235, 238]. This partially explains 
the two different phenotypes that we observe when we overexpress Shroom in MDCK cells or 
Cos7 cells. Shroom3 elicits apical constriction in polarized epithelial MDCK cells, whereas it 
localizes to actin stress fibers and cortical actin in fibroblast like Cos7 cells. We think that 
Shroom3 binds to a specific population of actin at the apical domain of MDCK cells to induce 
contractility. However, it binds to cortical actin and actin stress fibers in Cos7 cells to reorganize 
actin into higher order structures. Therefore the cell specific effects that we observe are probably 
due to Shroom localizing to different populations of actin in a cell. 
Also, our collaborator, the VanDemark lab, is currently extending efforts to solve the 
structure of the Shroom-Rock complex and the conformational changes that are involved in this 
interaction. The structure of Shroom-Rock complex along with information gleaned from the 
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structure of the Shroom SD2 and Rock SBD will provide structural insights into the protein 
conformational rearrangement during Shroom-Rock binding and facilitate understanding of its 
influence on Rock activity, as well as the precise stoichiometry of Shroom-Rock interaction. 
5.4 CLINICAL IMPLICATIONS OF SHROOM-ROCK-MYOSIN II PATHWAY 
Rock has been implicated in many debilitating diseases like cancer, pulmonary hypertension, 
diabetes, CNS disorders, cardiovascular diseases, atherosclerosis, obesity and many others [357-
359, 379-388]. In all of these examples, Rock imparts pathophysiologic effects by modulating 
the cytoskeletal architecture of the cell. Rock positively regulates myosinII and negatively 
regulates myosin phosphatase targeting subunit by phosphorylating Serine and Threonine 
residues of these downstream targets. This leads to the activation of myosinII ATPase activity 
and assembly of a contractile actomyosin network. Thus phosphorylation of RMLC or MYPT is 
considered as a direct readout of Rock activity and activated myosinII. Shroom3, a binding 
partner for Rock has also been shown to cause apical enrichment of activated myosinII during 
apical constriction. My previous work on Shroom SD2 and Shroom ENU mutants has shown the 
essentiality of Shroom-Rock binding in activating the Rock-myosinII pathway and bringing 
about apical constriction in polarized MDCK cells. Previous work has established the clinical 
importance of Shroom family of proteins in vertebrate embryonic development especially during 
neural tube closure, gut morphogenesis, eye development, kidney development, vascular 
development, neuronal development and function [5, 8-15, 195, 231, 232, 237, 243, 244]. By 
knowing the role of Shroom and Rock individually in vertebrate development, it becomes 
important to understand the implications of the Shroom-Rock-myosinII pathway for assessing 
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the clinical significance of this signaling module and establishing a paradigm for cellular and 
tissue morphogenesis. 
The kinase activity of Rock is central to cytoskeletal reorganization. The autoinhibited 
conformation of Rock adds another layer of complexity to Rock regulation. Lack of conclusive 
proof regarding a Rho-dependent or independent mode of Rock activation has opened up new 
vistas of research. Rock is a direct downstream target of Rho family of GTPases specifically 
RhoA and this interaction is thought to relieve the intramoelcular inhibition between the kinase 
domain and C-terminal domain of Rock rendering it catalytically active. Work from our lab has 
provided evidence of a Rho-independent mode of Rock activation. We therefore propose a model 
whereby Shroom-Rock interaction is necessary and sufficient for Rock subcellular localization 
and activation.  Rock’s involvement in a multitude of cell processes like cell migration, 
adhesion, division, polarity, epithelial morphogenesis and neurite retraction and its involvement 
in a variety of different diseases makes it an interesting therapeutic target for drug development. 
This has indeed proven to be a daunting task since blocking or increasing Rock activity without 
causing global perturbations in the cell has been impossible [382, 385, 389-396]. A clear 
understanding of the molecular mechanism of the Shroom-Rock-myosinII pathway fills in this 
void and would prove beneficial for selective modulation of Rock activity by targeting Rock 
localization and activation. It will facilitate understanding of the spatial and functional regulation 
of Rock activity via Shroom and would help us to target defined aspects of Rock activity leaving 
others untouched. Additionally, Rock1 and 2 exhibit unique roles as well as functional 
redundancy. To dissect the contributions of each isoform in vertebrate development and disease, 
knowing the critical residues in Rock that mediate dimerization, protein binding and kinase 
activity, may elucidate targets for an isoform specific inhibitor of Rock. Future experiments 
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ultilizing isoform specific siRNAs will also be able to address the differential roles of Rock1 and 
Rock2 in altering cell morphology. Since Shroom, Rock, Rho and myosinII are involved in 
myriad different processes we predict that a clear understanding of the molecular mechanism of 
Shroom-Rock interaction will provide insights into how different signaling network and 
pathways are integrated. Also, understanding this signaling module will provide a paradigm as to 
how cell morphology is controlled during normal development and how lesions in this pathway 
can lead to disease development. This will further help in the designing of pharmaco-therapeutic 
inhibitors or drugs as treatment options for these diseases. 
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6.0  MATERIALS AND METHODS 
6.1 MUTAGENESIS OF SHROOM SD2 AND ROCK SBD PROTEINS 
 Mouse Shroom SD2 mutants  (SC and HD mutations) were made using the QuickChange Site-
Directed Mutagenesis kit. Mutagenesis was performed on mShroom3 in pCS2-Endolyn-Shroom3 
expression plasmid spanning amino acids 1372-1986. For in vitro expression of mShroom3 SD2 
mutant proteins the mutated sequence encoding amino acids 1562-1986 was cloned from the 
Endolyn-Shroom3 vector into pGex-2TK for expression in E.coli CodonPlus (RIPL) cells. 
Shroom SD2 mutants (R1844A, R1844C in mouse Shroom3 and R1474A and R1474C in 
Drosophila) were made using the QuikChange Site-Directed Mutagenesis Kit (Stratagene, Santa 
Clara, CA). mShroom3 mutagenesis was performed on the pCS2 vector harboring ShroomS 
(amino acids 286-1986) [11]. The mutated Shroom SD2 sequences were further cloned from 
pCS2 into pGEX-3X vector for various biochemical assays and in vitro expression in E.coli 
CodonPlus RIPL cells. The dShroom mutants were created in a pET151-D/TOPO vector 
(Invitrogen, Carlsbad, CA) harboring the dShroom SD2 coding sequence for amino acids 1393-
1576. Recombinant proteins were expressed in codon plus BL-21(DE3) E.coli cells and purified 
as described [9, 327, 328]. Human Rock SBD mutants were made using the QuickChange Site-
Directed Mutagenesis Kit (Stratagene, Santa Clara, CA). hRock1  mutagenesis was performed on 
pET151D/TOPO vector harboring  either hRock1 amino acids 707-946 or amino acids 834-913. 
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hRock SBD mutants that were tested for colocalization assays were made in pCS3-myc tag 
vector harboring hRock1 amino acids 681-942. 
 
6.2 PROTEIN EXPRESSION AND PURIFICATION 
Large-scale protein expression of His-tagged SD2 and Rock SBD proteins was performed in 
BL21(DE3) Escherichia coli cells using ZY autoinduction media as described [9, 344].  The 
Shroom3 and Rock proteins were concentrated to 0.78 mg/ml (WT Shroom) and 1.43 mg/ml 
(R1838A) and 1.7 mg/ml (R1838C) and 1mg/ml (WT Rock) in 20 mM Tris, pH 8.0, 0.5 M 
NaCl, 8% glycerol, and 5 mM dithiothreitol (DTT). For purification of GST-Shroom3 SD2 or 
small-scale (<50 ml) expression of His-tagged hRock SBD proteins, BL21 cells or RIPL cells 
harboring the relevant plasmids were induced with 0.5 mM isopropyl β-D-1-
thioglactopyranoside(IPTG) for 2 hours and collected by centrifugation.  Cells were lysed by 
sonication in NETN buffer (for GST-fusion proteins; 20mM Tris, pH 8.0, 0.1 M NaCl, 1mM 
EDTA, 0.5% NP-40) or His-lysis buffer (for His-fusion proteins; 20mM Tris, pH 8.0, 0.5 M 
NaCl, 8% glycerol, 5mM β-mercaptoethanol) supplemented with Protease inhibitor cocktail and 
soluble proteins were purified using either glutathione-sepharose resin or Ni-NTA beads. Beads 
were washed in lysis buffer and the proteins eluted with either free glutathione or imidazole in 
the respective lysis buffers. Protein expression of dShroom SD2 proteins was performed in 
BL21(DE3) Escherichia coli cells using ZY autoinduction media as described in Mohan etal, 
2012 [328].  The dShroom proteins were concentrated to 2 mg/ml (WT and R1474A) and 
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10mg/ml (R1474C) in 20 mM Tris, pH 8.0, 0.5 M NaCl, 8% glycerol, and 5 mM dithiothreitol 
(DTT).  
 
6.3 IN VITRO PULL DOWN ASSAYS 
GST-pull down assays was performed with either wild type GST-mShroom3 SD2 or SC and HD 
mutants spanning amino acids 1562-1986 bound to glutathione beads and mixed with soluble 
hRock1 (residues 707-946). Complexes were washed with NETN, resuspended in SDS-PAGE 
sample buffer, resolved on 12% SDS-PAGE and detected using Coomassie Blue. GST pull-down 
assays were also performed using either wild type GST-Shrm3 SD2 or R1844A and R1844C 
mutant versions (spanning amino acids 1562-1986) bound to Glutathione beads (GE Healthcare) 
and mixed with soluble, His tagged hRock1 SBD (residues 707-946).  The binding reaction was 
incubated for 2 hours at room temperature. Complexes were washed with NETN, resuspended in 
SDS-PAGE sample buffer, resolved on 12% SDS-PAGE, and detected using Coomassie Blue.  
His-tagged versions of hRock1 SBD wild type or mutant proteins harboring either amino acids 
707-946 or 834-913 were bound to Ni-resin and mixed with untagged mShroom3 SD2 (residues 
1642-1951), incubated for 2 hours at room temperature. Complexes were washed with Lysis 
Buffer, resuspended in SDS-PAGE sample buffer, resolved on 12% SDS-PAGE and detected 
using Coomassie Blue. 
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6.4 COMPLEX FORMATION 
For native gel electrophoresis, a fixed concentration (5 µM) of hRock SBD spanning amino acids 
707-946 was mixed with increasing concentration of purified Shroom3 SD2 spanning amino 
acids 1642-1951 (0.25-5µM) and incubated for 2 hours at 40C. Samples were then loaded on 8% 
PAGE gels, resolved by electrophoresis at 4O C and proteins detected with Coomassie blue. For 
solution binding and native gel electrophoresis, a fixed concentration (5 µM) of dRock 724-938 
was mixed with increasing concentration of dShrmSD2 (1-10 µM) and incubated overnight at 
40C. Samples were then loaded on 8% PAGE gels, resolved by electrophoresis at 4O C and 
proteins detected with Coomassie blue. 
 
6.5 CELL CULTURE AND IN VIVO ANALYSIS 
T23 MDCK cells were grown in EMEM supplemented with 10% FBS (Hyclone), pen/strep, and 
L-Glutamine at 370C and 5% CO2. Cos7 cells were grown in DMEM supplemented with 10% 
FBS (Hyclone), pen/strep, and L-Glutamine under similar conditions. Cells were removed from 
the plates using Trypsin-EDTA and passaged every 2-3 days. For transient transfection of cells 
on transwell filters, cells were plated at a density of 8x105 cells (MDCK) or 6x105 cells per well 
(Cos7) and grown for 24 hours. Cells were transfected with the DNA of interest (1μg) using 
Lipofectamine 2000 (Invitrogen) and grown for 24 hours prior to processing. For 
immunofluorescent analysis, cells were fixed using either –20°C methanol for 5 minutes or 4% 
paraformaldehyde (PFA) in PBS for 15 minutes. Fixed cells were stained with primary antibody 
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for 1 hour at RT, washed in PBT three times for 5 minutes at room temperature, stained with 
secondary antibody for 1 hour at room temperature, washed as above and mounted using 
VectaShield (Vector Labs) or Immuno-fluore Mounting medium (MP Biomedicals). 
Shroom3-induced apical constriction using expression plasmids pCS2-Endolyn-
Shroom3(WT) or the SC and HD mutants, pCS2-Shroom3, pCS2-Shroom3 R1838A, pCS2-
Shroom3 R1838C was performed and imaged as described previously [15]. Transfected cells 
were stained with primary antibodies UPT132 (1:100, rabbit anti-Shrm3) [15]  and Rat anti-ZO1 
(1:100, Chemicon) and Alexa-488 or 568 conjugated goat anti-rabbit or goat anti-rat secondary 
antibodies conjugated to (1:400, Invitrogen). Apical constriction was quantified by measuring 
the apical area of either parental or transfected cells, as determined by ZO1 staining, in ImageJ.    
To determine colocalizaton of Shroom3, Rock SBD, and pRLC, MDCK cells or Cos7 cells 
expressing Shroom3 variants and/or myc-tagged, wild type hRock1 SBD (spanning amino acids 
681-942) were plated on either transwell membranes or fibronectin (Sigma Life Sciences) coated 
coverslips, respectively, for 24 hours.  Cells were stained with UPT132 (1:100, rabbit anti-
Shrm3, Hildebrand, 2005), 9E10 (1:100, mouse anti-myc, a gift from Dr. Ora Weisz), and mouse 
anti-pS19 myosin RLC (Cell Signaling). Primary antibodies were detected using Alexa-488 or 
568 conjugated secondary antibodies goat anti-rabbit or goat anti-mouse (1:400, Invitrogen) and 
imaged as described above. To determine the degree of colocalization in Cos7 cells, ImageJ 
plug-ins Colocalization Finder and Mander’s Coefficients were used to analyze individual 
channels from merged confocal images.  To analyze the co-distribution of Shroom3 and pRLC, 
fluorescent intensities along line segments drawn on individual channels were measured and 
plotted using Excel. Images were acquired using a Biorad Radiance 2000 Laser Scanning System 
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mounted on a Nikon E800 microscope or Olympus Fluoview FV1000 Confocal microscope 
(FV10-ASW) with 40X oil objectives and processed using either ImageJ or Photoshop.  
 
6.6 LIMITED PROTEOLYSIS 
This assay was performed by Jenna Zalewski and Swarna Mohan from the VanDemark lab. 
50μM of wild-type and mutant Shroom3 SD2 proteins were treated with 40μg of the protease 
Subtilisin A for the indicated times and samples taken at each time point were resolved via SDS-
PAGE.  
6.7 SIZE-EXCLUSION CHROMATOGRAPHY 
This assay was performed by Jenna Zalewski from the VanDemark lab. Purified WT and mutant 
proteins were concentrated to 1mg/mL in buffer containing 2% glycerol, 250mM NaCl, 20mM 
Tris pH 8.0, and 1mM β-mercaptoethanol. 500uL were run over a Sephacryl S-200 gel filtration 
column, and traces were generated using Unicorn 6.3.2.89 Control Software. 
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6.8 CHEMICAL CROSSLINKING 
This assay was performed by Jenna Zalewski and Swarna Mohan from the VanDemark lab. 
dShrm SD2 mutants and wild type protein was incubated with the indicated concentration of 
glutaraldehyde in a reaction buffer containing 25 mM HEPES pH 7.5, 8% Glycerol, 500 mM 
NaCl and 5 mM β-ME, with a final dShrm SD2 concentration of  16μM. At each time point, 20μl 
of the crosslinking reaction was removed and the reaction stopped with 2 μl of 1.0 M Tris at pH 
8.0 and the sample subjected to SDS-PAGE and visualized using Coomassie blue staining. 
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APPENDIX A 
PROTEIN PURIFICATION 
A.1 HUMAN ROCK1 SBD MUTANT PROTEINS PURIFICATION 
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Figure 27: hRock1 SBD mutant proteins expression and purification 
pET151D/TOPO expression plasmid harboring hRock1 SBD (amino acids 707-946 or 
834-913) was used as a template to create the different SBD mutants via Site-Directed 
mutagenesis. Correct clones were selected after sequencing and transformed into RIPL cells. 
Protein expression was induced using IPTG and purified from a 50ml culture using Ni-NTA 
beads. 10ul of 10uM purified His-tagged protein was run on a 12% SDS-PAGE to assess for 
expression levels and purity. 
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A.2 HUMAN ROCK1 RBD PROTEINS PURIFICATION AND PULL DOWN  
 
Figure 28: hRock1 RBD mutant proteins expression and purification 
pGEX expression plasmid containing hRock1, spannig amino acids 593-1062, was used 
as a template to generate the RBD mutants I1009A, E1008A and 1004NKL1006/AAA via Site-
directed mutagenesis. Correct clones were selected after sequencing and transformed into RIPL 
cells. Protein expression was induced using IPTG and purified using Glutathione beads. 10 ul of 
purified GST-tagged hRock1 RBD proteins were run on a 12% SDS-PAGE and stained with 
Coomassie Blue to assess for expression and purity. 
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APPENDIX B 
OLIGONUCLEOTIDE SEQUENCES 
B.1 SHROOM SD2 OLIGONUCLEOTIDES 
1766 KKAEL1770/1766AKARA1770 
(F) 5’ GAG GAT GTC TAT GAG GCT AAG GCT CGC GCT ATC GGA AGC CTC ACC 3’ 
(R) 5’ GGT GAG GCT TCC GAT AGC GCG AGC CTT AGC CTC ATA GAC ATC CTC 3’ 
1840 SLSGRLA1846/1840ALEADLE1846 
(F) 5’ GTC AAC CTG CTG CTG GCT CTG GAG GCT GAC CTG GAG CGC GTG GAG 
AAC GTC 3’ 
(R) 5’ GAC GTT CTC CAC GCG CTC CAG GTC AGC CTC CAG AGC CAG CAG CAG 
GTT GAC 3’ 
1878LKENLDRR1885/1878AAENLDDA1885 
(F) 5’ GAG GAC GCA CGG GAG GCT GCT GAG AAC CTG GAC GAC GCT GAG CGC 
GTG GTG CTG 3’ 
(R) 5’ CAG CAC CAC GCG CTC AGC GTC GTC CAG GTT CTC AGC AGC CTC CCG 
TGC GTC CTC 3’  
1832LLSL1835/1832AASA1835 
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(F) 5’ AAG GTG GTC AAC CTG GCT GCT TCC GCT TCT GGA CGC CTG GCC 3’ 
(R) 5’ GGC CAG GCG TCC AGA AGC GGA AGC AGC CAG GTT GAC CAC CTT 3’ 
1915LLIEQRKL1922/1915ALIEQAKA1922 
(F) 5’ AAG ATG AAG TCC ACA GCT CTC ATT GAG CAG GCT AAG GCT GAT GAC 
AAG AAG ATA AAG 3’ 
(R) 5’ CTT TAT CTT GTC ATC AGC CTT AGC CTG CTC AAT GAG AGC TGT GGA CTT 
CAT CTT 3’  
1840SLSGRLA1846/1840SLSGALA1846 (mouse) 
(F) 5’ CTG TCC CTG TCT GGA GCC CTG GCC CGC GTG GAG 3’ 
(R) 5’ CTC CAC GCG GGC CAG GGC TCC AGA CAG GGA CAG 3’ 
1840SLSGRLA1846/1840SLSGCLA1846 (mouse) 
(F) 5’ CTG TCC CTG TCT GGA TGC CTG GCC CGC GTG GAG 3’ 
(R) 5’ CTC CAC GCG GGC CAG GCA TCC AGA CAG GGA CAG 3 
1470SLSERLA1476/1470SLSEALA1476 (Drosophila) 
(F) 5’ CTG TCG CTT TCC GAG GCC TTG GCC CAA ACC GAA 3’ 
(R) 5’ TTC GGT TTG GGC CAA GGC CTC GGA AAG CGA CAG 3’ 
1470SLSERLA1476/1470SLSECLA1476 (Drosophila) 
(F) 5’ CTG TCG CTT TCC GAG TGT TTG GCC CAA ACC GAA 3’ 
(R) 5’ TTC GGT TTG GGC CAA ACA CTC GGA AAG CGA CAG 3’ 
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B.2 ROCK SBD OLIGONUCLEOTIDES 
843QDQ845/843AAA845 
(F) 5’ CAG ATG CGG GAG CTA GCT GCT GCT CTT GAA GCT GAG CAA 3’ 
(R) 5’ TTG CTC AGC TTC AAG AGC AGC AGC TAG CTC CCG CAT CTG 3’ 
865EE866/865AA866 
(F) 5’ GTA AAG GAA CTT AAA GCT GCT ATT GAA GAA AAA AAC 3’ 
(R) 5’ GTT TTT TTC TTC AAT AGC AGC TTT AAG TTC CTT TAC 3’ 
900ESE902/900AAA902 
(F) 5’ GCA GAA ACA AAA GCT GCT GCT GCT CAG TTG GCG CGA GGC 3’ 
(R) 5’ GCC TCG CGC CAA CTG AGC AGC AGC AGC CTT TTG TTT CTG 3’ 
850QYF852/850AAA852 
(F) 5’ CAA GAT CAG CTT GAA GCT GAG GCA GCT GCC TCG ACA CTT TAT AAA 
ACC C 3’ 
(R) 5’ GGG TTT TAT AAA GTG TCG AGG CAG CTG CCT CAG CTT CAA GCT GAT CTT 
G 3’ 
857KTQ859/857AAA859 
(F) 5’ GAG CAA TAT TTC TCG ACA CTT TAT GCA GCC GCG GTA AAG GAA CTT 
AAA GAA G 3’ 
(R) 5’ CTT CTT TAA GTT CCT TTA CCG CGG CTG CAT AAA GTG TCG AGA AAT AAT 
ATT GCT C 3’ 
872,873,876,879RE..K..Q/872,873,876,879AA..A..A 
(F) 5’ GAA GAA ATT GAA GAA AAA AAC GCA GCA AAT TTA GCG AAA ATA GCG 
GAA CTA CAA AAT GAA 3’ 
 146 
(R) 5’ TTC ATT TTG TAG TTC CGC TAT TTT CGC TAA ATT TGC TGC GTT TTT TTC 
TTC AAT TTC TTC 3’ 
842,846Leu/842,846Ala 
(F) 5’ GAA GGA CAG ATG CGG GAG GCA CAA GAT CAG GCT GAA GCT GAG CAA 
TAT TTC 3’ 
(R) 5’ GAA ATA TTG CTC AGC TTC AGC CTG ATC TTG TGC CTC CCG CAT CTG TCC 
TTC 3’ 
860,863V..L/860,863A..A 
(F) 5’ GAC ACT TTA TAA AAC CCA GGC AAA GGA AGC TAA AGA AGA AAT TGA 
AG 3’ 
(R) 5’ CTT CAA TTT CTT CTT TAG CTT CCT TTG CCT GGG TTT TAT AAA GTG TC 3’ 
849EQYF852/849AAAA852 
(F) 5’ GAT CAG CTT GAA GCT GCT GCT GCT GCT TCG ACA CTT TAT AAA 3’ 
(R) 5’ TTT ATA AAG TGT CGA AGC AGC AGC AGC AGC TTC AAG CTG ATC 3’ 
900ESEQLAR906/900AAAAAAA906 
(F) 5’ GCA GAA ACA AAA GCT GCT GCT GCT GCT GCT GCT GCT GGC CTT CTG 
GAA GAA 3’  
(R) 5’ TTC TTC CAG AAG GCC AGC AGC AGC AGC AGC AGC AGC AGC TTT TGT 
TTC TGC 3’ 
842,846,855Leu/ 842,846,855Ala 
(F) 5’ ATG CGG GAG GCT CAA GAT CAG GCT GAA GCT GAG CAA TAT TTC TCG 
ACA GCT TAT AAA ACC 3’  
 147 
(R) 5’ GGT TTT ATA AGC TGT CGA GAA ATA TTG CTC AGC TTC AGC CTG ATC TTG 
AGC CTC CCG CAT 3’ 
856YKTQ859/856AAAA859 
(F) 5’ TAT TTC TCG ACA CTT GCT GCT GCT GCT GTA AAG GAA CTT AAA 3’ 
(R) 5’ TTT AAG TTC CTT TAC AGC AGC AGC AGC AAG TGT CGA GAA ATA 3’ 
855LYKTQ859/855AAAAA859 
(F) 5’ CAA TAT TTC TCG ACA GCG GCC GCT GCT GCT GTA AAG GAA CTT AAA 3’ 
(R) 5’ TTT AAG TTC CTT TAC AGC AGC AGC GGC CGC TGT CGA GAA ATA TTG 3’  
881,888Leu/ 881,888Ala 
(F) 5’ AAG AAA ATA CAG GAA GCT CAA AAT GAA AAA GAA ACT GCT GCT ACT 
CAG TTG GAT 3’ 
(R) 5’ ATC CAA CTG AGT AGC AGC AGT TTC TTT TTC ATT TTG AGC TTC CTG TAT 
TTT CTT 3’ 
842LQDQL846/842AAAAA846 
(F) 5’ GGA CAG ATG CGG GAG GCT GCT GCT GCT GCT GAA GCT GAG CAA TAT 3’ 
(R) 5’ ATA TTG CTC AGC TTC AGC AGC AGC AGC AGC CTC CCG CAT CTG TCC 3’ 
B.3 ROCK RBD OLIGONUCLEOTIDES 
1009I/1009A 
(F) 5’ AAC AAA TTG GCA GAA GCT ATG AAT CGA AAA GAT 3’ 
(R) 5’ ATC TTT TCG ATT CAT AGC TTC TGC CAA TTT GTT 3’ 
1008E/1008A 
 148 
(F) 5’ GTT AAC TTG GCA GCT ATA ATG AAT CGA AAA 3’ 
(R) 5’ TTT TCG ATT CAT TAT AGC TGC CAA TTT GTT AAC 3’ 
1004NKL1006/1004AAA1006 
(F) 5’ AAA ACA CAG GCT GTT GCT GCT GCT GCA GAA ATA ATG AAT 3’ 
(R) 5’ ATT CAT TAT TTC TGC AGC AGC AGC AAC AGC CTG TGT TTT 3’ 
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